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Despite huge strides being made towards decreasing the number of individuals getting newly 
infected with HIV-1, and in reducing AIDS-related deaths, unfortunately current predictions are 
that the 2020 UNAIDS goals (90-90-90 targets, where 90% of people living which HIV-1 are 
diagnosed as such, from which 90% will will receive sustained antiretroviral therapy, resulting 
in viral suppression in 90% of these individuals by 2020) are out of reach. This of course 
means that the numbers of newly infected indivuals and AIDS-related deaths will be above 
the target derived from the 2020 UNAIDS goals. The development of an effective HIV vaccine 
could therefore be an important step towards realising these objectives. In work done for this 
thesis, a heterologous HIV-1 vaccine platform regimen was developed using antigen 
sequences from the predominant circulating HIV-1 subtype (subtype C) in South Africa. 
Specifically, this involved use of the envelope glycoprotein sequence of the CAP256 
superinfecting virus (CAP256_SU) from the CAPRISA 002 cohort, and a mosaic Gag 
sequence which resulted in robust autologous Tier 2 neutralisation of CAP256_SU 
pseudovirions. 
The envelope glycoprotein sequence was modified so as to replace the native leader 
sequence with the tissue plasminogen activator leader, the furin cleavage site with a glycine 
rich flexible linker, and to introduce an I559P mutation. DNA and modified vaccinia virus 
Ankara (MVA) vaccines were generated where Env was truncated to gp150, thereby retaining 
the transmembrane domain and a partial cytoplasmic tail (Env). The Env sequence for the 
protein vaccine was further trimmed by removal of the transmembrane domain to give gp140, 
leading to a soluble, secreted protein (soluble Env). This allowed for the latter vaccine to be 
affinity purified using lectin (soluble Env (GNL)), and after generating stable cell lines, soluble 
Env yields were high enough to enable size exclusion chromatography which allowed isolation 
of the trimeric fraction of Env as determined by molecular weight (soluble trimeric Env). A C-
terminal His-tagged version of soluble Env was generated as well. Surprisingly, the folding of 
Env-His was inferior to soluble Env, with a switch in profile from mainly trimeric Env to mainly 
monomeric Env. Nevertheless, soluble Env-His (GNL) and soluble trimeric Env-His were 
assessed for the presence of Env broadly neutralising antibody (bnAb) epitopes in an ELISA 
assay. The V3-glycan supersite (binding of bnAbs PGT128 and PGT135), the CD4-binding 
site (VRC01) and the V2-glycan site (PG9) were detected for both Env-His (GNL) and soluble 
trimeric proteins, whereas low signals for PG16, PGT145 and CAP256-VRC26.08, bnAbs 
which specifically recognise Env trimers in a native-like conformation, were only detectable for 
soluble trimeric Env-His. 
Soluble Env (GNL) was subsequently used as a protein vaccine in rabbits to test the 
immunomodulatory effects of the two adjuvants AlhydroGel (similar to alum) or the MF59-like 
squalene-based oil-in-water nano-emulsion AddaVax. Soluble Env (GNL) adjuvanted in 
AlhydroGel resulted in improved immune response in rabbits, with significantly higher serum 
binding antibodies to soluble Env (GNL) and scaffolded CAP256 V1V2-loop in comparison to 
AddaVax and unadjuvanted protein. Furthermore, significantly higher neutralisation titres to 
Tier 1A subtype C virus (MW965.26), in combination with an improved breadth to subtype C 
Tier 1A and 1B viruses, were observed in the AlhydroGel group. However, no neutralisation 
of Tier 2 viruses was detected. Nonetheless, AlhydroGel was selected as the best protein 
adjuvant for all further rabbit immunogenicity studies. Furthermore, in all subsequent 
experiments, soluble trimeric Env was used as a protein vaccine. 
DNA and recombinant MVA vaccines were generated using a membrane anchored gp150 
(Env) with the aim that co-expression with mosaic Gag (GagM) would lead to the incorporation 
of Env into Gag virus-like particles (VLPs). Electron microscopy of cells expressing Env+GagM 
from DNA and recombinant MVA vaccines verified VLP formation from these constructs, and 
the presence of Env was observed in VLPs purified using a two-step OptiPrep gradient 
centrifugation protocol. The presence of Env bnAb epitopes in cellular membrane-bound Env 
was verified by qualitative immunofluorescent microscopy of live-cell stainings and a 
quantitative FACS assay. The same bnAb epitopes as for the Env protein vaccine were 
detectable, including bnAbs recognising only native-like Env trimers (PG16, PGT145 and 
CAP256-VRC26_08). However, expression levels of native-like Env trimers were lower, at 
approximately 20% when normalised to VRC01. 
These HIV-1 DNA, rMVA and soluble trimeric Env protein vaccines were tested in different 
heterologous vaccine platform immunogenicity studies in rabbits. These consisted of either 
priming with two recombinant MVA vaccines and boosting with three protein vaccines 
(MMPPP), or priming with DNA vaccines followed by two MVA vaccines, followed by two 
protein vaccines (DDMMPP). Furthermore, the inclusion of GagM into the DNA and MVA 
vaccines was compared to use of Env alone. Both vaccine regimens resulted in binding 
antibodies to soluble trimeric Env and a scaffolded CAP256 V1V2-loop; however, these were 
induced by MVA and protein vaccines, but not by DNA vaccines. Despite the lack of Env 
binding antibodies after DNA vaccination, better neutralisation was observed for the DDMMPP 
regimen compared to MMPPP, resulting in higher sera neutralisation titres towards vaccine-
matched, autologous Tier 2 CAP256_SU virus. Most encouragingly, when compared to Env 
alone, the inclusion of Gag (Env+GagM) into DNA and MVA vaccines improved the 
immunogenicity of the DDMMPP regimen even further. For Env+GagM DDMMPP, more 
animals developed Tier 2 neutralising antibodies, and improved titres, whereas Tier 2 
neutralisation in general started to develop after fewer vaccinations, as for most rabbits this 
was observed after the second MVA inoculation.  
In an attempt to improve the spike density of Env on VLPs and the plasma membrane, two 
Env chimaeras were made replacing parts of gp41 with the corresponding elements of 
influenza A H5 haemagglutinin (HA2) (Env:HA2 chimaeras). Increased Env spike density was 
observed in a previous study using this strategy for the gp41 transmembrane domain and 
cytoplasmic tail (gp140HA2tr). A similar construct was generated here for CAP256_SU and a 
second chimaera was included replacing the whole of gp41 with HA2 (gp120HA2). Surprisingly, 
in experiments where VLPs were purified from OptiPrep gradients or the whole-cell bnAb 
FACS assay conducted with these Env:HA2 chimaeras, there was no evidence of increased 
spike density on VLPs or the plasma membrane as compared to Env. Furthermore, the folding 
of Env was severely impacted, especially regarding gp120HA2 where no binding of PG16, 
PGT145 and CAP256 VRC26.08 - bnAbs recognising native-like Env trimers - was observed. 
Although results for gp140HA2tr was improved over gp120HA2, in general the data for gp150 
(Env) was superior in both the bnAb live-cell staining and FACS assay. Consequently, when 
both Env:HA2 chimaeras in combination with GagM were tested in the DDMMPP regimen, no 
improvement was observed with regard to autologous Tier 2 neutralisation. For rabbits 
receiving gp120HA2, no animals developed Tier 2 nAbs, whereas for gp140HA2tr, Tier 2 
neutralisation in general developed later and to lower titres compared to Env+GagM.  
In conclusion, different HIV-1 DNA, recombinant MVA and protein vaccines were generated 
and characterised both in vitro and in vivo, leading to a vaccination regimen that induced both 
high titre Env binding and vaccine-matched Tier 2 neutralising antibodies in rabbits. 
Furthermore, a new Env sequence, the first from the South African CAPRISA cohort, has been 
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Infection with the retrovirus known as human immunodeficiency virus type 1 (HIV-1) causes 
acquired immunodeficiency syndrome (AIDS) due to the progressive depression of cell-
mediated immunity [1-4]. The origin of HIV is most likely zoonotic transmission(s) of a simian 
retrovirus affecting primates in west and central Africa, possibly by hunting or slaughtering 
infected animals and/or handling of uncooked diseased meat [5]. Although it is thought that 
this event happened between 1915 and 1945 [5], and with the oldest sample known sample 
containing HIV found in Congo dating to 1959 [6-8], a clinical description of AIDS was only 
published in 1981 after reports of homosexual men presenting with a series of unexplained 
opportunistic infections and rare cancers [9]. The main modes of HIV transmission (in order of 
importance) are via 1) unprotected sexual contact with an infected person; 2) bodily fluids 
(blood and blood products) mainly through use of contaminated hypodermic needles or 
transfusion of infected blood or donor organs, although the latter is much less likely nowadays 
with adequate screening; and 3) mother-to-child transmission during pregnancy, delivery 
and/or breastfeeding [10-12]. 
1.1 HIV origin 
Two types of HIV have been identified: these are HIV-1 and HIV-2, with the latter originating 
from a simian retrovirus found in the sooty mangabey [13-18] and compromising 8 lineages 
mainly confined to West Africa [19]. HIV-1, however, is ascribed to four unconnected zoonotic 
transmissions giving rise to groups M, N, O and P [20-23], with groups M and N originating 
from the chimpanzee (Pan troglodytes troglodytes) and groups O and P from gorillas (Gorilla 
gorilla gorilla) [20, 21, 24, 25]. The global pandemic of HIV-1 can be traced back to group M, 
which is further classified into nine subtypes (A-D, F-H, J and K) [26]. Furthermore, 
recombination between subtypes has resulted in numerous circulating recombinant forms 
(CRFs) [26]. The global prevalence of group M subtypes and CRFs has a very distinct 
distribution (Figure 1.1), with subtype C being the predominant subtype in sub-Saharan Africa 
and South Africa [26-29].  
1.2 HIV-1 epidemiology 
Based on the 2018 data provided by Joint United Nations Programme on HIV/AIDS (UNAIDS), 
almost 75 million [58.3 million – 98.1 million] people have become infected with HIV since the 
start of the pandemic, and 32 million [23.6 million – 43.8 million] people have died from AIDS-
related illnesses [30]. Upon closer inspection of the global distribution of this epidemic, it 
becomes clear that developing countries, especially those situated in eastern and southern 
Africa, carry the largest burden in people living with HIV, new HIV infections and deaths from 
AIDS (Figure 1.2A-C) [30-32]. For instance, of the ~5000 new daily infections with HIV-1 in  
 
 
Figure 1.1 Global prevalence of HIV-1 group M subtypes and CRF [taken from: [29]] 
 
2018, 61% occurred in sub-Saharan Africa. Within this region, adolescent girls and young 
women are most vulnerable to HIV infection with 80% of new infections among adolescents 
aged 15–19 years in girls, meaning that young women aged 15–24 years are twice as likely 
to be living with HIV than men [30-32]. Although gains have been made in reducing new 
infections from a peak in 1997 (2.9 million [2.3 million – 3.8 million]), and of people dying from 
AIDS-related illnesses (peak 2004, 1.7 million [1.3 million – 2.4 million]), in 2018 these 
numbers were still staggering at 1.7 million [1.4 million – 2.3 million] new infections and 770 
000 [570 000–1.1 million] AIDS-related deaths [31].  
1.3 The structure of the HIV-1 virion  
HIV-1 virions assembles at the host cell plasma membrane into near-spherical structures to 
form particles of roughly 120-200nm, encapsulating two copies of the positive-sense RNA 
genome and viral enzymes required for replication. This is encompassed by a lipid bilayer, 
taken from the host cell during budding, which has a protein shell on its inside formed by the 
unprocessed Gag polyprotein, and contains the viral trimeric glycoprotein trimers (Env) that 
are required for viral entry into target cells (Figure 1.3A-C) [33-37]. In a final maturation step 
after viral budding, the viral Gag polyprotein precursor is proteolytic cleaved, resulting in the 










Figure 1.2. UNAIDS, HIV by numbers – 2018. 
(A) Adults and children estimated to be living with 
HIV.  
(B) Estimated number of adults and children 
newly infected with HIV.  
(C) Estimated adult and child deaths from AIDS. 








Figure 1.3 HIV-1 virion.  
(A) Schematic representation of a HIV-1 virion 
[taken/adapted from: [38]].  
(B) Budding (↓), immature () and mature () 
HIV-1 particles from a host cell captured by 
electron microscopy.  
(C) Schematic representation of (B).  
: Env trimers. 






1.4 The HIV-1 genome 
The ssRNA viral genome, present in two copies protected by the viral capsid within the virion, 
is nearly 10kbp in length and contains nine genes which encode for 15 different proteins in 
between 5’ and 3’ terminal repeats (LTR) (Figure 1.4). Transcription of three of these genes 
results in translation into polyproteins, with env, from a spliced mRNA, being translated into a 
gp160 glycoprotein which is proteolytically cleaved by host cell-derived furin into the 
extracellular protein gp120 (SU) and the transmembrane protein gp41 (TM). In mature virions, 
non-covalently linked gp120-gp41 is present as a trimer (native Env trimer) and is responsible 
for target cell entry through the engagement of the CD4 receptor (cluster of differentiation 4 
glycoprotein) and co-receptors CCR5 (C-C chemokine receptor type 5) or CXCR4 (C-X-C 
chemokine receptor type 4) on the plasma membrane. Secondly, gag also provides structural 
proteins. The 55kDa protein precursor is cleaved into P17, P24, P7, and P6 proteins upon 
viral maturation, this time by the viral protease within virions (Figure 1.3). Each component of 
Gag plays a crucial role in viral assembly and maturation, with P17 (matrix (MA)) targeting 
Gag towards the plasma membrane where it assembles as an inner shell against the 
membrane directing virion assembly, and it is involved in anchoring the gp160 glycoprotein 
[39-43]. Upon cleavage of Gag during virion maturation, P24 or Capsid domain (CA) 
multimerises into the conical shaped capsid [44, 45]. Before cleavage, P7 (Nucleocapsid, NC) 
is essential for the recruitment of the viral genome into the virion, after maturation it associates 
with the viral genome within the core and is vital in the initiation of reverse transcription of the 
viral genome during early target cell entry [43, 46-48]. Finally, P6 not only is important in the 
incorporation of Vpr into the virion but plays a crucial role in recruiting the host cell endosomal 
sorting complex required for transport (ESCRT) to initiate viral budding [49-53]. Next to the 
55kDa Gag precursor, a 160kDa Gag-Pol polyprotein is expressed from an overlapping 
reading frame at a ratio of 20:1 due to an intentional ribosomal frameshift in Gag translation 
[54, 55]. Besides coding for MA, CA, NC, trans-frame protein (TF), the Gag-Pol polyprotein 
precursor produces the viral enzymes protease (PR), reverse transcriptase (RT), and 
integrase (IN) [34, 56]. Whereas PR cleaves both Gag and Gag-Pol polyprotein precursor 
during virion maturation, both RT and IN are involved in the early event phase of target cell 
infection with RT converting the HIV-1 viral genomic RNA into double-stranded DNA and IN 
facilitating random integration of this into the target cell genome [34, 57-61]. 
The final six genes encoded by HIV-1 are the regulatory genes rev (regulator of expression of 
viral proteins) and tat (trans-activator of transcription), both generated by mRNA splicing and 
the accessory genes vif (viral infectivity factor), vpr (viral protein R), vpu (viral protein U) and 
nef (negative regulatory factor). Interaction between Tat and the 5’ and 3’ LTRs regulates viral 
gene expression, whereas Rev switches mRNA splicing during early and late stages of 
infection [62-65]. Three accessory genes are involved in modulating the cellular immune 
response. Firstly, Vpu suppresses the MHC class I response by downregulating HLA 1 [66]. 
Vif promotes the degradation of the antiviral restriction factor APOBEC3G [67, 68]. Whereas 
Nef down-regulates HLA 1 and 2 molecules on the cell surface [69]. Furthermore, Vpu assists 
with gp160 targeting towards the plasma membrane by downregulating CD4 and thereby 
preventing trapping of Env by CD4 in the ER [70-72]. An additional role to immune suppression 
has been ascribed to Nef as well, in which it decreases CD4, CXCR4 and CCR5 to prevent 
superinfection [69]. The final protein, Vpr, allows for the accumulation of viral mRNA by 
inducing a G2 cell-cycle arrest in the host cell and assists in macrophage infection [73]. This 
might however not be the full story, as a predicted product in the negative strand ORF in the 
HIV-1 Class M genome is expressed in HIV-1 infected patients and induces as specific cellular 
and humoral response [74-78]. Although the function of this putative transmembrane protein 
called antisense protein (ASP) is unknown, in vitro experiments of chronically infected cell 
lines, show translocation from the nucleus to the plasma membrane and inclusion into virion 
upon the right stimulation [74]. Furthermore, reports suggest that the HIV-1 genome can 
express non-coding RNAs such as microRNA (miRNA) and long non-coding RNA (lncRNA) 
[79]. However, because of the low expression levels of these products, it is unclear whether 
these have any functionality in vivo. 
 
 
Figure 1.4. Genomic organisation of HIV-1 integrated DNA.  
Genes are depicted in italics in their representative orientation, and dotted lines indicate RNA splicing 
event to generate those particular genes. Each arrow specifies proteolytic cleavage events to 
generate products from polyprotein precursors, with the molecular weight of thus generated proteins 
in brackets below. LTR long-term repeat, Gag (group-specific antigen), MA (matrix protein), CA 
(capsid domain), NC nucleocapsid, TF (trans-frame protein), Pol (polymerase), PR (protease), RT 
(reverse transcriptase), IN (integrase), Env (envelope protein), SU (surface membrane protein), TM 
(transmembrane protein), Vif (viral infectivity factor), Vpr (viral protein R), Vpu (viral protein U), Rev 
(regulator of expression of viral proteins), Tat (trans-activator of transcription) and Nef (negative 
regulatory factor) [taken from: [43]]. 
 
1.5 Structural characteristics of the Env glycoprotein  
A functional HIV-1 Env glycoprotein spike consists of three gp120 molecules, non-covalently 
linked to three gp41 subunits which anchor the trimeric structure into the virion membrane 
[80]. The exterior gp120 protein modular structure consists of five conserved and five variable 
loops (Figure 1.6). Within the conserved regions, several cysteine residues are present which 
are essential in the formation of a well-folded Env protein by forming intramolecular disulphide 
bonds [81-83]. Upon interaction with CD4 receptor the gp120 trimer undergoes a 
conformational change, forming an inner domain, an outer domain and a bridging sheet that 
leads to surface-exposure of the variable loops [84]. Flanking the aforementioned 
transmembrane domain, gp41 has an extracellular ectodomain and cytoplasmic tail (Figure 
1.6) (Checkley et al., 2011). The ectodomain contains a N-terminal fusion peptide and C-
terminal membrane-proximal external region (MPER) flanking two α-helical coiled coils (HR1 
and HR2) which are split by a disulphide bonded region (DSR) that is important for association 
between the gp120 and gp41 subunits [85-88]. 
 
Figure 1.6. Modular structure of the HIV-1 Env glycoprotein.  
Linear map of the gp160 precursor protein before furin cleavage. C(1-5): conserved regions, V(1-5): 
variable regions, FSP: fusion peptide, HR(1-2): α-helical coiled coils, DSR: disulphide bonded region, 
MPER: membrane-proximal external region, TMD: transmembrane domain and Cyto-tail: 
intracellular cytoplasmic tail. 
 
Protein crystallography experiments resolving the structure of different versions of Env have 
further aided in understanding the function of the different domains of the Env protein. The 
trimer presents gp120 in a characteristic mushroom shape with a distinctive 3-blade propeller 
on top, with gp41 as a pedestal-like structure at the base of the trimer which anchors it in the 
viral membrane (Figure 1.7 for diagrammatic representation) [89-92]. For gp120 this has 
elucidated some important characteristics for immune evasion where 1) the positioning of the 
V1V2 region at the trimer apex restricts access to the CD4 binding site below [92]; 2) access 
to this region is further hindered by a number of neighbouring glycans [93, 94]; 3) with another 
set of conserved glycans, this time at the base of the V3 region and 4) the combination of the 
V1V2 region and the solitary glycan N197 in the V2 region severely obstructs access to the 




Figure 1.7 Diagram depicting the structure of the Envelope trimer (includes antibody binding 
sites).  
The main regions in Env which are targeted by broadly neutralising antibodies are colour coded 
(orange: CD4 binding site, purple: V3-glycan supersite, green: V1/V2 region and grey: MPER), with 
respective, representative broadly neutralising F(ab)s shown approximately to scale (NIH45-46, 
PGT128, PG16 and 2F5) or lines indicating the approximate region for the gp120/gp41 interface, 
fusion peptide and silent face centre (under Fab NIH45-46). Table depicts additional examples of 
bnAbs for the respective regions in Env [adapted from: [96]]. 
1.6 HIV-1 and immune evasion 
Several unique features in HIV-1 are responsible for proficient evasion of the human immune 
system (Figure 1.8), and most of these characteristics are hampering the design of an 
effective prophylactic vaccine. HIV-1 can only infect cells which express the CD4 receptor and 
co-receptors CCR5 or CXCR4 on their plasma membrane. Unfortunately, these CD4+ cells 
are macrophages, dendritic cells and especially helper T cells (specifically CD4+ T cells), 
which are an integral part of the adaptive immune response and which will be lost upon 
persistent infection. Not only are CD4+ cells killed as a result of infection and/or viral 
replication, but it has also been shown that apoptosis can be induced in uninfected CD4+ 
bystander cells. This can lead to severely impaired lymph nodes, which generally consist of a 
large quantity of CD4+ target cells or antigen-presenting cells [97-99]. This can be a fairly slow 
process, as after integration of the HIV-1 viral DNA into the host cell genome, the virus 
generally replicates extremely slowly or can even lie dormant for a prolonged amount of time, 
thus creating a latent HIV-1 reservoir. This trait amplifies the effect of the broad sequence 
diversity observed in HIV-1. The high error rate of the viral reverse transcriptase, 1–10 
mutations/genome/replication cycle, is the underlying mechanism of this sequence variability 
and can lead to 5–10% sequence divergence in a single infected person [99]. From this, one 
can imagine that a Darwinian environment evolves in which mutations in HIV-1 allows escape 
from the surveillance of the (adapting) immune system. 
 
 
Figure 1.8. Main features in HIV-1 underlying immune evasion. [Adapted from [99, 100]]. 
 
Considering that Env is the only viral protein present on the outside of the HIV-1 virion (Figure 
1.3), and is therefore an ideal target for the immune response to prevent infection, an 
anthrompomorphic observer might conclude that the virus has gone to great lengths to keep 
the immunogenicity of the Envelope glycoprotein to a minimum. The HIV-1 virion itself has an 
extremely low Env surface density (~14 spikes per virion), which could hamper the immune 
response by preventing cross-linking between surface-bound antibodies and/or induction of 
an effective B-cell response, due to the large distance between spikes [34, 101-105]. In the 
host cell, Env is initially produced as the protein precursor gp160 and entered into the 
secretory pathway, where it multimerises into trimers in the endoplasmic reticulum (ER) with 
further processing and cleavage into gp120 and gp41 by furin proteases taking place in the 
Golgi [34, 99, 106, 107]. When in the ER, Env gets heavily glycosylated, acquiring 
approximately half of its molecular weight in glycans, thereby protecting immunogenic regions 
with a glycan shield [99, 108-110]. Because of the non-covalent link between gp120 and gp41, 
the two subunits can readily dissociate, leading to unbound, monomeric gp120 and gp41 
stumps on the plasma membrane and virion in a process called shedding. Both dissociated 
components will present immunodominant, non-neutralising epitopes, which can divert the 
antibody-based immune response towards non-neutralising epitopes in a similar way as 
misfolded and non-functional Env epitopes [99, 111, 112]. In a process called breathing, the 
native Env trimer can switch between conformations which can lead to exposure of different 
epitopes, further confounding the immune response [99, 100, 113]. In a final immune-
protective measure, although the binding of Env to CD4 leads to a conformational change 
opening up the native trimer in order to present the binding epitopes to the co-receptor, this 
happens in close proximity to the plasma membrane, therefore hampering access of 
antibodies that could potentially prevent cell entry of the virion [99, 114].  
1.7 The neutralising antibody response during natural infection 
As mentioned previously, the only protein presented on the HIV-1 virion is Env. It is therefore 
not surprising that although antibodies to other HIV-1 proteins do develop, Env is the main 
target for the antibody response in an infected person. In general, this response starts with 
the production of binding Abs, followed by strain-specific neutralising antibodies (nAbs, 
autologous) and these sometimes develop into cross-neutralising antibodies [115]. The initial 
response consists of non-neutralising antibodies, with antibodies against free gp41 and gp120 
in general developing within the first month of infection [116]. This is followed by the 
appearance of autologous nAbs which can take between 3 to 12 months to develop [110, 117]. 
In general these nAbs are targeted towards the V1V2 or V3 region, although interestingly for 
HIV-1 subtype C, the C3-V4 region is more commonly targeted by these strain-specific 
neutralising antibodies [118-120]. However, both these non-neutralising and strain-specific 
neutralising antibodies have negligible effect on viraemia [110, 116, 117]. The latter probably 
due to their slow development from which the circulating virus can readily escape via the 
mechanisms outlined in Section 1.6 [110, 117]. 
Depending on the criteria used to define broadly cross-neutralising antibodies (bnAbs) and/or 
study cohort, 10-50% of infected individuals develop these bnAbs [121-129]. An extremely 
small proportion of these individuals, defined as elite neutralisers, go on to develop potent, 
cross-clade bnAbs which are able to neutralise the bulk of HIV-1 viruses [125]. In most cases 
the development of this bnAbs response takes over 2.5 years, at which stage the virus has 
already established a latent reservoir [129, 130]. It is therefore thought that there is minimal 
clinical advantage of these bnAbs for the infected individual by then, although some viraemic 
control has been suggested [121, 127, 131, 132]. Interestingly, administration of bnAbs in mice 
and non-human primates have shown to be protective in viral challenge models [133-152]. 
Although the exact mechanisms on how these bnAbs develop in infected individuals is beyond 
the scope of this thesis, additional background to this can be found in an excellent review from 
2018 by Subbaramann et al. or the introduction to a paper on HIV-1 vaccine design by 
Seabright et al. in 2019 [151, 153].  
Over the last 30 years a large number of these bnAbs from infected individuals have been 
identified and characterised. It is interesting to note that every single bnAb for HIV-1 identified 
to date are directed against Env. Initially the identification was an extremely slow and laborious 
process involving phage display and human hybridomas [154-159]. Advances in technologies 
such as the use of large cohorts of infected individuals, high throughput screening of culture 
supernatant from memory B cells and single cell sorting of HIV-1 specific B cells developed in 
the late 2000s accelerated the identification of bnAbs from HIV-1 infected individuals 
massively [121, 125, 160-164]. These early identified bnAbs are now usually referred to as 
First-generation bnAbs, whereas bnAbs identified after 2008/9 are known as Second-
generation bnAbs with the latter in general showing increased breadth and potency in their 
neutralisation profile compared to the First-generation bnAbs. With the identification and 
characterisation of these bnAbs a picture has emerged of several sites of vulnerability within 
Env that are specifically targeted (Figure 1.7). These regions are nowadays defined as the 
CD4 binding site, V3 glycan supersite, V1V2 region (trimer apex), MPER region of gp41, the 
gp120-gp41 interface, silent face centre and fusion peptide [96, 100, 165, 166]. An in depth 
analysis of the  HIV-1 bnAb field lies outside the remit of this thesis. However, a recent review 
published in 2020 by Wang and Zhang can be recommended for that [166].  
The flipside of the identification of the different bnAbs and their site of recognition allows them 
to be used to interrogate the presence of these epitopes in Env and the structure of Env 
produced for vaccines. Together with our collaborators at NICD in Johannesburg, South 
Africa, a panel was selected which allows this for CD4 binding site, V3 glycan supersite, V1V2 
region (trimer apex) and MPER region of gp41 (Table 1.1). Three of the bnAbs selected 
(PG16, PGT145 and CAP256 VRC26.08) are of particular interest as they only recognise 
native-like Env and are the gold standard in assessing correctly folded Env trimers [167]. 
Whereas F105 and 447-52D, originally identified as bnAbs [168, 169] are nowadays regarded 




Table 1.1 Overview bnAbs and MAbs used for characterisation of Env vaccines in this thesis  
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1.8 Justification for an HIV-1 vaccine 
The decline in both new HIV-1 infections and AIDS-related deaths can for a large part be 
ascribed to a combined strategy of blood product screening [176, 177], education/counselling 
of the public and health workers, condom use [178-184], free hypodermic needles for drug 
users [185], male circumcision [186-189] and antiretroviral therapy (ART) [190-195]. The latter 
not only prevents disease progression in HIV-1 infected patients but by decreasing viral loads 
below detectable levels, counteracts transmission to sexual partners and mother-to-child 
transmission. Furthermore, when given as Pre-Exposure Prophylaxis (PrEP) it can prevent 
infection [196-198]. However, adherence to life-long antiretroviral medication is challenging 
[199-204]. The stigmatisation of HIV-1 positive individuals and ART/PrEP usage is another 
reason for the lack of compliance [205-209]. Whereas costs can form a barrier as well, even 
after countries start with free ART treatment [210-213]. It is also worth noting that in developing 
countries and especially in sub-Saharan Africa, there is still a lack of access to treatment for 
HIV-1 infected individuals [214]. All of this could be compounding factors as to why the current 
predictions of the 2020 UNAIDS goals (90-90-90 targets, where 90% of people living which 
HIV-1 are diagnosed as such, from which 90% will will receive sustained antiretroviral therapy, 
resulting in viral suppression in 90% of these individuals by 2020) will not be reached, leading 
to higher new HIV-1 infection and AIDS-related death rates then was aimed for under these 
goals (Figure 1.9A+B) [31]. Therefore, the development prophylactic HIV-1 vaccine would 
hugely benefit the effort to control the HIV-1 pandemic in a similar way to how vaccines have 
been able to eradicate or nearly eliminate severe and/or life-threatening infectious diseases 
such as smallpox [215], measles [216, 217] and polio [218, 219]. Diseases such as malaria, 
meningitis, diphtheria, hepatitis B, tetanus, mumps and rubella, are now controlled in 
especially the developed world through vaccines and healthcare management [220]. Although 
research into a prophylactic HIV-1 vaccine has been hugely frustrating in the last 35 years, 
the 31% efficacy of a HIV-1 vaccine used in the RV144 clinical trial [221] has reinvigorated the 
field again, and top experts have suggested that a HIV-1 vaccine with suboptimal efficacy 
would be sufficient to control the epidemic if combined with other prevention and treatment 





Figure 1.9. Global numbers in new HIV infections.  
(A) The number of new HIV infections, worldwide, 1990–2018 and 2020 target.  
(B) The number of AIDS-related deaths, global, 1990–2018 and 2020 goal [both taken from: [31]]. 
 
There is reason to be optimistic that an HIV-1 vaccine is achievable. Even though the 
development of nAbs and bnAbs against Env in HIV-1 infected individuals fails to impact 
clininal outcome, when the administration of a select number of bnAbs were tested in non-
human primates and humanised mice, this was protective in viral challenge models [133-152]. 
Furthermore, cell-mediated immune responses to other HIV-1 genes have been implicated in 
viraemic control. CD4+ and CD8+ T-cell responses especially towards Gag are correlated with 
decreased viral loads in natural infection of children, long-term non-progressors (HIV-1 
positive controlling viral replication, not developing AIDS, viral loads <1000 HIV RNA 
copies/ml) and elite controllers (as long-term non-progressors but viral loads <50 copies/ml) 
[224-229]. Interestingly, in so called HIV-exposed seronegative (HESN) individuals, such as 
observed within commercial sex workers cohorts, persistent T-cell responses towards Gag 
are low, but detectable [230-232]. Therefore, a cell-mediated immune response could be 
important in controlling viraemia and potentially disease progression or viral transmission 
[233]. This suggests that a vaccine regimen combining HIV-1 Env for the induction of an 
antibody response, together with Gag for generating a cell-mediated response, would have 
the best chance to succeed. 
1.9 Preventative HIV-1 vaccines in clinical trials 
It is not by want of effort in the last 35 years that the development of a prophylactic HIV-1 
vaccine has eluded scientists. Currently, for instance, there are more than 25 recruiting and/or 
active phase I HIV vaccine clinical trials ongoing (search on https://clinicaltrials.gov). However, 
few of these studies make it into Phase IIb/II, with only six completed studies (See Section 
1.9.1). Even in these studies, only one (RV144) resulted in modest protection in HIV-1 
acquisition [234]. A mechanism in which HIV-1 evades the immune system such as was 
discussed in section 1.5 might be underlying this lack of success, and specifically the focus in 
earlier vaccines on immunising with gp120. However, the outcome of these studies have been 
taken into account, and in recent years two new studies have entered Phase IIb/III testing 
(discussed in Section 1.9.2). Furthermore, several novel vaccine strategies aimed at inducing 
broadly neutralising antibodies, dubbed HIV-1 vaccine 2.0 by Professor R. W. Sanders at the 
2018 HIV R4P meeting in Madrid [222], are entering vaccine safety testing in healthy 
volunteers and will be briefly highlighted in Section 1.9.3.  
1.9.1 HIV-1 vaccines evaluated in efficacy trials 
In the 6 Phase IIb/III studies finished to date, with the vaccine design similar in VAX003 to 
VAX004 and HVTN 502 to HVTN 503, four different vaccine concepts have been tested in 
late-phase clinical trials studies (Table 1.2). 
Table 1.2 Overview of all finalised Phase II/III HIV-1 clinical trials investigating prophylactic vaccines 
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Table 1.2 Overview of all finalised Phase II/III HIV-1 clinical trials investigating prophylactic vaccines (continued) 
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* For HIV infection. HVTN: human vaccine trials network; MSM: men who have sex with men; ADCC: antibody-dependent cellular cytotoxicity; ADCVI: 
antibody-dependant cell-mediated viral inhibition. Ad5: Adenovirus type 5 Table adapted from: [221, 245-247]  
In the late 90s, VAX003 and VAX004 were the first prophylactic HIV-1 vaccines to be tested 
in efficacy studies. In these trials, recombinant Env subunit vaccines were tested to prevent 
HIV-1 infection by inducing neutralising antibodies [235, 236, 248]. Both studies consisted of 
bivalent monomeric gp120 protein vaccines adjuvanted in alum, but differed in vaccine antigen 
depending on trial site, with Subtype B (viral isolates MN and GNE8) in VAX004 (USA and 
The Netherlands) and Subtype B/E (viral isolates MN and CRF01_AE CM244) in VAX003 
(Thailand). Furthermore, different groups at risk of HIV-1 acquisition were tested with MSM 
(men who have sex with men) and heterosexual individuals in VAX004 compared to injecting 
drug users in Thailand. However, both studies failed to show any vaccine efficacy in preventing 
HIV-1 acquisition or affect post-acquisition HIV-1 viraemia [235, 236]. This disappointing 
outcome can probably be mainly attributed to vaccine design, as these recombinant Env 
subunit vaccines only induced neutralising antibodies against laboratory-adapted HIV-1 
isolates (Tier 1) but failed to induce neutralising antibodies against primary HIV-1 strains in 
sera from the matching phase I trial [249]. Similarly, sera collected in VAX003 only caused 
weak and transient neutralisation against Tier 1 HIV-1 isolates [250]. 
A second vaccine concept was tested in the HVTN 502 (STEP) and HVTN 503 (Phambili) 
studies: this used a replication defective-adenovirus serotype 5 (Ad5) vector for the expression 
of Gag, Pol and Nef antigens in order to induce cell-mediated immune response which might 
result in protection and/or control viraemia [237, 240, 245, 251]. The rationale for this concept 
can be explained with the observations that a robust T-cell response has been associated with 
viral control in both nonhuman primate models and more importantly patients which are long 
term non-progressors after HIV-1 infection [252-256]. In both HVTN 502 and HVTN 503 the 
same Clade B vaccine was tested, this was matched to the primary circulating HIV-1 virus for 
HVTN 502 (North America, the Caribbean, South America and Australia), but not for HVTN 
503 (South Africa, Subtype C) [237, 240]. Unfortunately, already during the active phase of 
the HVTN 502 trial, an increase in HIV-1 acquisition was observed in the vaccine arm 
compared to the placebo group which was associated with circumcision state and pre-existing 
immunity towards Ad5 [237, 238]. A similar higher rate in HIV-1 infection was consequently 
observed in the then recently started HVTN 503 study, although without the association of the 
same risk factors as reported for HVTN 502 [241]. Because of the lack of vaccine efficacy and 
more importantly, the increased HIV-1 acquisition rates, both trials were terminated 
prematurely. In a subsequent study in NHPs it was found that chronic infection with Ad5 prior 
to a rAd5 vaccine containing SIVmac239 Gag, Pol and Nef increased the number of activated 
CD4+ T-cells, which correlated with an increased acquisition in a SIV challenge model [257]. 
This would suggest that pre-existing immunity in humans against Ad5 might have led to 
vaccine-induced increased CD4+ T-cell activation, thereby increasing the pool of HIV-1 target 
cells and thus making vaccinees more susceptible to HIV-1 acquisition. Therefore, these 
findings do underline the importance of avoiding vaccine platforms with circulating pre-existing 
immunity in the broader population for an effective HIV-1 vaccine. 
With HVTN 502 and 503 trials in mind, volunteers recruited from MSM and transgender risk 
groups in the USA were only enrolled into the Phase IIb HVTN 505 study if they were 
seronegative for Ad5 and circumcised [244]. In this trial, the Ad5 clade B Env and Gag-Pol 
fusion protein vaccine was primed with six different DNA vaccines (Subtype B Gag, Pol and 
Nef and Subtype A-C Env. Again, no vaccine efficacy was observed during this trial, although 
no increase in HIV-1 acquisition was reported either. The lack of effectiveness combined with 
the futility of a vaccine only safe in an Ad5 seronegative population, the study was terminated 
prematurely [244]. 
Despite disapproval within part of the vaccine research community upon initiating of the study 
due to a perceived lack of efficacy at earlier clinical testing of the regimen, the RV144 trial 
conducted in Thailand has so far been the only late-phase study resulting in partial protection 
in HIV-1 acquisition [234, 258]. The trial aimed at inducing both a cellular and humoral 
response in heterosexual volunteers by priming with a recombinant canarypox virus prime 
encoding Gag, Pol and Env (ALVAC-HIV [vCP1521]) which was boosted with ALVAC-HIV 
plus a bivalent gp120 protein vaccine (AIDSVAX B/E) formulated in the adjuvant alum with 
antigen sequences matched to circulating subtype B and CRF01_AE isolates [234]. The 
vaccine regimen resulted in moderate efficacy of 60.5% after one year. However, this declined 
over time resulting in the reported lower efficacy against HIV acquisition of 31.2% after 42 
months [234, 259]. Analysis of immune correlates identified serum IgA binding to Env to 
correlate directly with the rate of infection, whereas the protective effect of the vaccine was 
correlated to serum IgG binding to the V1V2-loop [243]. The importance of the V1V2-loop in 
vaccine efficacy was further emphasised in genetic sieve analysis where improved vaccine 
efficacy against viruses with the conserved residue K169 (as present in the vaccine) was 
observed [260, 261].  
Although antibody-dependent cellular cytotoxicity (ADCC) wasn’t a primary immune correlate, 
high levels of ADCC combined with low levels of low plasma IgA Env antibodies associated 
with a reduced risk of HIV-1 acquisition in a secondary analysis [243, 262]. Furthermore, 
ADCC towards HIV-1-infected CD4+ T cells was observed by several V2-specific monoclonal 
antibodies that were isolated from participants of the RV144 trial, again stressing the 
importance of the V1V2-loop in the vaccine efficacy in this study [263]. Interestingly, a 
comparison between RV144 and VAX003 trials which both used the same protein vaccine 
revealed that IgG3 responses correlated with protection in RV144 [264]. Re-evaluation of the 
CD4+ T-cell data from RV144 trial showed that the vaccine-induced two subsets of 
polyfunctional CD4+ T-cell, which correlated with decreased HIV-1 acquisition [265]. Some 
recent gene transcriptome studies using PBMCs isolated from participants of RV144 identified 
the IRF7 antiviral pathway as a correlate of protection from HIV-1 infection, whereas activation 
of mTORC1 was associated with the risk of acquisition [266]. It should be noted that all 
humoral correlates of protection from the RV144 trial are binding antibodies and not 
neutralising antibodies, and are primarily targeted towards the V2 region in Env, which should 
be taken into account in vaccine design and efficacy assays in vaccine studies. 
Several follow-up studies have been conducted with vaccinees of the RV144 trial, notably 
RV305 and RV306. In both studies, uninfected participants of RV144 received late boosts with 
either ALVAC-HIV, AIDSVAX B/E or a combination of both. So far only data from RV305 has 
been released. In this study volunteers received the two boosts 24 weeks apart 6-8 years after 
the conclusion of RV144. Transient increases in IgG binding to gp120 and the VV2-loop were 
reported when AIDSVAX B/E was part of the boosting, but not for ALVAC-HIV alone [242, 
267]. Interestingly, increased CD4+ functionality upon stimulation with HIV-1 Env peptides two 
weeks after each boost was reported for the same groups which displayed an increased 
humoral response [242]. 
1.9.2 Ongoing HIV-1 vaccine efficacy trials 
Currently, two efficacy trials are still underway, one in Africa and another study outside this 
continent which started in the second half of 2019 (Table 1.3). A third trial (HVTN 702 or 
Uhambo) which started in 2016 was recently cancelled. This particular study conducted in 
South Africa was aimed at building on the foundations of the RV144 trial. It was using the 
same canarypox virus (ALVAC) and boosting with a gp120 protein, but differed in several key 
elements: 1) antigens were matched to the main circulating subtype in southern Africa 
(subtype C) in ZM59 for membrane-anchored gp120 for the canarypox platform (ALVAC-HIV 
[vCP2438]) and TV1.C gp120 Env + 1086.C gp120 Env for proteins; 2) an additional ALVAC-
HIV [vCP2438] + bivalent gp120 Env boost was included and 3) a different adjuvant in MF59 
was selected for the current study [268, 269]. Unfortunately, from provisional analysis of the 
data emerged a picture of similar HIV-1 acquisitions rates for vaccinated and unvaccinated 
participants, and due to this lack in vaccine efficacy, the sponsors decided terminate the trial 
prematurely [270]. 
Table 1.3 Overview active Phase IIb/III HIV-1 prophylactic vaccine clinical trials  
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It should be noted that when the HVTN 702 protocol was tested in a Phase I study (HVTN 
100), it did perform better in inducing IgG binding antibodies to vaccine-matched gp120 
proteins, and inciting CD4+ T-cell responses upon ZM96.C env protein stimulation, compared 
to the data from vaccine matched assays for RV144 [268]. However, IgG binding antibodies 
towards the V1V2-loop in HVTN100 were observed in fewer individuals compared to RV144, 
which was disappointing as this was the main correlate of protection in that trial. Although the 
responder rate towards the V1V2-loop was lower in HVTN100, it was still well above predicted 
63% threshold needed for 50% vaccine efficacy using a V1V2 correlate of protection model 
[268]. Strong neutralising antibody responses were measured for highly sensitive Tier 1A 
isolates, whereas the response rates dropped for slightly less susceptible Tier 1B isolates; no 
Tier 2 isolates were neutralised [268]. Interestingly, in a vaccine safety study in South Africa 
(HVTN 097) where the exact regimen of RV144 was combined with a tetanus toxoid vaccine 
and hepatitis B vaccine, significantly higher cellular and humoral immune responses were 
measured compared to those in RV144, despite the use of Subtype B/E antigens [271]. It will 
be interesting whether it can be established if any of these observations from HVTN 100 and 
097 are responsible for the failure of the HVTN 702 study. 
A new vaccine concept is being tested in the first currently active efficacy trial with the use of 
mosaic antigens. Mosaic sequences (Mos) are generated in silico to maximise potential T-cell 
epitopes within the antigen, thereby hopefully increasing immunogenicity [272]. Participants 
from southern Africa in the HVTN 705 (Imbokodo) study will receive a total of four vaccinations 
with a mixture of four different adenovirus serotype 26 (Ad26) vectors for the expression of 
Mos1.Env, Mos2.Env Ad26.Mos1.Gag-Pol, Ad26.Mos2.Gag-Pol, with all mosaic sequences 
based on Group M HIV-1 viruses. For the last two inoculations, vaccinees will also receive 
trimeric Clade C gp140 protein (isolate C97ZA.012). Therefore both a cellular and humoral 
response will be anticipated. Although the Ad5 vaccine platform was discredited in the HVTN 
502 and HVTN 503 studies, the Ad26 vector is deemed to be much safer in humans [273]. In 
the APPROACH phase I/IIa clinical trial similar vaccine regimen was tested with the only 
difference being that Ad26.Mos2.Env wasn’t included. In the APPROACH study, all 
participants developed binding antibodies against vaccine matched clade C gp140, several 
cross-clade gp140 isolates and the V1V2-loop in 81% of vaccinees. Furthermore, antibody-
dependent cellular phagocytosis was detected in 80% of participants after the final boost. 
Moderate neutralising antibody responses were measured for a highly sensitive Tier 1A 
isolate, with neutralisation observed against Tier 2 isolates. Apart from these antibody 
responses, cellular immune responses against Env, Gag and Pol peptide pools were observed 
in most participants as well [273]. With these exciting results obtained in HVTN 100, HVTN 
097 and APPROACH phase I/IIa clinical trials, the results of the Uhambo and Imbokodo 
studies are eagerly anticipated. 
A second Phase III clinical trial (HVTN 706) has started at the end of 2019: this is in design 
reasonably similar to the HVTN 705 study, but contains a Clade C and Mosaic gp140 HIV 
bivalent protein vaccine instead. Furthermore, this study is conducted in a geographical region 
outside of sub-Saharan Africa (USA, Mexico, Brazil, Argentina and Europe), and will enrol 
cisgender men and transgender individuals having sex with cisgender men and/or transgender 
individuals, rather than women at risk of HIV-1 acquisition. 
Although not HIV-1 vaccine studies, two other essential efficacy trials for HIV-1 prevention are 
currently underway. HVTN 703/HPTN 081 and HVTN 704/HPTN 085 are both studies into 
Antibody Mediated Prevention (AMP). Conducted in either women in sub-Saharan Africa 
(HVTN703) or men and transgender persons who have sex with men in North America, South 
America, and Switzerland (HVTN704), participants are receiving the anti-Env broadly 
neutralising monoclonal antibody VRC01 intravenously every 8 week for two years to test if 
neutralising antibodies can prevent HIV-1 acquisition in a human setting. Complete protection 
was observed against SHIV challenge in rhesus macaques after infusion of VRC01 [152]. 
Results for both efficacy studies are expected in late 2020. I do not support these studies for 
the reason that HIV-1 viral breakthrough events will almost certainly occur because only a 
single monoclonal antibody is used, which negates the idea of a prevention study.  
1.9.3 HIV-1 vaccine 2.0 
Discussing all the different HIV-1 vaccine hypotheses currently being tested in Phase I/IIa 
clinical trials will go beyond the purpose of this review. However, with the recent pre-clinical 
HIV-1 vaccine studies heavily focussed on inducing broadly-neutralising antibodies (bnAbs) 
towards circulating HIV-1 sequences (Tier 2) in animal models, I will discuss a subset of Phase 
I safety studies testing several vaccine concepts aiming to achieve this in humans (Table 1.4). 
These ideas were dissected into four different hypotheses at the 2018 HIV R4P meeting in 
Madrid, and coined “HIV-1 vaccine 2.0” [222]. Most of these have been covered in a review in 
the same year by Kwong and Mascola [274]. The first principle was developed around 
molecular strategies for producing correctly folded Env trimers as protein vaccines which 
resemble the native trimer on HIV-1 virions (in-depth discussion in Section 1.10.3). One of 
the earliest successful examples of this is soluble, trimeric cleavage-dependent BG505.664 
SOSIP Env, which has now entered phase I clinical trials (IVAI W001) [275-277]. Similar 
studies are also planned for Env protein vaccines ConM SOSIP.v7 and ConS SOSL.UFO. 
 
Table 1.4 Phase I HIV-1 vaccine clinical trials investigating HIV-1 vaccine 2.0 
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IAVI: The International AIDS Vaccine Initiative. Data from: https://clinicaltrials.gov/ 
 
The next two strategies are collectively known as antibody lineage-based vaccine design or B 
cell ontogeny-based vaccine design, which is aimed at guiding the immune system through 
the different stages or B-cell lineages to arrive at the final B-cell producing the intended broadly 
neutralising antibody [274]. This can potentially be achieved in vaccinees with a series of 
lineage Env immunogens from individuals who developed broadly neutralising antibodies 
against Env over time after HIV-1 infection. An approach which was effective in an animal 
model, using four different gp120 sequences matched to those which developed during natural 
infection with virus isolate CH505, will be administered as sequential protein vaccines in the 
Phase I clinical study HVTN 115 [278]. Similar studies are planned for CH505 SOSIP series 
and Env SOSIP trimers from acute neutralisers. 
In a far more specific concept, engagement of specific bnAb germline precursor B cells by 
specific germline-targeting Env immunogens will be tested to investigate if this will lead to the 
induction of this bnAb. For the bnAb VRC01, such a strategy has been developed with the 
germline-targeting immunogen (eOD-GT8) which has progressed to a Phase I clinical study 
(IAVI G001) [279]. 
In the final hypothesis, bnAbs are to be induced by epitope focusing to circumvent potential 
immune-dominant non-neutralising epitopes within the Env sequence. Two different strategies 
using fusion-peptide targeting immunogen FP8_v1-rTTHC and MPER liposomes have been 
used successfully in animal models [280-283]. The latter is currently being tested in the Phase 
I clinical trial HVTN 133. 
1.10 Vaccine platforms 
Vaccines which are currently approved for the use in humans can broadly be divided in two 
groups. The first contains whole pathogens which are either live-attenuated or inactivated 
preparations to reduce or remove the pathogen virulency. Safety concerns (such as reversion 
of attenuated vaccine, recombination between vaccine and circulating virus and incomplete 
inactivation) with regards to an HIV-1 vaccine using these whole pathogen approach makes 
these strategies non-viable options. Therefore, there is an intense focus on the second group 
of vaccines, which are defined by the use of only a part of the pathogen. This group includes 
toxoid vaccines, carbohydrate vaccines, conjugate vaccines and antigen vaccines. Antigen 
vaccines can be either the purified (recombinant) protein or antigen expression from vectors. 
For HIV-1 vaccines, a broad array of these expression vectors have been tested as vaccine 
platforms, including naked DNA plasmids, bacteria (such as Mycobacterium bovis Bacille 
Calmette Guerin (BCG)), and replication competent and attenuated viruses. Especially the 
viral platforms have received a lot of attention in the HIV-1 vaccine research community, with 
the current focus on adenovirus (Ad) 5 alternatives such as Ad35 and Ad26; poxviral vectors 
(including ALVAC, NYVAC and MVA); and replication competent viral vectors (for example 
rhCMV and rVSV). With such a vast array of different vaccine platforms used for HIV-1 
vaccines, it is beyond the scope of this thesis to review all of them and the focus will be on the 
platforms used in this thesis, which is DNA, recombinant MVA and protein vaccines. An 
excellent review on HIV-1 viral vaccine vectors was recently published by Alayo et al. [284]. 
1.10.1 DNA vaccines 
The use of plasmid DNA as a vaccine regimen is a relatively recent development, first explored 
in mice for an influenza vaccine in the early 1990s [285]. The interest in DNA vaccines can be 
explained by its multiple apparent advantages in usage: 1) production is relatively cheap, easy 
and similar between different vaccines; 2) vaccines are thermostable and can be lyophilised 
for additional stability, thereby decreasing the cost of the supply chain; 3) plasmid DNA has 
no risk of virulence and is safe in humans even when they are immunocompromised; 4) no 
anti-vector immunity is anticipated; and 5) multiple antigens can be targeted by combining 
different vaccines [286]. The main mechanism of action through which DNA vaccines work is 
by inducing a cellular response to antigens expressed within transfected cells, where antigen 
presenting cells (APCs) are either activated directly or indirectly within the inoculation site. In 
the first instance, APCs themselves have taken up the DNA vaccine, whereas in the latter they 
are activated by non-immune cells which express the antigen after uptake of the DNA vaccine. 
Subsequent migration of the activated APCs towards draining lymph nodes results in antigen 
presentation leading to the induction of immune responses [287-291]. Furthermore, antigen 
presentation from DNA vaccines by APCs is through the major histocompatibility complex 
molecules class I, similar as for viral pathogens upon infection [292]. However, it should be 
emphasised that in general DNA vaccines only induce a short and transient cell-mediated 
immune response, and usually fail to induce an antibody response. This lack in 
immunogenicity of DNA vaccines is reflected in the fact that so far, no DNA vaccine has been 
licensed for use in humans [286]. Nonetheless, they are being investigated in clinical trials for 
the use in HIV-1 vaccines and although these have mainly been Phase I studies, DNA 
vaccines were used in the vaccine efficacy study HVTN 505.  
Research has gone into enhancing the weak immunogenicity of DNA vaccines. For instance, 
measures include improving DNA, mRNA and protein (including codon usage) characteristics, 
resulting in increased stability, translation and expression [293-298]. These kinds of 
modifications can of course be used for all recombinant systems, including viral and protein 
expression platforms. Next, improving expression of DNA vaccine can be achieved by 
promoter and/or enhancer usage within the plasmid, which can consequentely enhance the 
immune response [286, 299-302]. As an example, in this thesis an enhanced mammalian 
expression plasmid pTHpCapR was used, which was shown to enhance in vitro expression 
and in vivo immunogenicity compared to the unaltered donor plasmid pTH, which has 
previously been used in HIV vaccine trials [286, 299]. Furthermore, DNA vaccine delivery 
methods such as electroporation and the use of needleless devices such as from PharmaJet 
can also increase immunogenicity [303-310]. Additionally, genetic adjuvanting (co-expression 
of immunomodulatory genes such as IL-2 or GM-CSF) and use of polymer or lipid adjuvants 
have also been shown to improve the immune responses to DNA vaccines [311-313]. 
1.10.2 Modified Vaccinia Ankara (MVA) virus vaccines 
The use of vaccinia virus (VACV) as a smallpox vaccine was instrumental in the eradication 
of variola virus. One of the reasons why VACV was so effective is that it was an infectious live 
vaccine. Despite the successful campaign, incidental cases of severe complications, including 
fatalities upon VACV administration, have been reported. Therefore, it was proposed to 
generate attenuated strains of VACV to assist in the eradication approach. An example of this 
is the highly attenuated modified vaccinia Ankara (MVA) virus, obtained after passaging a 
Turkish VACV strain almost 600 times in chick embryo fibroblasts (CEFs) [314]. This caused 
mutations and large deletions of the genome (~15%), resulting in MVA becoming replication -
deficient in mammalian cells (including in humans), bar a handful of select cell lines [315-317]. 
Many of the genetic changes affected genes with functions in virus–host interaction, which 
may underlie this replication deficient phenotype [316, 317]. MVA was used on a small scale 
in Germany as part of the smallpox eradication campaign, in which no severe adverse 
reactions associated with VACV were reported, indicating MVA as a safe vaccine platform 
[318, 319]. Therefore, MVA is now frequently used as a vaccine platform for the expression of 
recombinant antigens. MVA has several key advantages over other viral vaccine platforms: 1) 
MVA replicates and is located solely in the cytoplasm, minimising integration into the host 
genome; 2) MVA can tolerate large insertions of DNA (>15kbp), and when an antigen (or 
multiple) is inserted into the MVA genome under a pox promoter, strong transgene expression 
is observed in vitro and in vivo; 3) MVA is thermostable and can be lyophilised for additional 
stability, thereby decreasing the cost of the supply chain; 4) MVA can induce both a humoral 
and cellular response; and 5) high titres stocks of recombinant MVA can be generated in CEFs 
and BHK-21 cells, both can be used in cGMP production of vaccines. The induction of a strong 
humoral and cellular immune response could be due to self-adjuvanting effects of MVA: these 
are due to the deletion of viral immunomodulators within the MVA genome, which could lead 
to immune response skewing towards genes (antigens) inserted into recombinant vector [317, 
320, 321]. Finally, as vaccinations after the eradication of smallpox have ceased since 1979, 
a large proportion of the worldwide population, especially those <40 years of age, will have 
very little chance of developing vector immunity towards MVA. Incidentally, this same age 
group is mostly at risk for becoming HIV-1 infected, especially in southern Africa. All of this 
underlines the attractiveness of recombinant MVA as a vaccine platform. A particularly 
thorough review on all aspects of MVA was published by Volz and Sutter in 2018 if more 
background is required [317]. 
1.10.3 Protein vaccines 
A popular component of experimental HIV-1 vaccines is the use of Env protein to induce a 
mainly humoral immune response. Protein vaccines are highly successful in activating B-cells 
to produce antigen-specific binding antibodies. However, the aim of an Env protein vaccine is 
to induce antibody pathway maturation in B-cells towards generating antibodies which can 
neutralise HIV-1 viral entry into cells - preferably to a broad spectrum of HIV-1 isolates - and/or 
antibodies that have antibody-dependent cell-mediated effector cell functions [99, 100]. The 
advantage of using Env protein vaccines is that the antigen can be specifically designed and 
purified to contain the specific characteristics for inducing this kind of B-cell maturation, which 
might not easily be feasible for DNA and viral vector based vaccines platforms. The safety 
risks for protein vaccines are extremely low as they contain no live viral components. However, 
the immune response is much less broad compared to whole cell vaccines or viral vector 
vaccine platforms, and could be even different. For instance, the subunit vaccine for pertussis 
(whooping cough) used in children by some countries induces a Th2 response compared to 
Th1 + Th17 for the inactivated, whole cell preparation vaccine. These differences might be 
one of the underlying factors in the increase in pertussis disease rates observed in children 
that received the subunit vaccine, even though one of the main correlates of protection are 
pertussis toxin antibodies [322-325]. Furthermore, production costs of complex proteins are 
often extremely high, and vaccine thermostability is poor especially upon lyophilising, thus 
requiring increased supply chain costs.  
1.10.4 Heterologous use of vaccine platforms (prime-boost) 
As HIV-1 is particularly efficient in evading the immune system, an effective vaccine will almost 
certainly require the activation of both the cellular and humoral arms of the immune response. 
Although most vaccines exert their effectiveness through an antibody response*, cell-
mediated immunity plays a crucial role in inducing this response, mainly through activation of 
T follicular helper (Tfh) cells and CD4+ T cells [246, 326, 327]. Tfh cells play a pivotal role in 
this process within the germinal centre by stimulating B-cell proliferation, antibody affinity 
maturation and B-cell differentiation, which, as mentioned above, are thought to be extremely 
important for the induction of neutralising antibodies [246, 328]. This effect can be enhanced 
by vaccine boosting [246, 329]. Considering the different qualities of the vaccine platforms 
(DNA: cellular immunity; MVA or other viral platforms: cellular+humoral immunity; and protein: 
humoral immunity), heterologous vaccine platform prime-boosting could potentially broaden 
the immune response by activating both arms of the adaptive immune response, preventing 
the potential development of vector-based immunity when multiple vaccines are required. 
Further improvements on these kind of heterologous vaccine platform regimens can be 
realised by the addition of different Env sequences. This is of course not a novel concept and 
has been extensively used in the development of an HIV-1 vaccine: for instance, past (RV144, 
HVTN 505) and current (HVTN 702, 705 and 706) phase II-III clinical trials have made use of 
this strategy. With regard to the vaccine platforms used in the experiments discussed in this 
thesis, combinations involving MVA have been extensively studied by different groups [273, 
330-358], either as a prime for protein vaccines and/or boost for DNA or other viral vaccine 
platforms. These experiments have given rise to the notion that although DNA vaccines in 
general lead to a fairly weak immune response, they are very effective in priming cell-mediated 
immune responses towards MVA, whereas MVA itself acts as an excellent prime for protein 
vaccines. These studies using MVA in different heterologous vaccine platform regimens have 
not only been done in animal models [343-358], but also in clinical trials [273, 330-342]. A final 
advantage worth considering for the use of heterologous vaccines platforms over especially a 
protein vaccine alone, is the much lower production and supply chain costs of DNA and MVA 
compared to protein vaccines. Developing a vaccine regimen which requires substantially less 
protein vaccines would be a more cost-effective solution.  
*Authors note: most clinical tests are antibody based, whereas testing of cellular responses is much 
less common. Therefore the importance of cell-mediated responses as correlates of protection could 
be grossly underestimated [359]. 
1.11 Vaccine adjuvants 
With the advantage of an improved safety profile of subunit vaccines comes the disadvantage 
of decreased immunogenicity with the lack of the whole pathogen [360]. Therefore, adjuvants 
have been widely used to improve the vaccine-induced immune response, where the adjuvant 
acts as an immunomodulator or immune potentiator of the immune response targeted by the 
vaccine. Surprisingly, there is only limited research into vaccine adjuvants, resulting in only a 
very small number of reagents being approved by the FDA (Food and Drug Administration , 
USA) for the use in human vaccines [361]. HIV-1 vaccines have mainly been adjuvanted using 
aluminium salts, but recently scientists have started to utilise AS01B (liposomes with MPL + 
QS-21) and oil-in-water emulsions such as MF59 and AS03 (based on [362]). In my research, 
the adjuvants AlhydroGel and AddaVax were selected to test if they could improve the 
immunogenicity of the soluble Env protein vaccine: both will be discussed briefly below. An 
informative review on all FDA approved adjuvants was recently published by Shi et al. [361]. 
1.11.1 Aluminium salt-based adjuvants (AlhydroGel) 
Aluminium salt-based vaccine adjuvants have been used for at least 80 years, and were for a 
long period of time the only adjuvant approved in human vaccines. Currently, different 
formulations such as aluminium hydroxide, aluminium phosphate and amorphous aluminium 
hydroxyphosphate sulphate are approved by the FDA [361]. Of these formulations, a 2% 
aluminium hydroxide wet gel suspension, often referred to as alum, is the most widely used 
for HIV-1 vaccines. In the research for this thesis, alum was acquired from InvivoGen under 
the brand name AlhydroGel®.  
Aluminium adjuvants mainly enhance antibody based immune responses without significantly 
promoting Th1 cellular responses [361]. Originally it was assumed that this was mainly 
accomplished by the adjuvant acting as a depot for the adsorbed antigen, resulting in a slow 
release at the inoculation site [361]. However, later studies have falsified this concept. In mice, 
aluminium phosphate-adsorbed antigen is rapidly cleared from the injection site, and removal 
of the inoculation site containing alum several hours after administration of ovalbumin-
adsorbed alum had no effect on the antibody responses [363, 364]. The immune enhancing 
properties of aluminium adjuvants can however be explained through several other 
mechanisms. Firstly, they enhance infiltration of immune cells into the injection site, with these 
cells subsequently migrating to the draining lymph node [365]. Secondly, they increase antigen 
uptake and presentation by antigen presenting cells [361], and inflamosome activation via the 
nucleotide-binding oligomerization domain-like receptors (NLR) pathway, specifically through 
the pattern recognition receptor NLRP4 [361]. Furthermore, interaction of aluminium adjuvants 
with the membrane of dendritic cells enhances soluble antigen uptake and induces lipid 
reordering in the membranes of dendritic cells and CD4+ T-cells, increasing antigen uptake 
for the first while activating the latter [361]. Furthermore, evidence is emerging that aluminium 
adjuvants can both stimulate and induce differentiation of CD4+ T-cells. Finally, activation of 
the complement system by aluminium hydroxide has been reported as well [361]. Interestingly, 
several of the mechanisms of the immunostimulatory effects of aluminium adjuvants described 
above are through a cellular response, despite its reputation as acting mainly though the Th2 
antibody response. 
1.11.2 Oil-in-water emulsion adjuvant AddaVax 
The oil-in-water nano-emulsion AddaVax from InvivoGen is similar in formulation to the 
Novartis adjuvant MF59, in containing squalene (a natural oil originally derived from shark 
liver), Tween 80 and sorbitan trioleate buffered in trisodium citrate dehydrate 
(https://www.invivogen.com/addavax and [366]). Although MF59 is licensed and mainly used 
for influenza vaccines, it has replaced alum (used in the RV144 trial) as adjuvant for the HVTN 
702 study. As MF59 not only improves antigen specific antibody production, it also enhances 
both Th1 and Th2 immune responses, therefore making MF59 in theory an attractive adjuvant 
compared to aluminium adjuvants [361]. The main mechanism by which MF59 enhances 
immunogenicity is by creating an immune competent environment in the injection site. 
Attracted immune cells show improved antigen uptake and are stimulated to produce and 
secrete different chemokines and cytokines, leading to additional influx of immune cells into 
the injection site [361]. Upon antigen uptake and activation, these different classes of antigen 
presenting cells accumulate in the draining lymph nodes where it is proposed they can prime 
naïve CD4+ T-cells [361]. 
1.12 Modifications to improve the antigenic profile of Env 
The majority of vaccines which are licensed for the use in humans exert their protective 
properties through the induction of an effective broadly neutralising antibody response towards 
the pathogen [325]. Therefore, this remains the main target for an HIV-1 vaccine as well. This 
of course limits the target selection to the envelope glycoprotein, despite the fact that Env-
specific bnAbs development in infected individuals fails to improve clinical outcomes 
(discussed in Section 1.7). In favour of the notion that the induction of bnAbs against Env 
could be protective in HIV-1 acquisition are experiments in non-human primates and 
humanised mice, in which administration of bnAbs are protective in viral challenge models 
[133-152]. Encouragingly, bnAbs concentrations showing efficacy in some of these 
experiments are within the range which could be achieved with vaccines [142, 147, 151]. 
However, this raises a new issue as to how to induce this bnAb response using HIV-1 Env 
vaccines. Almost all bnAb epitopes are conformational, formed by the quaternary structure of 
the Env trimer, so that mAbs interact with the different, correctly folded subunits [112, 165, 
367, 368]. Therefore the characteristics of native-like Env trimers need to be reflected in the 
vaccine design, as a large proportion of misfolded Env would skew the antibody response 
towards immunodominant non-neutralising epitopes. Design concepts and modifications of 
Env relevant to this thesis are discussed below. Additional approaches can be found in 
Section 1.9.3. 
1.12.1 Stabilising the Env trimer 
Two vital issues need to be addressed in this project in order to get to the stage where a high 
proportion of Env produced as a vaccine is in this favoured native-like conformation. Critical 
for this was the use of soluble Env constructs lacking the transmembrane and cytoplasmic tail 
by truncation at residue 664 [369]. First was the observation that proteolytic cleavage of the 
polyprotein into gp120 and gp41 is essential for the formation of native-like trimers [370, 371]. 
Co-expression of furin and optimisation of the native furin cleavage site in Env (from REKR to 
6x Arg residues, RRRRRR) significantly improves processing of Env by furin [372]. This 
elegant solution now amplified the second problem, in which the non-covalent link between 
gp120 and gp41 is readily disrupted in a process called shedding, leading to disassembly of 
the trimer which again would result in the display of immunodominant non-neutralising 
epitopes. The most well studied solution to this was the introduction of a de novo disulphide 
bond (SOS) between gp120 and gp41, thereby stabilising the two subunits after cleavage 
[373]. In seminal work, this SOS mutation was combined with the single amino acid mutation 
I559P that stabilize the pre-fusion conformation of gp41 and promote trimer formation in the 
subtype A transmitted/founder virus BG505 [374]. Expression of this BG505 SOSIP.664 
resulted in high levels of native-like Env trimers presenting mainly bnAbs epitopes, which was 
poorly recognised by non-neutralising antibodies [275, 375, 376]. As a protein vaccine tested 
in rabbits, BG505 SOSIP.664 trimers were the first to induce robust, vaccine matched 
(autologous) Tier 2 neutralising antibodies (nAbs) [277]. These immunogenicity results and 
high-resolution X-ray and cryo-electron microscopic structures of BG505 SOSIP.664 have 
assisted towards improvements in (BG505 SOSIP.664) trimer design and has been 
fundamental in developing SOSIP trimers for different Env sequences which are now eliciting 
Abs that cross-react with different subtypes [377, 378]. For instance, BG505 SOSIP.664 
mutants are now being generated with improved presentation of bnAb epitopes in the V2 
region, whilst displaying increased trimer stability [379]. Another has the V3 region, considered 
neutralisation irrelevant, being sequestered away within the trimer, resulting in decreased 
induction of V3 binding antibodies without affecting the autologous Tier 2 neutralisation 
response [380]. Encouragingly, rhesus macaques vaccinated with native-like SOSIP Env 
trimers displayed protection in a vaccine matched SHIV challenge model, but only when serum 
contained high nAb titres [381]. An informative review was written in 2018 by Torrents de la 
Peña and Sanders about the evolution of SOSIP Envs over the years [377]. 
To emphasise that the generation of native-like Env trimers is extremely complicated, and that 
there is no guarantee of success, can be seen in an example where this was applied to an 
Env consensus M sequence (ConM) [382]. ConM SOSIP.v6 failed to produce enough protein 
required for characterisation full stop. Protein yields were improved when based on a 
SOSIP.v4.2 design (four additional mutation to SOSIP) or on SOSIP.v5.2 (v4.2 plus additional 
intermolecular disulphide bond). However, high-quality trimer yields were much lower 
compared to SOSIP.v7, which contained eight additional amino acid mutations within the 
trimer interface based on BG505. Disappointingly, despite the excellent in vitro properties of 
ConM SOSIP.v7, when it was subsequently tested as a protein vaccine in rabbits, sera was 
all but devoid of autologous Tier 2 neutralisation. 
Alternative strategies circumventing the need for processing of Env by furin to produce native-
like Env trimers have also been developed. In one approach, the furin site was replaced with 
a flexible linker: these were initially of varying size, but work by Sharma et al. let to identification 
of an optimal motif (GGGGS GGGGS) that is being used often nowadays [383, 384]. From 
that same paper, the name native flexible linker (NFL) was dubbed, which is now the defining 
name of this concept as long as native-like Env trimers are produced. Interestingly, SOSIP-
stabilising mutations improve native-like trimer yields from these NFL Env constructs [371, 
384, 385]. As with SOSIP Envs, additional mutations improving trimer stability are identified 
regularly [371, 384-387]. Although not as intensively studied in animal models as SOSIP Envs, 
it has been shown that NFL Envs are able to induce nAbs as well [386, 388-395].  
A completely novel approach was taken by Kong et al., where in silico modelling was utilised 
to re-design the HR1 region in gp41, which led to the stabilisation of uncleaved trimers in a 
pre-fusion conformation (UFO). This led to increased trimer stability compared to equivalent 
SOSIP constructs [396]. Subsequent testing of these UFO Env trimers in animal models 
showed the induction of Tier 2 nAbs [397]. 
In the context of work reported in this thesis, heterologous platforms in DNA, recombinant 
MVA and protein vaccines were to be tested. Given that the first two strategies rely on host-
cell expression of the Env antigen where adequate furin processing might not take place, it 
was decided to opt for introduction of the same flexible linker as optimised by Sharma et al. 
[384]. A case in point for this decision was that poor furin cleavage was observed for BG505 
SOSIP.664 expressed in vitro from chimpanzee adenovirus (ChAd) and MVA vaccines [343]. 
For the protein vaccine used in this thesis, Env was truncated at a similar position as BG505 
SOSIP.664, whereas for DNA and MVA vaccines the transmembrane domain was retained 
(see Section 1.12.2 for further information). However, gp160 was truncated to AA 730, which 
was shown to result in higher expression levels and increased stability of gp150, the latter 
holding especially true for the rMVA platform [398-400]. Furthermore, the I559P mutation was 
included in the constructs used within this project; however, the original intramolecular 
cysteine bridge between gp41 and gp120 (SOS) was not included. 
1.12.2 Presentation of Env on virus-like particles 
Recently, there has been an increased interest in particulate vaccine designs for displaying 
Env. These can take form of self-assembling protein nanoparticles such as virus-like particles 
(VLPs), those which use protein scaffolds (for example, the popular bacterial protein ferritin), 
or synthetic nanoparticles including lipid nanoparticles/liposomes, silica nanoparticles and 
particles based on polymers [401, 402]. Interestingly, the recombinant protein subunit 
vaccines currently licensed for hepatitis B and human papillomavirus are VLP-based vaccines 
[403, 404]. A particulate vaccine approach could be an especially powerful tool for presenting 
Env antigens: for example, after isolation and purification of native-like trimers, these could be 
assembled into nanoparticles, which would circumvent the presentation of unwanted, non-
native Env epitopes on the underside of the Env trimer [401, 402, 405]. One of the main 
objectives of Env particulate vaccines is better engagement of B-cell activation, where the 
repetitive display of high density Env trimers might improve B cell receptor (BCR) cross-linking 
and could potentially compensate for low affinity antigen-BCR interactions between Env and 
naïve B-cells [402, 405]. One such approach is to display Env on the surface of HIV-1 Gag 
VLPs. Work from the early 1990s showed that Env readily incorporates into Pr55Gag VLPs 
when the proteins are co-expressed in vitro [406-412]. It has also been suggested that by 
anchoring Env into the native environment of a lipid bilayer, the trimeric conformation is further 
stabilised [405]. As discussed previously (Section 1.8), cell-mediated immune responses to 
especially HIV-1 Gag (CD4+ and CD8+ T-cell responses) have been implicated in viraemic 
control. Therefore, inclusion of Gag in a vaccine regimen has the potential to increase the 
efficacy of such a strategy; consequently, this concept has been widely used within the HIV-1 
vaccine community, including in vaccine efficacy studies such as RV144, HVTN 702, 705 and 
706. 
For the research presented in this thesis, the aim was to have VLP- based vaccines for the 
DNA and recombinant MVA vaccine platforms by either combining two DNA vaccines (one for 
Gag, the other for Env), or by co-expression of Gag and Env from the same recombinant MVA 
genome. For this purpose, a HIV-1 mosaic Gag sequence was selected. This sequence, 
designed in silico to maximise potential T-cell epitopes derived from HIV-1 subtype C 
sequences, was known to improve immunogenicity in mice as a BCG, DNA and recombinant 
MVA vaccine [272, 413, 414]. For Env to incorporate into VLPs, it would require the Env to 
contain the transmembrane domain and at least a partial cytoplasmic tail. However, while a 
shorter  tail is known to increase spike density, this could still potentially result in low Env spike 
density on the VLP, thereby thwarting the intended increased B-cell activation. Therefore, 
some modifications to the Env were included that could potentially lead to higher expression 
levels and therefore increase spike density on VLPs. As mentioned previously, the gp160 
encoding sequence was truncated in the C-terminal tail region so as to produce gp150, for 
improved stability and expression. Sequences were humancodon-optimised by GenScript, as 
these optimisations usually lead to significantly increased expression [294, 302, 415]. 
Additionally, replacing the native Env signal peptide with the commonly used human tissue 
plasminogen activator (tPA) leader could potentially increase cellular trafficking towards the 
plasma membrane and subsequent budding and/or secretion [302, 399, 416, 417].  
Alternatively, a number of labs have used chimaeric constructs between HIV-1 Env and 
glycoproteins from high spike-density viruses to improve HIV-1 Env display on virus-like 
particles. In general, this was done by replacing the transmembrane domain (TM) and 
cytoplasmic tail (CT) of gp41 with those of other viral glycoproteins, in combination with 
changing the Env native signal peptide. In one early paper, the whole of HIV-1 Env gp41 was 
replaced with the TM of Epstein–Barr virus gp220/350 (EBV) without changes to signal peptide 
[418]. The display of this resulting gp120-EBV-TM fusion protein onto Gag VLPs was 10 times 
higher compared to the equivalent HIV-1 gp160 [418]. Significantly increased incorporation of 
Env chimaeras into Gag VLPs produced in insect cells was also observed when the TM and 
CT of HIV-1 Env was replaced with those of the mouse mammary tumour virus, influenza 
haemagglutinin or baculovirus gp64 envelope glycoproteins, in combination with honeybee 
melittin protein signal peptide (HMSS) instead of the HIV-1 Env native signal peptide [399, 
419]. Similar results were obtained for a SOSIP modified gp140 containing the HMSS and 
fused to the TM and CT of baculovirus gp64 envelope glycoprotein [420]. It should however 
be emphasised that although spike density on HIV-1 Gag VLPs was increased for all the Env 
chimaeras, folding of these constructs was never assessed with bnAbs recognising only 
native-like Env trimers. Furthermore, when some of these VLP preparations were tested as 
vaccines in animal models, they failed to induce vaccine-matched Tier 2 neutralisation. For 
this thesis, Env chimaeric constructs were designed using the influenza haemagglutinin 
protein HA2 from the influenza A H5N1 strain. Either the whole HIV-1 gp41 was replaced with 
influenza haemagglutinin HA2, or only the TM and CT of gp41 would be substituted for the 
corresponding domain of HA2. These chimaeric Env (Env:HA2 chimaeras) constructs would 
then be characterised in depth in vitro, including spike density on Gag VLPs, bnAb epitope 
mapping on cell-surface expressed protein and immunogenicity in rabbits, and compared to 
the corresponding HIV-1 gp150 construct. One of the driving reasons for the selection of 
influenza haemagglutinin HA2 to generate these Env:HA2 chimaeras has been that depending 
on the expression platform, these proteins can assemble into particles without the need of 
Gag or other structural viral proteins [421]. An overview of all the different Env and Env:HA2 
chimaeras that were generated for the work in this thesis can be found in Figure 1.10. 
 
Figure 1.10. Schematic representation of Env immunogens.  
Env constructs in bold and italics were generated. HIV-1 Env gp120 in red, corresponding influenza 
HA1 in purple. In white ectodomain (ecto), transmembrane domain (TM) and cytoplasmic tail (cyto) 
modules of HIV-1 Env gp41 and matching influenza HA2 domains in blue. A flexible linker (FL) 
consisting of two glycine rich motifs (GGGGS) replaced the Env furin cleavage site. The I559P 
mutation was introduced to stabilise the gp41 trimer and is present in all Env immunogens apart from 
gp120HA2. Env immunogens containing a transmembrane domain were used for DNA and rMVA 
vaccines whereas the transmembrane domain was removed to generate a soluble Env (gp140) for 
the protein vaccine. For all constructs the Env native signal peptide was replaced with the tissue 
plasminogen activator (tPA) leader. 
 
1.13 Concluding remarks 
Despite over 35 years of research into prophylactic HIV-1 vaccines, progress has been 
underwhelming. In general, the main lessons learned is what doesn’t work, rather than what 
does. Even after stretching the analysis of the only partially successful clinical trial (RV144) 
as far as possible in order to gain insight into correlates of protection, this has failed to aid 
vaccine design, as can be seen from the early termination of the follow-up Phase IIb/III clinical 
trial HVTN 702 in Africa due to lack of vaccine efficacy. Part of the problem is the lack of 
effective pre-clinical models. Small animal models such as guinea pigs and rabbits are being 
used to investigate vaccine-induced bnAbs. However, the immune systems in these models 
are poorly understood, and although guinea pigs and rabbits can develop bnAbs to a certain 
degree, the underlying mechanisms are unknown. Furthermore, research is hampered by the 
fact that no assays are available to assess cellular responses (T-cell assays) in guinea pigs 
and rabbits. To top this off, translatability between small animal models and non-human 
primates (NHPs) is weak, with vaccine-induced development of bnAbs in one model not being 
predictive to garner the same response in the other. Challenge models in NHPs present their 
own set of problems, as in general these either consist of simian immunodeficiency virus (SIV) 
or SHIV (SIV but Env adapted from HIV-1 Env sequences), and therefore fail to completely 
mimic HIV-1 infection and progression to AIDS. The humanised mouse model is even more 
precarious. In this model, the bone marrow of severe combined immunodeficiency (SCID) 
mice is destroyed with radiotherapy and replaced with material from human embryonic tissue 
whereupon these mice are subjected to vaccine regimens. The question is how informative 
data from immune responses in these extremely sick and severely immune-compromised 
animals really is.  
The current obsession in the HIV-1 vaccine community with Env-based protein vaccines, B 
cell ontogeny-based vaccines and the induction of bnAbs appears misguided, or at the least 
flawed. The flimsy evidence of bnAbs being protective in NHP challenge models can be 
counteracted with evidence where 1) no clinical benefits are reported in HIV-1 infected 
individuals which develop bnAbs; 2) viraemic control is correlated CD4+ and CD8+ T-cell 
responses towards Gag, not the development of bnAbs; and furthermore 3) development of 
bnAbs was also not a correlate of protection in the RV144 trial. Even if bnAbs against HIV-1 
Env are protective against acquisition, as is the case for almost all other vaccines licensed for 
human use, the scientific community has so far failed to develop a vaccine regimen that 
induces this in animal models. Infusion of bnAbs as in the AMP trials (HVTN 702 and 704) is 
aspirational at most, as the production volumes needed and the cost of application will be 
extremely prohibitive, to say nothing of the impracticalities of rolling out mass intravenous 
infusions. Additionally, adherence to monthly or even annual treatments will slowly diminish 
over time, putting people back at risk.Furthermore, the logistics and infrastructure for mass 
rollout in developing countries for this kind treatment is essentially nonexistent.  
There is, however, some reason for optimism as well. Even though currently no vaccine 
regimens are able to induce bnAbs, HVTN 702 and 704 will inform the scientific community if 
the induction of bnAbs in humans could potentially be protective against HIV-1 acquisition. 
Furthermore, the vaccine efficacy trials HVTN 705 and 706 where mosaic antigens 
theoretically could result in improved immunogenicity compared to all other regimens tested, 
as a superior cell-mediated response is anticipated because of the mosaic antigens which 
could prime the antibody/humoral response more effectively. However, it is clear that there is 
still a long way to go and additional pre-clinical work is required. The work presented in this 
thesis fits nicely into this category. HIV-1 subtype C Env and Gag antigens were selected to 
target the prevalent subtype circulating in South Africa. Furthermore, the Env sequence was 
modified to improve stability and trimer formation. For Gag, a subtype C mosaic Gag was 
selected which already had been shown to result in improved immunogenicity compared to a 
naturally occurring subtype C Gag. As a final remark though, the best advice is still as it was 
40 years ago: that is, protect yourself, have safe sex, please use a condom. 
1.14 Project aims 
The HIV/AIDS pandemic is putting a large burden on the social economics of developing 
countries. Developing an effective vaccine against HIV, therefore, would be both a large step 
towards eradication of AIDS, and towards improved economies. As HIV-1 subtype C is the 
most prominent strain in sub-Saharan Africa, in this project the aim was to generate and 
characterise HIV-1 subtype C (1C) candidate immunogens that will induce high titre antibody 
responses to HIV-1 envelope glycoproteins (Env), as well as generating neutralising 
antibodies in rabbits.  
To achieve the aforementioned aims the following objectives are addressed: 
1. Generation and in vitro characterisation of a soluble Env protein vaccine candidate. 
2. Immunogenicity studies in rabbits testing the immune enhancing properties of different 
adjuvants for the soluble Env protein vaccine. 
3. Generation and in vitro characterisation of DNA and recombinant MVA vaccine 
platforms which express Env alone, or Env combined with Gag (including VLP 
formation) 
4. Immunogenicity studies in rabbits testing different heterologous vaccine platforms in 
prime-boost regimens: these are comparing recombinant MVA vaccines with or without 
DNA priming, boosted by a soluble Env protein vaccine with the preferred adjuvant 
from Objective 2. This will include characterising the effect of the inclusion of Gag in 
the DNA and recombinant MVA vaccines 
5. Generation and in vitro characterisation of DNA and recombinant MVA vaccine 
platforms which express Env or Env:HA2 chimaeras, all combined with Gag to allow 
VLP formation 
6. Immunogenicity studies in rabbits with an optimised vaccine regimen (objective 4), 
comparing Env to Env:HA2 chimaeras in the relevant DNA and/or recombinant MVA 
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2.1 Introduction 
The remit of this project was to develop a HIV-1 subtype C vaccine for sub-Saharan Africa 
eliciting high-titre antibody responses to HIV-1 envelope glycoproteins (Env). Therefore, a 
subtype C Env sequence was chosen from the Centre for the AIDS Programme of Research 
in South Africa (CAPRISA) 002 acute infection cohort [167, 174]. This particular virus was the 
superinfecting virus (SU) from participant CAP256 who developed broadly cross-neutralising 
antibodies targeting the V1V2 loop 15 weeks after the second viral infection event. 
Furthermore, the CAP256_SU virus was shown to be sensitive to a range of broadly 
neutralising antibodies (bnAbs) targeting different epitopes within the Env sequence [167]. 
Therefore this Env sequence has the potential not only to induce high-titre antibodies towards 
Env, but also to elicit a neutralising antibody response in animal models. The sequence of 
CAP256_SU Env will be referred to as CAP256 Env throughout this thesis. 
The emphasis in current HIV-1 vaccine research on developing neutralising responses is 
mainly with the use of protein vaccines, focused on soluble, native-like Env trimers [367, 368]. 
Mammalian cell lines are the main vehicle for the production of HIV-1 Env protein vaccines 
[275, 383-385, 422], with HEK293, HEK293T and CHO-K1 cells, using transient and stable 
expression platforms, being explored for production of a soluble CAP256 Env mimetic. To this 
end, and keeping in mind the ever-increasing knowledge base as to how to manipulate soluble 
Env proteins to direct the immune response towards desired attributes within Env [377], I 
investigated several modifications of CAP256 Env aimed at making a stable, immunogenic 
trimeric molecule. I focussed on making a soluble CAP256 Env mimetic generated by 
removing the cytoplasmic tail and transmembrane domain, with the truncation in a similar 
position as for BG505 SOSIP [275]. Similarly, I investigated stabilising the gp41 trimer by 
introducing the I559P present in BG505 SOSIP [275, 374]. In order to prevent furin processing, 
which is necessary for the Env trimer to take on a native-like conformation, I tested use of a 
glycine-rich flexible linker which successfully mimics this folding event [384]. Lastly, I 
investigated replacing the native single peptide of Env with the human tissue plasminogen 
activator (tPA) leader, as a means of improving secretion [416, 417]. 
Following successful scale up of production in the laboratory, the aim was to purify and 
characterise the CAP256 soluble Env produced in mammalian cells, and test the 
immunogenicity of the protein vaccine in rabbit immunogenicity studies. Considering protein 
vaccines have a tendency to be poorly immunogenic, different vaccine adjuvants were to be 
tested in order to improve the immune response in the animals [360]. Adjuvants act as 
immunomodulators or potentiators of the immune response targeted by the vaccine. HIV-1 
protein vaccines have mainly been adjuvanted using aluminium salts, but recently researchers 
have started to utilise AS01B (liposomes with MPL + QS-21) and oil-in-water emulsions such 
as MF59 and AS03 (based on [362]). In this project, the adjuvants AlhydroGel and AddaVax 
were selected to test their ability to improve the immunogenicity of the soluble CAP256 Env 
protein vaccine. AlhydroGel (InvivoGen) is a 2% aluminium hydroxide wet gel suspension and 
this formulation is often referred to as alum. The oil-in-water nano-emulsion AddaVax 
(InvivoGen) is similar in formulation to the Novartis adjuvant MF59 
(https://www.invivogen.com/addavax and [366]). Although MF59 is licensed and mainly used 
for influenza vaccines, it has replaced alum (used in the RV144 trial) as adjuvant for the HVTN 
702 study. As MF59 not only improves antigen specific antibody production, it also enhances 
both Th1 and Th2 immune responses, therefore making MF59 in theory an attractive adjuvant 
compared to aluminium adjuvants [361]. Importantly, both AlhydroGel and AddaVax have no 
detrimental effect on the native-like Env trimeric structure after adjuvanting [423]. 
2.2 Materials and methods 
2.2.1 Antibodies, plasmids, cell lines, media and reagents 
Goat anti-HIV-1 gp160 (MRC ADP 72 408/5104) (MRC, Potters Bar) and mouse monoclonal 
anti-goat/sheep IgG–AP GT34 (Sigma, St Louis) were used for western blotting. See Appendix 
A for western blot protocol. 
Chinese Hamster ovary cells subclone K1 (CHO-K1) (ATCC® CCL-61™), human embryonic 
kidney 293 cells (HEK293) (ATCC® CRL-1573™) and HEK293 cells expressing the simian 
virus 40 (SV40) large T antigen (HEK293T) cells (ATCC® CRL-3216™) (ATTC, Manassas) 
were grown in Dulbecco's Modified Eagle's medium (DMEM) High Glucose + L-Glutamine 
(Lonza, Basel) + 10% fetal calf serum (FCS) + 1x penicillin (Pen)/streptomycin (Strep) (both 
Thermo Fisher Scientific, Waltham). Serum-free medium: DMEM High Glucose + L-Glutamine 
+ 1x Pen/Strep. Small scale transfections (tissue culture plates) were performed using X-
TremeGENE (Roche, Basel), whereas large scale transfections (tissue culture flasks) were 
done with polyethyleneimine (PEI) (Sigma, St Louis). See Appendix B for tissue culture 
protocols. 
The enhanced mammalian expression plasmid pTHpCapR [299] was used as a backbone for 
all DNA expression plasmids.  
CAP256 SU V1V2 scaffolded protein was produced as described by McLellan et al. (2011) 
[424] and supplied by Professor Lynn Morris and Dr Penny Moore (NICD, Johannesburg). 
Anti-HIV-1 Env human monoclonal antibodies PG9, PG16, PGT128, PGT135, PGT145, 
CAP256-VRC26.08, VRC01, F105 and 447-52D were expressed in FreeStyle 293F cells 
(Thermo Fisher Scientific, Waltham) using the PEIMAX transfection reagent (Polysciences, 
Warrington). Monoclonal antibodies were purified from cell-free supernatants after 6 days 
using Protein-A affinity chromatography [425]. All these monoclonal antibodies were supplied 
by Professor Lynn Morris and Dr Penny Moore. 
CLC Main Workbench (Qiagen, Hilden) was used for in-silico cloning, generation of plasmid 
maps and DNA sequencing analysis. 
2.2.2 Design of soluble CAP256 Env 
The sequence of CAP256_SU gp160 (clone CAP256.206sp.032.C9) has been previously 
described (GenBank: KF241776.1) [167]. The Env sequence was altered as follows: the native 
leader (signal peptide) was removed; the furin cleavage site was replaced with two glycine-
serine based repeats (GGGGS) to form a flexible linker (FL) [383, 384], and an I548P mutation 
equivalent to the I559P in the SOSIP trimers was introduced to stabilise trimerisation of gp41 
[374]. Finally, the sequence was truncated to gp140 (AA 653), thus generating gp140-FL-IP. 
The Env sequences were human codon optimised and synthesised by GenScript (Nanjing).  
2.2.3 Soluble CAP256 Env expression plasmids 
The human tissue plasminogen activator (tPA) leader sequence (GenBank: CAX11668.1) was 
human codon optimised and synthesised by GenScript and cloned into pTHpCapR to increase 
secretion of the target antigen. This plasmid was renamed pMExT for Mammalian Expression 
with tPA leader (Figure 2.1A). CAP256 gp140-FL-IP was cloned into pMExT in-frame, behind 
the tPA leader using the NgoMIV and EcoRI sites to generate pMExT CAP256 gp140-FL-IP 
(Figure 2.1B). In this process, the NgoMIV site was lost. In order to create a stable cell line, 
an internal ribosome entry site + Neomycin resistance cassette (IRES Neo(RC)) was cloned 
directly downstream of CAP256 gp140-FL-IP in pMExT using EcoRI + XbaI restriction sites, 
thus generating pMExT CAP256 gp140-FL-IP IRES Neo(RC) (Figure 2.1C). The IRES 
Neo(RC) was synthesised by GenScript (Nanjing) with the Neo(RC) gene human codon 
optimised. An additional constructs were generated where a 6x His-tag with an alanine linker 
(AAA HHHHHH) was introduced in front of the STOP codon at the C-terminus of gp140-FL-IP 
to allow NiNTA trapping of soluble Env (pMExT gp140-FL-IP-His and pMExT gp140-FL-IP-




B) pMExT gp140-FL-IP 
 
C) pMExT CAP256 gp140-FL-IP IRES Neo(RC) 
 
Figure 2.1. Plasmid map of DNA vectors 
expressing CAP256 Env. 
(A-C) Amp(R): ampicillin resistance gene for 
bacterial selection. ColE1: bacterial origin of 
replication. Mammalian expression is driven by a 
promoter containing a porcine circovirus 
enhancer (pCAP) in the reverse orientation, the 
essential component of the CMV promoter 
(pCMV core) and the non-essential part of the 
CMV promoter (pCMV minor) for maximal 
expression. TPA leader: human tissue 
plasminogen activator leader sequence. IRES: 
internal ribosome entry site. Neo(RC): Neomycin 
resistance cassette. Arrows indicate the direction 





2.2.4 Generation of soluble Env stable cell lines 
The construct pMExT CAP256 gp140-FL-IP IRES Neo(RC) was transfected into HEK293 cells 
or CHO-K1 cells (T75 flask, 30µg plasmid DNA and 90µl PEI (Sigma, St Louis)) and passaged 
at least 10 times in medium containing 600µg/ml Geneticin (Thermo Fisher Scientific, 
Waltham) to generate the HEK293 or CHO CAP256 soluble Env stable cell line. Soluble Env 
expression was confirmed in media from these cells at passage 5 and 10 by western blotting. 
A stable cell line using CAP256 gp140-FL-IP-His IRES Neo(RC) in HEK293 cells was 
generated in a similar fashion. 
2.2.5 Soluble Env protein affinity purification 
2.2.5.1 Transient transfection of HEK293T cells 
For transient transfections, 20-30 confluent T150 flasks with HEK293T cells were switched to 
serum-free medium and transfected individually with 60µg of pMExT CAP256 gp140-FL-IP 
plasmid DNA and 180µl PEI. Agarose conjugated Galanthus nivalis lectin (Sigma, St Louis) 
affinity purification columns were used to purify CAP256 gp140-FL-IP (soluble Env) protein 
from media four days after transfection (Figure 2.2). Columns were first washed with 
PBS+0.5M NaCl, followed by PBS only. Protein was eluted in PBS + 1M methyl α-D-manno-
pyranoside (Sigma, St Louis) and subsequently concentrated and buffer exchanged into PBS 
using Vivaspin 20 MWCO 30 000 columns (GE Healthcare, Chicago). Thus purified CAP256 
soluble Env will be referred to throughout this dissertation as CAP256 soluble Env (GNL). 
100µl of concentrated protein was plated onto Luria Bertani (LB) agar plates without 
antibody selection, plates were incubated for 3 days at 37 °C to test for bacterial, fungal and 
yeast contamination. Protein was aliquoted and stored at -80°C for downstream usage. 
Protein concentration was determined using the DC Protein Assay (Bio-Rad, Hercules) 
against a BSA standard (Bio-Rad, Hercules) (see Appendix A for protocol). 
 
 
Figure 2.2. Schematic representation of CAP256 soluble Env protein isolation.  
Cleared media from HEK293 CAP256 soluble Env stable cell line or HEK293T cells transiently 
transfected with pMExT CAP256 gp140-FL-IP is dripped over an agarose lectin (Galanthus nivalis) 
affinity chromatography column using a peristaltic pump. After two wash steps, soluble Env is eluted 
off the column with ~50ml 1M methyl α-D-manno-pyranoside and concentrated to 5ml. 
 
2.2.5.2 HEK293 soluble Env stable cell lines 
Three to four Hyperflasks (Corning, New York) were coated with 0.006% w/v poly-l-lysine 
(Sigma, St Louis) in PBS (1 hour at 37°C) and seeded with HEK293 CAP256 soluble Env or 
HEK293 CAP256 soluble Env-His stable cell lines (passage >10) from two-three T175 flasks. 
An additional 50ml of FCS was added one day after seeding. When flasks had grown to 100% 
cell confluency, media was switched to serum-free and harvested after three days. CAP256 
soluble Env (GNL) isolation was performed as described above, including contaminant testing. 
The coating with Poly-L-Lysine allowed repeat harvesting where cells were switched from 
media + FCS (on Mondays) to serum-free media (on Fridays) for a total of 3-5 cycles. Protein 
concentration was determined using the DC Protein Assay against a BSA standard. 
2.5.5.3 Verification and characterisation 
To confirm isolation of soluble CAP256 Env protein and trimers, precast Native PAGE™ 
Novex® 3-12% Bis-Tris Protein Gels (Thermo Fisher Scientific, Waltham) were run. Gels were 
either stained with Bio-Safe Coomassie or blotted onto PVDF membrane (both Bio-Rad, 
Hercules) for western blotting. NativeMark™ Unstained Protein Standard (Thermo Fisher 
Scientific, Waltham) for native gel electrophoresis was used for estimating molecular weight. 
Furthermore, liquid chromatography–mass spectrometry, analysis and raking was performed 
by the Centre for Proteomic and Genomic Research (CPGR) in Cape Town to identify proteins 
present in CAP256 soluble Env (GNL) and CAP256 soluble, trimeric Env protein preparations. 
In order to characterise the antigenic structure of the CAP256 soluble Env protein isolated 
using the above strategies Ni-NTA HisSorb Plates (Qiagen, Hilden) were coated with 200 
ng/well CAP256 SU GP140-FL-IP-His protein for two hours at room temperature. 
Subsequently, plates were washed with PBS (3x) and blocked with 5% non-fat milk (Sigma, 
St Louis) in PBS (block buffer) for 1 hour at room temperature. After 3x PBS washes, plates 
were incubated with 100µl of serial dilutions (steps of 1:3) of anti-Env human monoclonal 
antibodies PG9, PG16, PGT128, PGT135, PGT145, CAP256 VRC26_08, VRC01, F105 and 
447-52D in block buffer. After 2 hours of incubation at room temperature, plates were washed 
with PBS (5x) and incubated with anti-human IgG HRP (1:10,000) (Dako, Santa Clara) in block 
buffer for one hour at room temperature. After washing with PBS (5x), 100µl TMB ELISA 
Substrate (Abcam, Cambridge) was added for detection and the reaction was stopped after 
10 minutes with 100µl 1N H2SO4. ELISA signal was analysed using a VersaMax ELISA 
Microplate Reader (Molecular Devices, Sunnyvale), which subtracted absorbance at 540 nm 
from 450 nm. Experiments were repeated for three different isolations (n=3) and these data 
points were averaged and fitted to a Four Parameter Logistic Regression curve (4PL curve) 
in GraphPad Prism 5.0 (GraphPad Software, San Diego). 
2.2.6 Rabbit immunisation for adjuvant testing using soluble Env protein 
Female New Zealand white rabbits were housed in the Research Animal Facility in the Faculty 
of Health Sciences at the University of Cape Town. All the animal procedures were approved 
by the UCT Animal Research Ethics Committee (UCT AEC 14-030 & UCT AEC 015/051) and 
performed by trained animal technologists Rodney Lucas and Inge Botes. The rabbits were 
monitored daily for any signs of pain, discomfort or stress and were weighed weekly. 
Three groups of 5 rabbits were selected to compare formulations of CAP256 soluble Env 
(GNL) protein with squalene oil-in-water emulsion AddaVax™ and with alum-based 
AlhydroGel® (both InvivoGen, San Diego) (see Table 2.1 for groups). Rabbits were 
immunised intramuscularly in the hind leg with 42-45µg of CAP256 soluble Env (GNL) in PBS, 
at weeks 0, 4, 12 and 20. The protein suspension was mixed 1:1 (v/v) with the adjuvants. All 
animals were bled 2 months before the first immunisation to obtain pre-bleed sera and were 
bled every four weeks once protein inoculations had started. Animals were sacrificed on week 
24. For the final collection of blood at the end of the experiment the rabbits received an 
intravenous injection of ACP, followed by a mixture of ketamine + xylazine and animals were 
monitored during treatment for respiratory rate, body temperature, heart rate and absence of 
pedal reflex. The rabbits were then exsanguinated.  
Table 2.1. Groups in adjuvant testing rabbit experiment 
 
2.2.7 Rabbit serum characterisation 
2.2.7.1 Soluble Env binding ELISA 
To assess Env binding antibody titres in rabbit sera, a matching soluble CAP256 Env binding 
ELISA was performed. Nunc MaxiSorp® flat-bottom 96 well plates (Sigma, St Louis) were 
coated with 10ng/well CAP256 soluble Env (GNL) overnight at 4°C. After protein coating, 
plates were washed 3x with PBS, blocked in PBS + 5% non-fat milk (block buffer) at room 
temperature for one hour. After washing (3x PBS), rabbit sera was used in the primary 
incubation in a serial dilution range in block buffer, starting at 1:10, for 2 hours at room 
temperature. Plates were washed 3x with PBS + 0.1% Tween20 (Sigma, St Louis) (PBST) 
and anti-rabbit IgG HRP (1:10,000 in block buffer) (Roche, Basel) was used for detection (1 
hour at room temperature). After washing (3x PBST) ELISA signal was visualised with TMB 
†
animal adjuvant 0 4 12 20 -10 4 8 12 16 20 22 24 †
1986 x (PBS)            
1987 x (PBS)            
1988 x (PBS)            
1995 x (PBS)            
1996 x (PBS)            
1989 AddaVax (1:1)            
1990 AddaVax (1:1)            
1991 AddaVax (1:1)            
1997 AddaVax (1:1)            
1998 AddaVax (1:1)            
1971*/1992** AlhydroGel (1:1)            
1993 AlhydroGel (1:1)            
1994 AlhydroGel (1:1)            
1999 AlhydroGel (1:1)            




week protein vaccine week serum collection
ELISA Substrate (Abcam, Cambridge). The reaction was stopped after 10 minutes with 1N 
H2SO4. The ELISA signal was analysed using a VersaMax ELISA Microplate Reader, which 
subtracted absorbance at 540nm from 450nm. ELISAs for the whole time course and each 
group were performed at the same time on duplicate plates. Duplicate data points were 
averaged and fitted to a 4PL curve in GraphPad Prism 5.0. Antibody end-point titres were 
calculated from 4PL curves with the threshold set as twice the geometric mean of the ELISA 
signal over the whole, matching pre-bleed serial dilution range: 
𝐸𝑛𝑑 𝑝𝑜𝑖𝑛𝑡 𝑡𝑖𝑡𝑟𝑒 = 𝐸𝐶50 ∗  (
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟 𝐶𝑢𝑟𝑣𝑒 𝑀𝑖𝑛





Data plotted as mean +/- SEM for whole group. 
2.2.7.2 V1V2-loop binding ELISA 
To test for antibodies to the CAP256_SU V1V2-loop, serum from the week 22 bleed was 
tested in a binding ELISA to CAP256 SU V1V2 scaffolded protein (provided by Penny Moore 
and Lynn Morris, NICD). A similar protocol was used as for soluble Env binding ELISA as 
described above with two permutations. 1) 500ng/well of CAP256 SU V1V2 scaffolded protein 
was coated onto MaxiSorp® flat-bottom 96 well plates and 2) PBST was replaced with PBS 
in all steps. 
2.2.7.3 Env-pseudotyped virus neutralisation 
Rabbit sera from different time points were tested for the ability to inhibit Env-pseudotyped 
virions to enter a reporter cell line. Neutralisation was measured as a reduction in luciferase 
gene expression after a single round of infection of JC53bl-13 cells, also known as TZM-bl 
cells (NIH AIDS Research and Reference Reagent Program), with Env-pseudotyped viruses 
(MW965.26, 6644, CA146, 1107356, CAP37, CT349, Du156, 188146, CAP256_SU, 
CAP256_SU K169E or BG0505N332+/CAP256_SU V1V2-loop and CAP84/CAP256_SU 
V1V2-loop). Titre was calculated as the reciprocal plasma/serum dilution causing a 50% 
reduction of relative light units (ID50). Dilutions were started at 1:20. For graphs, data was 
plotted as 19 when ID50 was <20. MuLV was used as negative control. 
All neutralisation assays were performed by Professor Lynn Morris’s group at Center for HIV 
and STIs, National Institute for Communicable Diseases of the National Health Laboratory 
Service, Johannesburg, South Africa. 
2.2.8 Statistical analysis 
All statistical analysis was performed in GraphPad Prism 5.0 and tests are indicated in results 
and/or corresponding figure legend 
2.3 Results 
2.3.1 Schematic overview of CAP256 Env 
The subtype C Env sequence chosen for this work was derived from the Centre for the AIDS 
Programme of Research in South Africa (CAPRISA) 002 acute infection cohort [167, 174]. 
This particular virus was the superinfecting virus (SU) from participant CAP256 who developed 
broadly cross-neutralising antibodies targeting the V1V2 loop 15 weeks after the second viral 
infection event and was labelled CAP256_SU. A range of modifications were introduced into 
CAP256_SU Env with the aim of increasing its yield, stability and immunogenicity (Figure 
2.3). Firstly, the native signal peptide was replaced with the commonly used human tissue 
plasminogen activator (tPA) leader to increase cellular trafficking towards the plasma 
membrane and subsequent budding and/or secretion [416, 417]. Next, the furin cleavage site 
was replaced with a flexible linker (FL) consisting of two repeats of glycine rich motif (GGGGS) 
based on the work of Sharma et al., 2015 [384] who showed that trimeric Env retained a native-
like state with this particular modification. This would alleviate the furin cleavage of gp120 from 
gp41 which can be inefficient in mammalian expression systems, and could result in 
incomplete processing and misfolded Env protein [107, 372]. Thirdly, the equivalent of the 
I559P mutation was introduced in CAP256 Env to stabilise the gp41 trimer [374]. Finally, the 
sequence was human codon optimised by GenScript (Nanjing) to increase expression levels. 
For protein vaccines, the transmembrane domain and cytoplasmic tail of gp160 were deleted 
by gene truncation to AA 653, equivalent to AA 664 for BG505 SOSIP.664, resulting in a 
presumably soluble Env protein which should be secreted from cells (Figure 2.3).  
 
Figure 2.3 CAP256 gp140-FL-IP protein vaccine design.  
Schematic representations comparing of wild type Env to soluble CAP256 Env (CAP256 gp140-FL-
IP) used for the experiments presented here. Truncation to amino acid 653 rendered CAP256 Env 
soluble, while containing further modifcations where the wild type signal peptide (HIV-1 SP) was 
replaced with the human tissue plasminogen activator (TPA) sequence, the furin cleavage site with 
a flexible linker (FL) sequence and an I559P mutation was introduced.  
 
2.3.2 Characterisation of affinity purified soluble Env 
In initial experiments, soluble Env was isolated from media of 20 T150 flasks transiently 
transfected with pMExT CAP256 gp140-FL-IP. This was done four days after transfection by 
lectin (Galanthus nivalis) affinity chromatography, with cells switched to media without FCS 
before transfection to prevent the Env being contaminated with large quantities of alpha-2-
macroglobulin. A clear enrichment in soluble Env levels, from (cleared) media to lectin column 
eluate and concentrated eluate, could be detected by western blotting of SDS PAGE gels 
(Figure 2.4A). However, some soluble Env failed to bind the column (lectin column flow-
through) and was washed off with the first wash step (PBS + 0.5M NaCl) or was lost during 
concentrating (conc. column flow through). A band of the same molecular weight as Env was 
detected in the concentrated eluate of a Coomassie stained gel (Figure 2.4B). This 
Coomassie stained gel also showed that this lectin eluate did not contain large amounts of 
impurities of other proteins, which was confirmed by liquid chromatography–mass 











Figure 2.4. Soluble Env expression from transiently and stably transfected HEK293 cells.  
(A) Soluble Env was affinity purified from cleared media of HEK293T cells transfected with CAP256 
gp140-FL-IP and was clearly enriched in concentrated (conc.) eluate compared to input (cleared 
media) as detected by α-Env western-blotting.  
(B) Coomassie staining revealed a protein band in the concentrated eluate of the same size as Env 
detected by western blotting indicating adequate yields.  
(C) Although a faint band for Env was detected by western blotting in media from the CHO CAP256 
gp140-FL-IP stable cell line (CHO-INC) at passage (P)11 and P12, levels were clearly much lower 
compared to the HEK293 CAP256 gp140-FL-IP stable cell line (HEK293-INC) at P4. (D) Soluble Env 
levels in the media of HE293K-INC were similar at P4, P9 and P11.  
 
Table 2.2. Top ten proteins identified in lectin affinity purified soluble Env by LC-MS.  
Ranking was based on |Log Probability| (third column). 
 
 
Although reasonable Env yields (Table 2.3) were obtained for small scale animal experiments 
as assessed by by Protein DC Assay with BSA standard, the transient platform was highly 
labour intensive for both tissue culture purposes and plasmid DNA generation, making it 
unsuitable for further upscaling. Therefore, stable cell lines were generated in both HEK293 
and CHO cells. For this an IRES-Neo(RC) was cloned directly behind the STOP codon of 
CAP256 gp140-FL-IP in pMExT (Figure 2.3). In this plasmid, Env and the neomycin 
resistance gene (Neo(RC) are expressed from the same promoter, with the IRES site allowing 
an additional binding site for the translational machinery to produce neomycin resistance 
(Geneticin in mammalian cells). This couples neomycin resistance to soluble Env expression, 
which favours good expression levels of soluble Env following selection. After initial 
transfection of pMExT CAP256 gp140-FL-IP, cells were passaged for 10 rounds (P10) under 
Geneticin selection after which the cell line was considered stable. Although both stable CHO 
and HEK293 CAP256 gp140-FL-IP (P>10) were resistant to Geneticin, only the latter showed 
high enough expression levels in media to be considered (Figure 2.4C). All lectin affinity 
purified CAP256 soluble Env isolated from stable cell lines discussed below is from HEK293 
CAP256 gp140-FL-IP (P>10). When yields were compared, isolations from the stable cell lines 
were similar to transient expression (n=2, Table 2.3). However, ease of use and repeat 
harvesting of the same flasks favours the stable cell line. Interestingly, soluble Env protein 
yields appeared to increase after the first harvest (Table 2.3). Note that transient expression 










# of unique 
peptides




1 CAP256 soluble Env 253.22 20766168743 1472 81 12 42.16
2 sp|P24821|TENA_HUMAN Tenascin 93.98 45076102.6 67 29 2 13.86
3 sp|P68371|TBB4B_HUMAN Tubulin beta-4B chain 74.64 136046989 95 21 6 32.58
4 sp|P07602|SAP_HUMAN Prosaposin 52.05 153907594.6 77 12 2 18.13
4 tr|C9JIZ6|C9JIZ6_HUMAN Prosaposin
5 sp|P14625|ENPL_HUMAN Endoplasmin 48.91 46242792 50 14 1 17.56
6 sp|P0DMV9|HS71B_HUMAN Heat shock 70 kDa protein 1B 48.01 69582202.8 58 16 2 22.78
6 sp|P0DMV8|HS71A_HUMAN Heat shock 70 kDa protein 1A
7 sp|P14543|NID1_HUMAN Nidogen-1 43.45 18829446.8 29 12 1 11.07
8 sp|Q92820|GGH_HUMAN Gamma-glutamyl hydrolase 41.64 24648663.1 37 14 2 32.39
9 sp|P07942|LAMB1_HUMAN Laminin subunit beta-1 41.44 20222558.8 26 11 0 7.89
9 tr|G3XAI2|G3XAI2_HUMAN Laminin subunit beta-1
10 sp|P11047|LAMC1_HUMAN Laminin subunit gamma-1 41.29 55247410.1 50 16 2 9.7
Table 2.3. Soluble Env protein yields after lectin affinity chromatography.  
Protein concentrations were measured using the DC Protein Assay against a BSA standard (three 
independent measurements per experimental sample and BSA standard concentration) 
 
 
To get an indication of the structural integrity of soluble Env isolated from the two platforms, 
lectin affinity purified protein was separated on Blue-Native PAGE gels and subsequently 
Coomassie stained or blotted using an α-Env antibody (Figure 2.5A+B). The profile appeared 
largely similar, consisting of mainly trimeric Env protein as determined by molecular weight. 
However, some monomeric Env, aggregates and dimers were present as well (in order of 
abundance). Surprisingly, when soluble Env-His was analysed in a similar fashion, the Env 
trimer appeared much less stable, with mainly Env monomers detected, with lower levels of 
Env dimers and almost no trimeric Env (Figure 2.5C). 
In an attempt to further characterise the Env quaternary structure and the presence of bnAb 
epitopes, several different ELISA protocols were assessed using Env bnAbs (Table 1.1). 
Trapping soluble Env straight on ELISA plates or using ELISA plates pre-coated with lectin 
(Galanthus nivalis) were unsuccessful (data not shown). Therefore, this was repeated with the 
His-tagged soluble Env, despite the unfavourable profile on Blue-Native PAGE gels. The bnAb 
10E8 was excluded from the analysis as soluble Env was truncated within the MPER binding 
region of this antibody. The bnAb epitopes detected for CAP256 soluble Env-His were for the 
V3-glycan supersite (PGT128 and PGT135), the CD4-binding site (VRC01) and the V1V2-
glycan bnAb PG9 (Figure 2.6A). However, no signal was observed for bnAbs that specifically 
detect native-like Env trimers (PGT145, PG16 and CAP256 VRC26.08) (Figure 2.6B). This 





transient 20x T150 1 0.17 0.93 0.05
transient 20x T150 2 0.18 1.00 0.05
stable 1A* 0.39 2.36 0.06
stable 1B* 0.61 3.67 0.09
stable 1C* 0.42 2.54 0.06
stable 1D* 0.49 2.95 0.07
stable 2A* 0.43 2.35 0.06
stable 2B* 0.70 3.85 0.10
stable 2C* 0.64 3.54 0.09
stable 2D* 1.01 5.56 0.14
stable 2E* 0.78 4.30 0.11











Figure 2.5. Characterisation of CAP256 soluble Env protein vaccines. 
Lectin affinity purified soluble Env (GNL) mainly consists in a trimeric conformation (***) as judged by 
molecular weight on BN PAGE gels stained by Coomassie (A) or as detected by Env western blotting 
(B), although some monomeric Env was detected as well (*). However, similarly purified soluble Env-
His is mainly in a monomeric (*) or dimeric (**) configuration with low levels of Env trimers (***) (C).  
Media: input on affinity chromatography column (Galanthus nivalis lectin conjugated agarose). 
 
presence of misfolded Env. The assay was verified by using a control His-tagged Env trimer 
(BG505 SOSIP.664, supplied by NICD) in parallel, where binding of all bnAbs tested was 
observed, with the lowest signal for F105 and 446-52D (Figure 2.6C), whereas the no protein 
control was negative (Figure 2.6D). 
2.3.3 Adjuvanting soluble Env with AlhydroGel® or AddaVax™  
2.3.3.1 Rabbit immunisation and serum anti-Env antibody characterisation 
This HIV-1 Env vaccine project was aimed at assessing different priming platforms (DNA 
alone, rMVA alone and DNA followed by rMVA) which were then boosted by a protein vaccine 
to induce higher α-Env binding antibody titres and viral neutralising antibody titres. However, 
the protein boosting effect can be highly influenced by adjuvanting as well. Therefore, in the 
first animal experiment the effect of different protein vaccine adjuvants was investigated. For 
this the adjuvant AddaVax™, a squalene-based oil-in-water nano-emulsion (MF59®-like) was 
compared to AlhydroGel® (aluminium hydroxide gel) in rabbits. The first can induce both 
cellular and humoral immune responses [426, 427], whereas the latter mainly enhances a Th2 
response [428]. A total of 40µg soluble Env (GNL) from transiently transfected HEK293T cells 
was injected intramuscularly in the rabbit hind leg in two different adjuvants (1:1 ratio) and 
compared to no adjuvant PBS control (Table 2.1, Figure 2.7A). The same soluble Env (GNL) 
was used to develop an in-house Env binding ELISA to test rabbit serum α-Env binding 









Figure 2.6. Soluble Env-His protein α-Env bnAb ELISA.  
Binding ELISAs using anti-Env human bnAbs to CAP256 gp140-FL-IP-His.(A) Several bnAb epitopes 
were verified to be present in CAP256 gp140-FL-IP-His: the Env V3-glycan supersite (PGT128 and 
PGT135), the CD4 binding site (VRC01) and the V2-glycan epitope (PG9). EC50 values, calculated 
from the curve fit, are given to indicate the affinity of each bnAb to Env. However, no native-like 
trimers are detected with bnAbs PGT145, PG16 and CAP256 VRC26.08 (B). Indicative of this are 
the positive ELISA signals for F105 and 446-52D, which recognise mainly misfolded trimers.  
(C) The assay was verified with a control protein: soluble, trimeric BG505_664-His Env. EC50 values, 
calculated from the curve fit, are given to indicate the affinity of each bnAb to Env.  
(D) No signal was observed in the no protein control (=PBS). 
 
titres compared to the PBS control group at all time points, animals in the AlhydroGel® group 
had significantly higher sera α-Env binding antibody levels over the whole time course 
compared to both the AddaVax™ and control groups (Two-way ANOVA; p<0.0001) (Figure 
2.7B). For all groups, α-Env binding antibody titres peaked at week 22, at a dilution of 1 in 
443,199 ±192,842 for the AlhydroGel group, 1 in 66,196 ±27,191 for AddaVax™ and 1 in 
71,398 ±34,647 for the PBS group. 
Binding antibodies against the V1V2 loop of Env are of particular interest as this was one of 
the main correlates of protection in the RV144 trial. Therefore, sera of the vaccinated animals 
at peak α-Env binding antibody titres (week 22) were tested in a binding ELISA against the 

























autologous CAP256 SU V1V2 loop: this was presented on a scaffold to retain the natively 
folded state [424], and was kindly provided Dr Penny Moore from the NICD. CAP256 soluble 
Env (GNL) was able to induce α-Env V1V2 loop-binding antibodies, and again end-point titres 
for the AlhydroGel® group were significantly higher compared to the other 2 groups (One-way 







Figure 2.7. Rabbit immunisation protocol and serum characterisation.  
(A) Immunisation regimen.  
(B) Rabbit sera soluble Env (GNL) binding ELISA. Soluble Env (GNL) adjuvanted in AlhydroGel® 
induces significantly higher serum anti-Env antibodies titres over the whole time course as compared 
to PBS control and AddaVax™ (Two-way ANOVA; * p<0.0001). Plates were coated with 10ng/well of 
soluble Env (GNL).  
(C) CAP256 SU V1V2 loop scaffold binding ELISA for week 22 sera. Animals inoculated with adjuvant 
AlhydroGel® had significantly higher binding to CAP256 V1V2 loop scaffold as compared to control 
group and AddaVax™ as adjuvant (One-way ANOVA; * p<0.05). Signal from week 0 was subtracted 
from week 22. Plates were coated with 500ng/well of scaffolded CAP256 V1V2-loop protein.  
All end point titres are plotted as group average ±SEM. 
 
2.3.3.2 Neutralisation responses after immunisation 
As expected from the two different binding ELISAs, soluble Env (GNL) adjuvanted in 
AlhydroGel® was superior at inducing antibodies that inhibited cell entry of Env-pseudotyped 
virions (Table 2.2, Figure 2.8A+B). This was most apparent for Tier 1A Clade C virions 
(MW965.26), where at all time points tested, the serum dilution resulting in a 50% decrease 
in cell entry (ID50), was significantly higher with all animals responding for the AlhydroGel® 
group, than for the control or AddaVax™ groups (Two-way ANOVA; p<0.05) (Figure 2.8B). 
Titres at week 16 and 22 were significantly higher (p<0.001 and p<0.05 respectively). Although 
a similar trend was observed for Tier 1A Clade B (MN.3), this was not significant. Tier 1B 
Clade C neutralisation titres were only assessed for week 22 sera (peak Env binding titres) 
and more animals in the AlhydroGel® group showed neutralisation of 6644, CA146, 1107356,  
Table 2.2. Serum neutralisation from rabbits vaccinated with different adjuvants as measured by TZM-bl assay.  
Sera from immunised animals were assessed for neutralising activity (serum dilution required for a 50% reduction in entry of the infecting virus into a reporter 
cell line (ID50) against a panel of Env-pseudotyped virions at different time points. The 50% neutralisation titres are color-coded to reflect their potency range 
as indicated.  







6644 CA146 1107356 CAP37 CT349 Du156 188146 MuLV
ID50 at
rabbit adjuvant pre w08 w16 w22 w24 pre w08 w16 w22 w24 w22 w22 w22 w22 w22 w22 w22 pre w08 w16 w22 w24 w24
ID50 at
 MN.3
ID50 at ID50 atID50 at
Clade C - Tier 1A Clade B - Tier 1A Clade C - Tier 1B Clade C - Tier 2
CAP256.SUMW965.26
1986 <20 52 496 386 404 <20 <20 <20 <20 <20 40 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1987 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1988 <20 24 70 64 74 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1995 <20 55 729 391 346 <20 <20 <20 <20  <20 62 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1996 <20 <20 <20 20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
PB
S
1989 <20 <20 20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1990 <20 <20 125 298 207 <20 <20 26 22 72 49 <20 <20 <20 <20 43 <20 <20 <20 <20 <20 <20 <20
1991 <20 37 92 58 35 <20 <20 <20 22 <20 25 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1997 <20 25 113 228 126 <20 <20 <20 <20 <20 117 20 24 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20





1992 <20 476 659 2077 1603 <20 <20 <20 34 <20 484 35 22 52 44 <20 <20 <20 <20 <20 <20 <20 <20
1993 <20 448 1824 2057 1026 <20 <20 218 200 220 533 34 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1994 <20 1262 1768 1195 933 <20 40 93 <20  <20 253 24 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
1999 <20 3942 9151 5896 6017 <20 99 42 42 23 1178 43 67 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
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Figure 2.8. Serum neutralisation at week 22 and full time course for MW965.26 as measured 
by TZM-bl assay.  
Dotted red line represents assay detection limit (1/20 dilution). All data points below detection limit 
are plotted as 19.  
(A) ID50 titres at week 22 reflecting enhanced neutralisation in the AlhydroGel® group.  
(B) Time course of ID50 titres for MW965.26 are significantly higher in the AlhydroGel® group (Two-
way ANOVA; ***p<0.001; *p<0.05).  
Vertical, dotted black lines represent time points of protein boosts. MW965.26 neutralisation titres for 
the whole time course are plotted as group average ±SEM. 
 
 
CAP37 and CT349 psuedovirions (Table 2.2, Figure 2.8A). Furthermore, neutralisation titres 
for 6644 and CA146 were significantly higher compared to control or AddaVax™ groups (One-
way ANOVA; p<0.05 and p<0.001). Unfortunately, none of the sera neutralised the vaccine-
matched Tier 2 Clade C virus (CAP256 SU WT) at any time point for any of the groups. 
 
2.4 Discussion 
2.4.1 Characterisation of CAP256 soluble Env 
During the course of this project, a protocol was developed to affinity purify CAP256 soluble 
Env using Galanthus nivalis lectin from the cell media of both transiently transfected HEK293T 
cells and HEK293 stable cell lines, with a high degree of purity as assessed by LC-MS. 
Harvesting CAP256 soluble Env from stably transfected cell lines turned out to be easily 
scalable, with repeat harvesting from the same flasks. As correct Env folding is critical for 
vaccine studies [112], the Env species present in affinity purify CAP256 soluble Env (GNL) 
was initially assessed by Blue-Native PAGE electrophoresis, where very similar profiles of  
soluble Env (GNL) purified from both transiently transfected and stable cell lines were 
observed, with Env present in a mainly trimeric conformation as based on molecular weight. 
Surprisingly, addition of a C-terminal His-tag to CAP256 soluble Env dramatically altered this 
profile, with monomeric Env representing the bulk of Env species present after affinity 
purification, whereas the fraction of Env trimers were lower to those observed for both Env 
dimers and monomers. Although in general the addition of His-tag to a protein has no 
detrimental effects, it has been reported to in some cases it can affect enzyme activity, protein 
folding and change disulphide-bonding patterns [429, 430], with the latter two of course being 
extremely important for HIV-1 Env [431]. 
Unfortunately, an ELISA-based assay to characterise the quaternary structure of the soluble 
Env proteins could only be developed for the His-tagged version of soluble Env, by capturing 
this protein on nickel coated ELISA plates (Ni-NTA plates) in a similar strategy as reported by 
other groups [277, 371, 432, 433]. The impaired folding of CAP256 soluble Env-His was 
confirmed by a lack of signal to bnAbs which recognise native-like Env trimers (PG16, PGT145 
and CAP256 VRC26.08), and the presence of misfolded Env was confirmed with the binding 
of F105 and 446-52D. However, bnAb epitopes for the V3-glycan supersite (PGT128 and 
PG135), the CD4 binding site (VRC01) and the V2-glycan in bnAb PG9 were present in 
CAP256 soluble Env-His. Although Env folding appeared far from ideal when a His-tag was 
included, with the far better BN-PAGE profile for CAP256 soluble Env (GNL) which mainly 
contained trimeric Env (based on molecular weight), an improvement in the presence of bnAb 
epitopes for this protein is anticipated, and therefore CAP256 soluble Env (GNL) was taken 
forward for testing in rabbits.  
2.4.2 Soluble Env is more immunogenic when adjuvanted with AlhydroGel® 
compared to AddaVax™  
In order to achieve the full potential of the different DNA, rMVA and protein vaccines generated 
in this project in different prime/boost protocols, the first round of animal experiments was 
designed to test the effect of the protein vaccine formulated in different adjuvants for their 
immunogenic properties as these can be significantly enhanced with the appropriate adjuvant, 
which is particularly important for subunit vaccines [360]. Different adjuvants can shift the 
immune system towards a more humoral and/or cellular response upon vaccination. In 
AddaVax™ (similar to MF59®), a squalene-based oil-in-water nano-emulsion adjuvant was 
tested. In general these types of adjuvants enhance both a cellular and humoral immune 
responses [426, 427]. This was compared to AlhydroGel®, an aluminium hydroxide gel akin 
to Alum, a class of adjuvants which results in stimulating mainly a Th2 helper T cell response 
[428]. Unadjuvanted protein was included as a control (PBS group) and lectin affinity purified 
soluble Env (GNL) was used for all three groups. Formulation in AlhydroGel®, AddaVax™ or 
PBS resulted in Env binding antibodies in rabbit sera, which peaked after every inoculation 
but then decreased before the next boost. This is a typical pattern for in α-Env binding 
antibodies titres when soluble Env protein is used and has been reported before [434]. Even 
to the extent that in the RV144 clinical study this decrease in antibody titres correlated with a 
loss in protection from HIV infection [221, 242]. Although the pattern in α-Env binding antibody 
titres was similar for all groups, they were significantly higher for the AlhydroGel® group. This 
probably underlies the significantly higher antibody titres against the CAP256 V1V2-loop at 
week 22 in this group as well. In line with this, soluble Env formulated in AlhydroGel® is also 
more immunogenic based on an improved Tier 1A and 1B neutralisation response compared 
to AddaVax™ or PBS. Although it should be emphasised that no vaccine matched 
CAP256_SU Tier 2 neutralisation was observed. This could be due to the Env protein used in 
this experiment which was only affinity purified using lectin. The neutralisation response might 
improve when further purification such as size exclusion chromatography for isolation of 
trimeric Env (as used in later experiments) [277, 371, 433], possibly followed by negative 
selection of misfolded trimers using MAbs such as F105 or 447-52D [385, 422] or positive 
selection of native-like trimers with MAbs PG16 or CAP256 VRC26.08 [371, 435]. 
Of note as well is that using AddaVax™ failed to show an improvement in binding or 
neutralising antibody responses over PBS in these experiments. This lower immunogenicity 
of protein vaccines adjuvanted in AddaVax™ compared to AlhydroGel® (in Alum or aluminium 
hydroxide) is contrary to what has been reported before [366, 436]. Similarly, in a nonhuman 
primate studies where in one gp140 TV1ΔV2 protein formulated in MF59® induces higher 
anti-Env binding and Tier 1A neutralisation titres compared to alum formulation (aluminium 
hydroxide gel) [437]. Another study showed that ALVAC-SIV plus MF59® adjuvanted gp120 
had stronger systemic and mucosal responses to Env than the group receiving alum [438], 
although this was not tested here. In the latter study though, the alum group gave better 
protection in a challenge model suggesting qualitative differences in antibody responses [438]. 
Directly comparing these different adjuvants for soluble Env protein vaccines is difficult 
however as this has either not been done or animal models (rabbit, mice, nonhuman primates), 
exact adjuvants (MF59® or AddaVax™; alum, aluminium hydroxide or AlhydroGel®), Env 
sequences (isolates and/or gp120, gp140) or virus (HIV-1, influenza) differ in these studies. 
But as AlhydroGel® out performed AddaVax™ to such an extent in this study, it was decided 
for usage in formulating the protein vaccines in prime-boost experiments even though 
concerns have been raised that aluminium based adjuvants might impair Env structure. 
However, this has recently been disproved for two soluble Env antigens (Clade A BG505 
SOSIP.664 and clade B B41 SOSIP.v4.1 trimers) formulated in AlhydroGel® [423]. 
Interestingly, in that same paper aluminium sulphate does disrupt Env structure, suggesting 
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3.1 Introduction 
Vaccines which are currently approved for the use in humans can be broadly divided in two 
groups. The first contains whole pathogens which are either live-attenuated or inactivated 
preparations, made so as to reduce or remove the pathogen virulency. Safety concerns with 
HIV-1 using these whole pathogen approach, such as reversion of attenuated vaccine, 
recombination between vaccine and circulating virus and incomplete inactivation, makes these 
strategies nonviable options. Therefore, there is an intense focus on the second group of 
vaccines, which is defined by the use of only a part of the pathogen. This group includes toxoid 
vaccines, carbohydrate vaccines, conjugate vaccines and antigen vaccines. Antigen vaccines 
can be either a purified recombinant protein, or antigen expressed from vectors in vivo. For 
HIV-1 vaccines, a broad array of expression vectors have been tested as vaccine platforms: 
these include naked DNA plasmids, bacteria (such as Mycobacterium bovis Bacille Calmette 
Guerin (BCG)), and replication competent or incompetent attenuated viruses. The viral 
platforms especially have received a lot of attention in the HIV-1 vaccine research community, 
with the current focus on adenovirus (Ad) 5 alternatives such as Ad35 and Ad26; poxviral 
vectors including ALVAC, NYVAC and MVA; and replication competent viral vectors such as 
example rhesus cytomegalovirus (rhCMV) and recombinant vesicular stomatitis virus (rVSV). 
The focus in this thesis is on three of these platforms. These are an Env protein vaccine, 
already discussed in Chapter 2, as protein vaccines are highly successful in activating B-cells 
to produce antigen specific antibodies. Second, DNA vaccines, which usually induce subtle 
and transient immune responses that are skewed towards a CD8+ rather than a CD4+ T-cell 
response [286, 439]. Finally, the attenuated modified vaccinia Ankara (MVA) virus, which can 
induce strong humoral and cellular immune responses towards antigen genes inserted into a 
recombinant vaccine [317, 320, 321].  
As HIV-1 is particular efficient in evading the immune system, an effective vaccine will almost 
certainly require the activation of both cellular and humoral immunity. I note that most clinical 
tests are antibody based, whereas testing of cellular responses is much less common. 
Therefore the importance of cell-mediated responses as correlates of protection could be 
grossly underestimated [359]. Although most vaccines are thought to exert their effectiveness 
predominantly through an antibody response, cell-mediated immunity plays a crucial role in 
inducing this response, mainly through activation of T follicular helper (Tfh) cells and CD4+ T 
cells [246, 326, 327]. Tfh cells play a pivotal role in this process within the germinal centres by 
stimulating B-cell proliferation, antibody affinity maturation and B-cell differentiation, which are 
thought to be extremely important for the induction of neutralising antibodies [246, 328]. This 
effect can be enhanced by vaccine boosting [246, 329]. Given that different vaccine platforms 
elicit different responses - DNA elicits mainly cellular immunity; MVA or other viral platforms 
elicit cellular and humoral immunity; and protein generally elicits humoral immunity - 
heterologous prime-boosting with different platforms could potentially broaden the immune 
response by activating both arms of the adaptive immune response, and preventing potential 
development of vector-based immunity when multiple vaccines are required.  
With DNA and recombinant MVA vaccines expressing Env relying on host cell expression of 
the Env antigen where adequate furin processing might not take place, it was decided to opt 
for introduction of the same flexible linker as optimised by Sharma et al. [384]. An important 
basis for this decision was observations of poor furin cleavage of BG505 SOSIP.664 
expressed in vitro from chimpanzee adenovirus (ChAd) and MVA vaccines [343]. For the 
protein vaccine used in this thesis, Env was truncated at a similar position as BG505 
SOSIP.664, whereas for DNA and MVA vaccines, the transmembrane domain was retained. 
However, the gp160 was truncated to AA 730, which was shown to result in higher expression 
levels and increased stability of the resulting gp150, the increased stability holding especially 
true for the rMVA platform [398-400]. Furthermore, the I559P mutation was included in the 
constructs used for this work; however the BG505 SOSIP intramolecular cysteine bridge 
between gp41 and gp120 (SOS) was not included. 
Furthermore, the DNA and recombinant MVA vaccines were tested for their ability to display 
Env on the surface of budded HIV-1 Gag VLPs. Work from the early 1990s showed that Env 
readily incorporates into Pr55Gag VLPs when co-expressed in vitro [406-412]. It has also been 
suggested that by anchoring Env into the native environment of a lipid bilayer, its trimeric 
conformation is further stabilised [405]. Furthermore, cell-mediated immune responses to 
especially HIV-1 Gag (CD4+ and CD8+ T-cell responses) have been implicated in viraemic 
control [226]. Therefore, inclusion of Gag into a vaccine regimen has the potential to increase 
the efficacy of such a strategy and consequently has been widely used within the HIV-1 
vaccine community, including in vaccine efficacy studies such as RV144, HVTN 702, 705 and 
706. Here, an HIV-1 mosaic Gag (GagM) sequence was selected for co-expression with Env. 
This GagM sequence, designed in silico to maximise potential T-cell epitopes derived from 
HIV-1 subtype C sequences, improved immunogenicity in mice as a BCG, DNA and 
recombinant MVA vaccine in previous studies [272, 413, 414]. 
In this chapter, I report in vitro characterisation of DNA and recombinant MVA HIV-1 vaccines 
before in vivo immunogenicity studies. The use of heterologous vaccine platforms was tested 
in rabbits in two different regimens: 1) two rMVA HIV-1 vaccines followed by three soluble Env 
protein boosts (MMPPP) and 2) two DNA, followed by two rMVA HIV-1 vaccine, boosted by 
two protein vaccines (DDMMPP). These rabbit immunogenicity experiments were utilised to 
compare the inclusion of GagM in the DNA and rMVA vaccines to Env alone. As discussed in 
Chapter 2, the Env protein vaccine adjuvanted in AlhydroGel resulted in a superior antibody 
response in rabbits compared to AddaVax or PBS, therefore AlhydroGel was selected for 
these animal experiments as well. 
3.2 Materials and methods 
Refer to Section 2.2 for materials and methods common to both investigations. 
3.2.1 Antibodies, plasmids, cell lines, media and reagents 
Goat anti-HIV-1 gp160 (MRC ADP 72 408/5104 (MRC/CFAR, Potters Bar)), rabbit α-gp120 
polyclonal antibody (Sigma, St Louis), rabbit anti-HIV-1 p24 (Gag) (ARP 432, (MRC/CFAR, 
Potters Bar), donkey anti-goat IgG Cy3, donkey anti-rabbit IgG Alexa 647, donkey anti-rabbit 
IgG FITC (Thermo Fisher Scientific, Waltham) and goat anti Human IgG (Fc specific)-Cy3 
(Sigma, St Louis) were used for immunofluorescence. 
Human cervical epithelial cells from adenocarcinoma (HeLa) (ATCC® CCL-2™), rabbit 
epithelial kidney cells 13 (RK13) (ATCC® CCL-37™), Syrian golden hamster kidney fibroblast 
cells 21 (BHK) (ATCC® CCL-10™) were grown in Dulbecco's Modified Eagle's medium 
(DMEM) High Glucose + L-Glutamine (Lonza, Basel) + 10% fetal calf serum (FCS) + 1x 
penicillin (Pen)/streptomycin (Strep) (both Thermo Fisher Scientific, Waltham). A final 
concentration of 600µg/ml Geneticin was added to this medium for culturing the HEK293 
CAP256 gp140-FL-IP (with or without C-terminal His-tag) stable cell line. Serum-free medium: 
DMEM High Glucose + L-Glutamine + 1x Pen/Strep.  
The mammalian expression plasmid pTJDNA4 containing the subtype C mosaic Gag gene 
(GagM) was described earlier and was cloned into pTHpCapR [299, 413].  
Anti-HIV-1 Env human monoclonal antibody 10E8 was expressed in FreeStyle 293F cells 
(Thermo Fisher Scientific, Waltham) using the PEIMAX transfection reagent (Polysciences, 
Warrington). Monoclonal antibodies were purified from cell-free supernatants after 6 days 
using Protein-A affinity chromatography [425]. This monoclonal antibody was supplied by 
Professor Lynn Morris and Dr Penny Moore (NICD, Johannesburg).  
3.2.2 Design of CAP256 Env 
The sequence of CAP256_SU gp160 (clone CAP256.206sp.032.C9) has been previously 
described (GenBank: KF241776.1) [167]. The Env sequence was altered as follows: the native 
leader (signal peptide) was removed, the furin cleavage site was replaced with two glycine-
serine based repeats (GGGGS) to form a flexible linker (FL) [383, 384] and an I548P mutation 
equivalent to the I559P in the SOSIP trimers was introduced to stabilise trimerisation of gp41 
[374]. Finally, the sequence was truncated to gp150 (AA 730) for MVA and DNA vaccines to 
increase expression and stability [440], thus generating gp150-FL-IP. 
3.2.3 CAP256 Env DNA vaccine 
The mammalian expression plasmid pTHpCapR was used as a backbone for all DNA vaccines 
[299]. The human tissue plasminogen activator (tPA) leader sequence (GenBank: 
CAX11668.1) was human codon optimised and synthesised by GenScript (Nanjing) and 
cloned into pTHpCapR to increase secretion of the target antigen. This plasmid was renamed 
pMExT for Mammalian Expression with tPA leader (See section 2, Figure 2.1A). CAP256 
gp150-FL-IP was cloned into pMExT in-frame, behind the tPA leader using the NgoMIV and 
EcoRI sites to generate pMExT CAP256 gp140-FL-IP (Figure 3.1A). An unique BamHI 
restriction site was introduced into gp150 within the flexible linker. See appendix A for general 
cloning and plasmid isolation protocols. 
3.2.4 CAP256 Env transfer vector for generating recombinant MVA 
A transfer vector was created where in between overlapping flanks of the MVA G1L–I8R locus, 
a selection cassette containing the eGFP gene under the control of the vaccinia virus (VACV) 
p7.5 promoter and K1L gene under the VACV pSS promoter was inserted to form the plasmid 
Shuttle and Selection for Pox Expression (pSSPEx) (Figure 3.1B). An Env ORF including the 
tPA leader was cloned using HindIII and EcoRI sites from the pMExT DNA vector downstream 
of the VACV mH5 promoter to generate pSSPEx CAP256 gp150-FL-IP (Figure 3.1C). 
3.2.5 Generation of rMVA CAP256 Env 
Wildtype modified vaccinia Ankara (MVA) (provided by Bernard Moss, NIH, Bethesda) [314] 
and recombinant MVA (rMVA) GagM [413, 414] were used for targeted integration of CAP256 
Env. Inclusion of the overlapping flanks of the MVA G1L–I8R locus in pSSPEx gp150-FL-IP 
allowed for targeted recombination into this MVA locus containing the G1L and I8R genes 
which are in convergent open-reading frames within the pox genome. Integration of pSSPEx 
into MVA can be positive selected for via both K1L host range selection and/or eGFP 
expression in RK13 cells. For this, BHK cells in 12-well plates were transfected with pSSPEx 
CAP256 gp150-FL-IP (2µg plasmid DNA and 1.5µl X-tremeGENE (Roche, Basel) two hours 
after infection with rMVA GagM with a multiplicity of infection (MOI) of 0.1. As a control, 
pSSPEx CAP256 gp150-FL-IP was transfected into cells infected with wildtype MVA. After 
recombination was confirmed by eGFP fluorescence, cells were freeze-thawed to release 
MVA virus. This virus was passaged for three rounds in RK13 cells, a cell line where MVA is 
solely permissive in the presence of K1L expression [316, 441], adding a second level of  
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Figure 3.1. Plasmid map of CAP256 Env 
vectors.  
(A) DNA vaccine plasmid. Amp(R): ampicillin 
resistance gene for bacterial selection. ColE1: 
bacterial origin of replication. Mammalian 
expression of CAP256 gp150-FL-IP (Env) is 
driven by a promoter containing a porcine 
circovirus enhancer (pCAP) in the reverse 
orientation, the essential component of the CMV 
promoter (pCMV core) and the non-essential part 
of the CMV promoter (pCMV minor) for maximal 
expression.  
(B+C) Transfer vector for generating 
recombinant MVA. CmpR: chloramphenicol 
resistance gene for bacterial selection. The 
eGFP gene is driven by VACV promoter p7.5. 
The positive selection marker K1L is expressed 
from the VACV promoter pSS. PEPV DR: 
penguin pox direct-repeat peptide, not expressed 
G1L and I8R flanks: portions of MVA G1L and I8R open reading frames. Arrows indicate the direction 
of all promoters and transcripts. 
(C) Transcription of Env is from the modified VACV H5 promoter (mH5). All transcripts include a 3` 
pox transcriptional termination signal (Pox terminator).  
TPA leader: human tissue plasminogen activator leader sequence. 
 
selection stringency. Single fluorescent foci in RK13 cells were selected and screened for 
correct integration of the targeting construct by PCR and expression of GagM and/or Env was 
verified by western blotting and immunofluorescence. Positive single foci were expanded in 
3x Hyperflasks for high titre stocks, see Appendix A for full protocol. Thus generated rMVA 
GagM CAP256 gp150-FL-IP or rMVA CAP256 gp150-FL-IP stocks were aliquoted and stored 
at -80°C for downstream usage. Titres were determined in BHK cells where GFP positive 
plaques were counted 48 hours after infection of a serial dilution range (in steps of 1 in 10) 
and calculated as plaque forming units (pfu)/ml. High titre stocks were screened for correct 
integration of the targeting construct by PCR and PCR sequencing. Expression of mosaic Gag 
and/or Env was verified by western blotting and immunofluorescence. See Appendix A for 
detailed protocols for rMVA DNA isolation, PCR screening, primers and large scale MVA 
production. 
3.2.6 Purification of CAP256 soluble Env trimers 
All CAP256 soluble Env used in this chapter was isolated from the HEK293 CAP256 soluble 
Env or CAP256 soluble Env-His stable cell lines (passage >10) as described in Section 2.2.5. 
The yields of soluble Env from HEK293 CAP256 soluble Env stable cell lines and repeat 
harvesting from Hyperflasks allowed for downstream Size Exclusion Chromatography (SEC) 
on a Superdex 200 HiLoad 16/600 column (GE Healthcare, Chicago) where the Env trimers, 
dimers and monomers could be separated based on molecular weight (Figure 3.2). Fractions 
containing putatively trimeric soluble Env protein were combined. Thus purified protein will be 
referred to throughout this dissertation as CAP256 soluble trimeric Env protein. Protein was 
aliquoted and stored at -80°C for downstream usage. CAP256 soluble trimeric Env protein 
was assessed for the presence of bnAb epitopes as described in Section 2.2.5. Protein 
concentration was determined using the DC Protein Assay (Bio-Rad, Hercules) against a BSA 
standard (Bio-Rad, Hercules (see Appendix A for protocol). 
 
 
Figure 3.2. Schematic representation of the purification of CAP256 soluble Env trimers. 
Cleared media from HEK293 CAP256 soluble Env stable cell line or HEK293T cells transiently 
transfected with pMExT CAP256 gp140-FL-IP is dripped over an agarose lectin (Galanthus nivalis) 
affinity chromatography column using a peristaltic pump. After two wash steps, soluble Env is eluted 
of the column with ~50ml 1M methyl α-D-manno-pyranoside and concentrated to 5ml before Size 
Exclusion Chromatography on a Superdex 200 HiLoad 16/600 column. Fractions containing trimeric 
Env protein as based on molecular weight were isolated. 
 
3.2.7 Verification and characterisation of DNA vaccines 
To characterise Gag and Env expression and co-localisation from DNA vaccines, HEK293T 
cells were co-transfected with pTJDNA4 (contains gagM gene) + pMExT CAP256 gp150-FL-
IP or each plasmid by their own. Transfections were performed in 24 well plates (Corning, 
New York) for western blotting or 4 Well Permanox® Slides (Sigma, St Louis) for 
immunofluorescent staining, using 1µg of plasmid DNA and 3µl X-tremeGENE. After 72 hours 
media was harvested from 24-well plates and cleared by low speed spin (5 minutes, 275g) for 
western blot analysis. For immunofluorescent staining, cells were fixed with 4% 
paraformaldehyde for 10 minutes, permeabilised with methanol (1 minute) and washed with 
PBS. Cells were blocked and primary goat anti-gp160 and rabbit anti-p24 (both 1:500) was 
added in block overnight. After washing with PBS (3x), secondary antibody (donkey anti-goat 
IgG Cy3 and donkey anti-rabbit IgG Alexa 647, both 1:500) in block was added for 1 hour and 
after PBS washing (3x), coverslips were mounted with mowiol. Cells were imaged on a LSM 
880 Fast Airyscan (Zeiss, Oberkochen) at the UCT Confocal & Light Microscope Imaging 
Facility. Pseudo-colouring for Cy3 is in red and Alexa 647 in green. Single images comprising 
of 13 merged z-stacks were generated using Zeiss Zen software. Only cells transfected with 
pTJDNA4 + pMExT CAP256 gp150-FL-IP were analysed by confocal and untransfected cells 
were used as control. See appendix A for detailed protocols for transfection and western 
blotting. 
The presence of Env bnAb epitopes after expression of the Env DNA vaccine was assessed 
in HeLa cells using live-cell staining with anti-Env human bnAbs PG9, PG16, PGT128, 
PGT135, PGT145, CAP256 VRC26.08, VRC01, 10E8 F105 and 447-52D. For this 4 Well 
Permanox® Slides were transfected as described above and after three days, medium was 
replaced with medium containing 10µg/ml mAb and for 1 hour. Following 3x PBS washes, 
cells were incubated with medium containing rabbit anti-Env (1:500) for 30 minutes. Upon a 
further three washes, cells were treated with media containing goat α-human IgG Cy3 (1:500) 
+ donkey α-rabbit IgG FITC (1:500) for 0.5 hour and after a final 3x PBS washes, cells were 
imaged in PBS on a Zeiss Axiocam ICm 1 Microscope using Zeiss Zen software. 
To investigate the formation of Gag virus-like particles (VLPs) from DNA vaccines, RK13 cells 
were transfected with pTJDNA4 (contains gagM gene) + pMExT CAP256 gp150-FL-IP or each 
plasmid by their own. Transfections were performed in 6-well plates using 4µg of plasmid DNA 
and 12µl X-tremeGENE. After 72 hours cells were collected by scraping, spun briefly and after 
washing the pellets with PBS fixed overnight in 2.5% glutaraldehyde in PBS (4ºC). The fix was 
replaced with PBS and pellets were sent to the Microscopy & Microanalysis Unit at the 
University of Kwazulu-Natal for electron microscopy (EM) post processing as described earlier 
[413], and EM imaging. Images were acquired on a JEOL 1010 platform and VLP size was 
measured with the imaging software.  
To characterise Env inclusion into Gag virus-like particles (VLPs), HEK293T cells were 
transfected with pTJDNA4 (contains gagM gene) + pMExT CAP256 gp150-FL-IP or each 
plasmid by their own. Transfections were performed in T150 flasks, using 60µg of plasmid 
DNA and 180µl polyethylenimine-branched (PEI) (Sigma, St Louis). After 72 hours VLPs were 
isolated from the media of transfected cells on OptiPrep (Sigma, St Louis) gradients. In short, 
media was cleared with a low speed spin (5 minutes, 275g), underlayed with 12, 24, and 60% 
OptiPrep (in 1x PBS, 3ml each) in Thinwall Ultra-Clear™ Tubes (38.5 ml, 25x89 mm, Beckman 
Coulter, Pasadena) and centrifuged at ~110,000g, 4°C for 90 minutes. A visible band (or 
equivalent) around the 12-24% interface was isolated, carefully overlayed on an OptiPrep 
gradient (18, 21, 24, 30, 36, 42% in 1x PBS, 5ml each) and subsequently centrifuged overnight 
at ~110,000g, 4°C. The only visible band (or equivalent) around 45mm from the bottom was 
isolated. This band was analysed for the presence of Gag and/or Env by western blotting. 
After cloning, verification and characterisation, DNA vaccines were synthesised by Aldevron 
(Fargo) for immunisation experiments.  
3.2.8 Verification and characterisation of recombinant MVA vaccines 
The recombinant MVA vaccines rMVA GagM CAP256 gp150-FL-IP, rMVA CAP256 gp150-FL-
IP or rMVA GagM were characterised in a similar fashion as for DNA vaccines above, with the 
following permutations. All characterisation was performed 48 hours after infection. For 
western blotting and confocal microscopy, HE293T cells were infected with a multiplicity of 
infection (MOI) of 0.5. For assessing the presence of Env bnAb epitopes in a live-cell staining 
assay, HeLa cells were infected with an MOI=0.5, cells were not stained with the rabbit α-Env 
antibody as rMVA infected cells could be identified by eGFP expression. RK13 cells were 
infected with an MOI=1 for EM. Whereas VLP characterisation by western blotting was done 
in HEK293T cells with an MOI=0.5. 
3.2.9 Rabbit immunisation comparing heterologous vaccine platforms 
Female New Zealand white rabbits were housed in the Research Animal Facility in the Faculty 
of Health Sciences at the University of Cape Town. All the animal procedures were approved 
by the UCT Animal Research Ethics Committee (UCT AEC 14-030 & UCT AEC 015/051) and 
performed by trained animal technologists Rodney Lucas and Inge Botes. The rabbits were 
monitored daily for any signs of pain, discomfort or stress and were weighed weekly. 
Four groups of 5 rabbits were selected to compare rMVA vaccines GagM CAP256 gp150-FL-
IP and CAP256 gp150-FL-IP with or without matching DNA vaccine priming (see Table 3.1 
for groups). 
Table 3.1. Groups of rabbits comparing heterologous vaccine platforms 
 
 
Groups 1 and 2 received 108 pfu in 500µl PBS + 10% glycerol rMVA GagM CAP256 gp150-
FL-IP or rMVA CAP256 gp150-FL-IP. Recombinant MVA vaccines were administered 
intramuscularly in the hind leg at week 0 and 4. All rabbits received 40µg of CAP256 soluble 
trimeric Env protein in 500µl 1:1 (v/v) AlhydroGel® (InvivoGen, San Diego) at week 12, 20 and 
28 to boost the immune response. This experiment is abbreviated as MMPPP. Animals were 
sacrificed at week 32.  
Groups 3 and 4 received 100µg pTJDNA4 (GagM) combined with 100µg pMExT CAP256 
gp150-FL-IP or 100µg pMExT CAP256 gp150-FL-IP only. Concentration of all DNA vaccines 
was 1mg/ml in PBS. Primes were administered intramuscularly in the hind leg at week 0 and 
4. At week 8 and 12, all groups received vaccine matched rMVA boosts. Groups 3 received 
108 pfu in 500µl PBS + 10% glycerol rMVA GagM CAP256 gp150-FL-IP, whereas group 4 
received 108 pfu in 500µl PBS + 10% glycerol rMVA CAP256 gp150-FL-IP. These rMVA 
DNA rMVA gp140-FL-IP wk 0 wk 4 wk 8 wk 12 First Second Third
6826 1 N/A gp150 + GagM AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6827 1 N/A gp150 + GagM AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6828 1 N/A gp150 + GagM AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6830 1 N/A gp150 + GagM AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6850 1 N/A gp150 + Gag
M
AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6832 2 N/A gp150 AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6833 2 N/A gp150 AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6834 2 N/A gp150 AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6835 2 N/A gp150 AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6836 2 N/A gp150 AlhydroGel (1:1) rMVA rMVA N/A N/A wk 12 wk 20 wk 28
6526 3 gp150 + GagM gp150 + GagM AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6528 3 gp150 + GagM gp150 + GagM AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6529 3 gp150 + GagM gp150 + GagM AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6530 3 gp150 + GagM gp150 + GagM AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6049# 3 gp150 + Gag
M gp150 + GagM AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6542† 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6543† 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6544 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6546 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6047# 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
6048# 4 gp150 gp150 AlhydroGel (1:1) DNA DNA rMVA rMVA wk 20 wk 28 N/A
# started 4 week behind




boosts were administered intramuscularly in the hind leg. Finally, all rabbits received 40µg of 
CAP256 soluble trimeric Env protein in 500µl 1:1 (v/v) AlhydroGel® at week 20 and 28 to 
boost the immune response. This experiment is abbreviated as DDMMPP. Animals were not 
sacrificed at week 32 as they were entered into a longitudinal study (not discussed in this 
dissertation). For each group, the regimen for one animal started 4 weeks later. In group 4, 
two rabbits died after the first MVA inoculation due to unrelated causes, for this group an 
additional animal was included in the delayed regimen resulting in 4 rabbits in group 2. 
3.2.10 Rabbit sera characterisation 
To assess Env or CAP256_SU V1V2-loop binding antibodies titres in rabbit sera, ELISA were 
performed as described in Section 2.2.7. However, binding ELISAs were run against CAP256 
soluble trimeric Env (SEC purified) and antibody end-point titres were calculated from 4PL 
curves with the threshold set as 4PL curve minimum + standard error of minimum for each 
time point: 
𝐸𝑛𝑑 𝑝𝑜𝑖𝑛𝑡 𝑡𝑖𝑡𝑟𝑒 = 𝐸𝐶50 ∗ (
𝑆𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝐸𝑟𝑟𝑜𝑟 𝐶𝑢𝑟𝑣𝑒 𝑀𝑖𝑛





Data plotted as mean +/- SEM for whole group. 
Rabbit sera from different time points were tested for the ability to inhibit Env-pseudotyped 
virions from entering a reporter cell line as described in Section 2.2.7. The Env-
pseudotypedviruses MW965.26, 6644, 1107356, CAP256_SU, CAP256_SU K169E or 
BG0505N332+/CAP256_SU V1V2-loop and CAP84/CAP256_SU V1V2-loop were assayed.  
All neutralisation assays were performed by Professor Lynn Morris’s group at Center for HIV 
and STIs, National Institute for Communicable Diseases of the National Health Laboratory 
Service, Johannesburg, South Africa. 
3.2.11 Statistical analysis 
All statistical analysis was performed in GraphPad Prism 5.0 (GraphPad Software, San Diego) 




3.3.1 Transient expression of CAP256 Env and mosaic Gag from DNA vaccines 
The CAP256 Env sequence was modified as described in the material and methods and 
cloned into the the mammalian expression plasmid to generate pMExT CAP256 gp150-FL-IP 
(Figure 3.1A and 3.3A), whereas pTJDNA4 expressing subtype C mosaic Gag (pTJDNA4) 
was previously described [413]. In this thesis pMExT CAP256 gp150-FL-IP will be referred to 
as DNA Env, pTJDNA4 as DNA GagM and when both plasmids are combined DNA Env+GagM. 
To test the Env and Gag DNA vaccines for in vitro expression and cellular secretion of the 
transgenes, HEK293T cells were transiently transfected with these vaccines, Env and Gag 
were detected by western blotting in the cell media 72 hours after transfection (Figure 3.3B), 
indicating secretion of both proteins. Furthermore, immunofluorescence staining and confocal 
imaging of transfected cells with DNA Env+GagM showed expression and co-localisation of 
the two transgenes (Figure 3.3C).  
The Env DNA vaccine was further characterised for the presence of a select list of Env bnAbs 
epitopes upon expression (Table 1.1) using a live cell staining protocol in HeLa cells. Using 
this method, only Env present on the plasma membrane would be detected and therefore be 
a suitable indication of the antigenic properties of the natively expressed (non-denatured) Env 
trimer. Binding was observed for all epitopes tested (Figure 3.4), including the V3-glycan 
supersite (identified with bnAbs PGT128 and PGT135), the CD4-binding site (bnAb VRC01), 
the MPER (10E8) and the V2-glycan by PG9. Although some signal was detected as well with 
the bnAbs F105 and 447-52D, suggesting that some of the Env expressed from the DNA 
vaccine was misfolded. However, immunofluorescent signals for bnAbs that specifically 
identify Env in a native-like trimer conformation (PGT145, PG16 and CAP256 VRC26.08) were 
observed, which is most encouraging. Only immunofluorescence for bnAbs was observed in 
cells that were positive for the rabbit α-Env polyclonal antibody (as assessed by FITC signal), 
indicating the specificity of the bnAb live-cell staining. However, especially for PGT145, PG16 
and CAP256 VRC26.08, bnAb signals was not detected in all cells positive for Env expression.  
3.3.2 Construction and characterisation of rMVA vaccines expressing Env 
3.3.2.1 Verification of the integrity of rMVA vaccines 
Env was subcloned from pMExT CAP256 gp150-FL-IP into the transfer vector pSSPEx to 
generate MVA recombinants (Figure 3.1C and 3.3A). Using the transfer vector, Env under 
the vaccinia (VACV) promoter mH5 was targeted into the transcriptionally convergent open 
reading frames of the essential I8R-G1L genes of rMVA GagM (Figure 3.5A) to generate rMVA 









Figure 3.3 CAP256 gp150-FL-IP protein vaccine design and characterisation of in vitro 
expression .  
(A) Schematic representations comparing wild type Env to CAP256 Env used in DNA and rMVA 
vaccines (CAP256 gp150-FL-IP). The Env sequence was truncated to amino acid 730 to improve 
transgene stability, while containing further modifcations where the wild type signal peptide (HIV-1 
SP) was replaced with the human tissue plasminogen activator (TPA) sequence, the furin cleavage 
site with a flexible linker (FL) sequence and an I559P mutation was introduced.  
(B+C) In co-expression studies of HEK293T cells after transfection pMExT CAP256 gp150-FL-IP 
(DNA Env) and pTJDNA4 (DNA GagM) or both (DNA Env+GagM) western blotting revealed Gag 
(bottom) and Env (top) secretion in media from HEK293T cells 72 hours after (B). (C) Confocal 
imaging (maximum intensity projections) showing co-localisation of Gag and Env within HEK293T 
cells after transfection with DNA Env+GagM.  
D) No Env or Gag immunofluorescent signal in untransfected controls.  
Pseudo-colouring for Cy3 is in red (Gag) and Alexa 647 in green (Env). Scale bar = 10μm. 
 
rMVA CAP256 gp150-FL-IP (referred to as rMVA Env). The presence of a fluorescent signal 
from the reporter gene eGFP under the control of the VACV promoter p7.5, was used to select 
for positive integration. Furthermore, expression of the host range K1L gene under the control  
A) bnAb PGT128 
 
B) bnAb PGT135 
 
C) bnAb 447-52D 
 
D) bnAb VRC01 
 
E) bnAb F105 
 
F) bnAb PG9 
 
G) bnAb PG16 
 
H) bnAb PGT145 
 
I) bnAb CAP256 VRC26.08 
 
J) bnAb 10E8 
 
Figure 3.4. Live cell staining to detect Env bnAb epitopes in 
HeLa cells transfected with pMExT CAP256 gp150-FL-IP.  
(A-J) HeLa cells transfected with DNA vaccines were visualised 
by their Env expression using a rabbit α-Env polyclonal antibody 
which was detected with α-rabbit IgG-FITC (RB; visualised in 
green). The Env bnAbs were detected with α-human IgG-Cy3 
(HMAb; visualised in red). Overlapping signal between the rabbit 
α-Env polyclonal and bnAbs appears as yellow.  
The V3-glycan super-site was detected with bnAbs PGT128 and 
PGT135, (A+B) the CD4-binding site with VRC01 (D), the V2-
glycan with PG9 (F) and the MPER with 10E8 (J).  
Env expressed from the DNA vaccine can take the form of a native-like trimer as assessed by bnAbs 
PG16, PGT145 and CAP256 VRC26.08 (G-I). However, some Env is expressed as a misfolded 
protein with the binding of bnAbs 446-52D and F105 (C+E).  
Bar = 20µm. 
 
of the VACV pSS promoter allowed for positive selection in RK13 cells which are only 
permissive to MVA with the expression of K1L. Single clones for all the different MVA vaccines 
were selected from RK13 cells and expanded to high titres stocks (rMVA Env+GagM = 1.3*109; 
rMVA Env = 0.5*109) in RK13 cells. To test for correct integration and stability of Env in the 
I8R-G1L locus, PCRs were carried out on DNA isolated from RK13 cells infected with the high 
titre stocks rMVA using a primer upstream of the VACV mH5 promoter and a reverse primer  
A) 
 
B) Deletion in rMVAGC5 mH5 promoter for GagM 
 
Figure 3.5. Targeting strategy for the generation of recombinant MVA expressing Env.  
(A) Schematic representation of targeting for CAP256 gp150-FL-IP into the I8R-G1L locus of wild 
type MVA or MVA GagM pox genome. Triangles indicate direction of open-reading frames. Env 
expression is driven by the VACV mH5 promoter 
(B) Deletion in the sequence contig of GagM insertion site for rMVA Env+GagM. This deletion is 
outside the core binding regions for immediate-early or late expression initiation. The arrow heads 
indicate the promoter element directions.  
 
within the G1L locus but outside the G1L recombination flank in pSSPEx. These PCR products 
were subsequently sequenced to check for possible mutations. The sequence was exactly as 
predicted for both recombinant MVA vaccines indicating correct integration of Env into the 
rMVA vaccines (data not shown). In a similar fashion, the 5’ and 3’ arms of GagM were verified 
for rMVA Env+GagM and surprisingly, there was one deletion within the mH5 promoter (Figure 
3.5B), but as this occurred outside the core binding sites for immediate-early or late expression 
initiation, it was deemed to have no effect on Gag expression. 
3.3.3.2 Expression of Env by rMVA vaccines 
To assess rMVA vaccines for in vitro expression of the recombinant antigens, HEK293T cells 
were infected rMVA Env+GagM or rMVA Env. Env and Gag could be detected by western 
blotting in the cell media 48 hours after infection (Figure 3.6A), indicating that both Env and 
Gag were secreted. Furthermore, immunofluorescent staining and confocal imaging of 
infected cells showed expression and co-localisation of Gag and Env (Figure 3.6B). 
Both rMVA vaccines were characterised for the presence of Env bnAb epitopes upon infection 
into HeLa cells in similar experiments as for the DNA vaccine, resulting in a very comparable 
outcome. The same bnAb epitopes as for pMExT CAP256 gp150-FL-IP were detected for 
rMVA Env+GagM (Figure 3.7) and rMVA Env. (Figure 3.8), with the V3-glycan supersite (using 
bnAbs PGT128 and PGT135), the CD4-binding site (bnAb VRC01), the MPER (10E8) and the 
V2-glycan by PG9. Again, some signal was detected as well with the bnAbs F015 and 447-
52D, suggesting that some of the Env expressed from the DNA vaccine was misfolded. 
However, immunofluorescent signals for bnAbs that specifically identify Env in a native-like 
trimer conformation (PGT145, PG16 and CAP256 VRC26.08) were observed, which was most 
encouraging. Infected HeLa cells were identified by the presence of an eGFP signal, 







Figure 3.6. Characterisation of in vitro expression of rMVA Env vaccines.  
(A) Both Env and Gag could be detected in media from HEK293T cells infected with rMVA 
Env+GagM, whereas only Env or Gag was detected for rMVA Env or with rMVA GagM (GagM) 
respectively.  
(B) Confocal imaging (maximum intensity projections) showing co-localisation of Gag and Env within 
HEK293T cells after infection with rMVA Env+GagM.  
(C) No Env or Gag immunofluorescent signal in uninfected controls.  
Pseudo-colouring for Cy3 is in red (Gag) and Alexa 647 in green (Env). Scale bar=10μm. 
 
3.3.3 Virus-like particle formation from Env DNA and rMVA vaccines 
It has previously been shown by electron microscopy that expression of GagM from DNA or 
rMVA vaccines in HEK293 cells leads to the formation of VLPs [413], and this was confirmed 
here in a similar fashion for the DNA vaccine in RK13 cells as well (Figure 3.9A). Furthermore, 
VLPs were also observed when Env was co-expressed for both DNA and rMVA vaccines 
(Figure 3.9B+C). However, no VLPs were observed for the rMVA vaccines expressing Env  
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B) bnAb PGT135 
 
C) bnAb 447-52D 
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J) bnAb 10E8 
 
Figure 3.7. Live cell staining to detect Env bnAb epitopes in 
HeLa cells infected with rMVA Env+GagM.  
(A-J) The Env bnAbs were detected with α-human IgG-Cy3 
(HMAb; visualised in red). Cells infected with rMVA are expressing 
eGFP present in rMVA.  
The V3-glycan super-site was detected with bnAbs PGT128 and 
PGT135, (A+B) the CD4-binding site with VRC01 (D), the V2-
glycan with PG9 (F) and the MPER with 10E8 (J).  
Env expressed from this rMVA vaccine can take the form of a 
native-like trimer as assessed by bnAbs PG16, PGT145 and 
CAP256 VRC26.08 (G-I). However, some Env is expressed as a 
misfolded protein with the binding of bnAbs 447-52D and F105 (C+E).  
Bar = 20µm. 
 
alone (Figure 3.9D). Interestingly, viral factories within RK13 cells producing immature and 
mature MVA particles were observed as well (3.9E+F). When VLPs from DNA and rMVA 
vaccines expressing both Env and GagM were isolated from the media of HEK293T cells by a 
two-step OptiPrep gradient centrifugation protocol, both Gag and Env were present as 
confirmed with western blotting of samples from the only visible band (~45mm from the 
bottom) isolated from the second OptiPrep gradient, suggesting Env inclusion into Gag VLPs 
(Figure 3.10). Encouragingly, no Env band was observed in the equivalent band isolated from 
DNA or rMVA vaccines containing only Env. 
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Figure 3.8. Live cell staining to detect Env bnAb epitopes in 
HeLa cells infected with rMVA Env.  
(A-J) The Env bnAbs were detected with α-human IgG-Cy3 
(HMAb; visualised in red). Cells infected with rMVA are expressing 
eGFP present in rMVA.  
The V3-glycan super-site was detected with bnAbs PGT128 and 
PGT135, (A+B) the CD4-binding site with VRC01 (D), the V2-
glycan with PG9 (F) and the MPER with 10E8 (J).  
Env expressed from this rMVA vaccine can take the form of a 
native-like trimer as assessed by bnAbs PG16, PGT145 and 
CAP256 VRC26.08 (G-I). However, some Env is expressed as a 
misfolded protein with the binding of bnAbs 447-52D and F105 (C+E).  Bar = 20µm. 
 
3.3.4 Characterisation of affinity purified soluble Env trimers 
As already discussed in Chapter 2, the CAP256 soluble Env affinity purified with lectin from a 
HEK293 stable cell line was mainly in a trimeric conformation as judged by molecular weight. 
This trimeric Env fraction was further purified by size exclusion chromatography (SEC). The 
first and largest peak observed in the SEC profile, fractions 35-39, corresponds to trimeric Env 
as judged Blue-Native (BN) PAGE electrophoresis (by molecular weight) (Figure 3.11A+B). 
These pooled fractions will be referred to in this thesis as soluble trimeric Env. It was confirmed 













Figure 3.9. In vitro Gag VLP formation from DNA and rMVA vaccines in RK13 cells.  
(A-C) Electron microscopy images showing in vitro formation of VLPs from (A) DNA GagM, (B) DNA 
Env+GagM (C) rMVA Env+GagM vaccine. VLP budding events are indicated with *.  
No VLP-like structures could be detected in wildtype MVA control (D).  
(E-F) Pox viral factories producing immature (E) and mature (F) MVA particles in rMVA infected cells. 
 
with lectin purified Env yields, total soluble trimeric Env levels appear to increase with repeat 
harvesting, as does the percentage of soluble Env trimer divided by total Env protein (Table 
3.3). When soluble trimeric Env was subsequently run on BN PAGE gels, it had an improved 
trimeric profile compared to soluble Env just purified by lectin affinity chromatography (GNL) 





Figure 3.10. Env inclusion into Gag-VLPs from Env + GagM DNA and rMVA vaccines.   
(A-B) Env (top) and Gag (bottom) could be detected by western blotting in VLPs isolated from the 
second OptiPrep gradient when both GagM and Env were co-expressed from DNA (A) and rMVA (B) 
vaccines. Likewise, VLPs containing Gag only are detected from DNA or rMVA GagM, whereas no 
Gag or Env signal was detected for cells alone, DNA or rMVA Env vaccines or wildtype MVA. 
 
on CAP256 soluble Env-His, some Env dimers were still present (Figure 3.12C). However, it 
was much improved compared to the corresponding CAP256 soluble Env-His GNL, and 
therefore these SEC purified Env-His fractions (nominally called soluble Env-His trimers) were 
tested in the bnAb binding ELISA as described in Chapter 2. As to be expected, soluble Env-
His trimers performed better compared to soluble Env-His GNL for all bnAb epitopes tested: 
the V3 glycan supersite (PGT128 and PGT135), the CD4-binding site (VRC01) and the V2 
glycan (PG9), but also for bnAbs 447-52D and F105, which would indicate more misfolded 
Env. In contradiction to this and more encouragingly, low signals for bnAbs recognising native-
like Env trimers (PG16 and CAP256 VRC26.08) were detectable (Figure 3.12D-F). 
3.3.5 Immunogenicity studies in rabbits comparing heterologous vaccine 
platforms 
With the in vitro confirmation of the expression of GagM and Env showing that the Env trimer 
is able to display in a native-like conformation from DNA and recombinant MVA vaccines, and 
with confirmation of the inclusion of Env into Gag VLPs, these vaccines were now ready for 
testing in rabbit immunogenicity studies. Furthermore, additional SEC purification to isolate 
soluble trimeric Env improved its antigenic properties. Therefore protein boosts adjuvanted in 
AlhydroGel (as described in Chapter 2) were included as well. For this, four groups of rabbits 
were selected to either test a regimen of rMVA priming, followed by protein boosting (MMPPP) 
or a regimen in which the rMVA vaccine was first primed with the matching DNA vaccine and 
again finishing with protein vaccines (DDMMPP) (Figure 3.13A). To investigate if the inclusion  
A) SEC profile of soluble Env 
 
B) BN-PAGE of soluble Env fractions 
 
Figure 3.11. Structural characterisation of soluble Env by SEC and BN-PAGE.  
(A) SEC profile of soluble Env affinity purified with lectin from the stable cell (soluble Env GNL).  
(B) SEC fractions 30-55 were run on a BN-PAGE and stained with Coomassie. Combined SEC 
fractions 35-39 was enriched for soluble, trimeric Env. Fraction E1: SEC input material: soluble Env 
GNL. 
 
Table 3.2. Top ten proteins identified in lectin affinity purified soluble trimeric Env by LC-MS. 









# of unique 
peptides




1 CAP256 soluble Env 358.94 69351075571 2257 115 19 48.25
2 sp|P07437|TBB5_HUMAN Tubulin beta chain 91.28 290889049.2 110 24 5 36.49
2 tr|Q5JP53|Q5JP53_HUMAN Tubulin beta chain
3 sp|P11047|LAMC1_HUMAN Laminin subunit gamma-1 67.24 96520216.5 69 19 1 12.55
4 sp|P24821|TENA_HUMAN Tenascin 66.23 76323972.8 60 27 1 12.9
5 sp|P14618|KPYM_HUMAN Pyruvate kinase PKM 58.37 122970676.5 48 15 0 32.96
6 sp|P13639|EF2_HUMAN Elongation factor 2 56.26 83358940.6 55 15 0 20.63
7 sp|P14543|NID1_HUMAN Nidogen-1 51.58 46683246.9 33 14 0 12.67
8 sp|Q14697|GANAB_HUMAN Neutral alpha-glucosidase AB 51.39 79875406.1 54 18 0 20.02
9 sp|P0DMV9|HS71B_HUMAN Heat shock 70 kDa protein 1B 50.45 267819742.4 58 15 1 20.59
9 sp|P0DMV8|HS71A_HUMAN Heat shock 70 kDa protein 1A
10 sp|P68363|TBA1B_HUMAN Tubulin alpha-1B chain 47.53 86299006.1 62 11 1 27.94
10 sp|Q9BQE3|TBA1C_HUMAN Tubulin alpha-1C chain
10 tr|F5H5D3|F5H5D3_HUMAN Tubulin alpha chain
Table 3.3. Soluble trimeric Env protein yields after lectin affinity chromatography 
Protein concentrations were measured using the DC Protein Assay against a BSA standard (three 
indenpent measurements per experimental sample and BSA standard concentration) 
 
of Gag in the DNA and rMVA vaccines improves the immunogenicity of the two different 
regimens, parallel groups received DNA or rMVA vaccines with Env alone. 
Serum was taken at regular intervals and tested in an Env binding ELISA using the same 
soluble trimeric Env as used as protein vaccine. Interestingly, in the DDMMPP regimen no 
Env binding antibodies could be detected after the DNA inoculation: these only developed 
after rMVA boosting (Figure 3.13B). Env binding antibodies did develop immediately after the 
first rMVA vaccine for both regimens (week 4 for MMPPP and week 12 for DDMMPP), and no 
significant differences were observed between groups inoculated with Env alone or 
Env+GagM. It appears that the soluble trimeric Env protein vaccine enhances the α-Env 
binding antibody response in all four groups. However, there were no significant differences 
in α-Env antibody titres after the second rMVA vaccine and any of the protein vaccines boost 
observed as tested in a Two-way ANOVA. The α-Env antibody response seems to plateau at 
titre of approximately 1*105, which could be the assay maximum. Longitudinal testing using a 
Two-way ANOVA showed no significant differences between groups receiving rMVA 
Env+GagM or Env alone in the MMPPP regimen and a similar result was obtained comparing 
DNA and rMVA Env+GagM or Env alone for DNA and rMVA in the DDMMPPP regimen. 
Binding antibodies against the V1V2 loop of Env are of particular interest, as this was one of 
the main correlates of protection in the RV144 trial. Therefore, sera of the vaccinated animals 
at select time points were tested in a binding ELISA against the autologous CAP256 SU V1V2 
loop: this was presented on a scaffold to retain the natively folded state [424] (kindly provided 
Dr Penny Moore from the NICD). Serum was either tested after the second rMVA vaccine 
(post MVA) (week 8 for MMPPP and week 14 for DMMPP) or after the final protein (post final 







total mg % trimer
stable 1A* 0.39 2.36 0.06 0.04 0.28 12
stable 1B* 0.61 3.67 0.09 0.20 1.48 40
stable 1C* 0.42 2.54 0.06 0.13 0.94 37
stable 1D* 0.49 2.95 0.07 0.14 1.07 36
stable 2A* 0.43 2.35 0.06 0.02 0.13 6
stable 2B* 0.70 3.85 0.10 0.20 1.70 44
stable 2C* 0.64 3.54 0.09 0.17 1.17 33
stable 2D* 1.01 5.56 0.14 0.34 2.74 49
stable 2E* 0.78 4.30 0.11 0.24 1.71 40

















Figure 3.12. Characterisation of CAP256 
soluble Env protein vaccine.  
(A-C) SEC fractions combined as soluble Env 
trimers are mainly trimeric (***) as judged by 
molecular weight on BN PAGE gels stained by 
Coomassie (A) or as detected by Env western 
blotting (B). Env monomers were detected in 
SEC fractions combined for this configuration (*). 
Whereas the SEC trimer fraction for Env-His still 
contains dimers as detected by Coomassie 
staining (C).  
(D-F) Better signals are observed for the bnAb 
ELISA for soluble, trimeric Env-His (red) 
compared to soluble Env-His GNL (blue) for all 
bnAbs tested, including PG16 and CAP256 
VRC26.08 which recognise native-like Env 
trimers. 
Note different Y-axis for (E).  
For soluble Env-His trimer: representative traces.  
For soluble Env-His average of n=3. 
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Figure 3.13. Rabbit immunisation regimens and Env binding ELISAs of rabbit sera.  
(A) Immunisation protocol for the four different groups. D: DNA and M: rMVA vaccines, expressing 
Env+GagM or Env alone. *Week 14 was only taken for the DDMMPP regimen.  
(B) Time course depicting binding of rabbit sera to soluble, trimeric CAP256 Env as measured by 
ELISA. Endpoint titre was plotted as 10 when no ELISA signal was observed.  
(C) CAP256 V1V2 loop scaffold binding ELISA of rabbit sera post MVA (second MVA inoculation) or 
post final protein (second protein boost for DDMMPP, third protein boost MMPPP). This binding 
ELISA was negative for week 0.  
All data are presented as group averages +/- SEMs. 
 
were observed in antibody titres against the V1V2-loop when different permutations were 
tested in a Two-way ANOVA: no differences between regimens (MMPPP vs DDMMPP post 
MVA or post final protein) or within regimens (MMPPP post MVA vs post final protein or 
DDMMPP post MVA vs post final protein. Furthermore, when data was analysed in a similar 
fashion comparing rMVA or DNA/rMVA Env+GagM to Env alone, no significant differences 
were observed as well, therefore the graph in Figure 3.13C was presented per regimen, 
combining the data of Env + GagM and Env alone. 
When these rabbit sera were tested for neutralising activity (ID50) against a panel of Env-
pseudotyped virions, some interesting patterns appeared (Table 3.4, Figure 3.14). As DNA 
priming failed to induce α-Env binding antibodies, these samples weren’t included. However, 
the development of α-Env binding antibodies upon rMVA vaccines corresponded with 
neutralisation titres for tier 1A virus MW965.26 and tier 1B virus 6644 in serum of rabbits 
Table 3.4. Serum neutralisation from rabbits vaccinated with different adjuvants as measured by TZM-bl assay.  
Sera from immunised animals were assessed for neutralising activity (serum dilution required for a 50% reduction in entry of the 
infecting virus into a reporter cell line (ID50) against a panel of Env-pseudotyped virions at different time points. The 50% 
neutralisation titres are color-coded to reflect their potency range as indicated. Bleeds were taken 4 weeks after the second MVA 
prime for MMPPPP (primes) or 2 weeks after the second MVA boost for DDMMPP (MVA B2) and 2 weeks after each protein 
inoculation (P1-3).  
As the Env binding ELISA was negative for bleeds after two DNA vaccines for the DDMMPP regimen, they were not tested here.  
The pre-bleeds and MuLV control for all rabbits and time points were negative in this assay.  
Titres below 20 are considered negative. 
The 50% neutralisation titres are color-coded to reflect their potency range as indicated.  
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Figure 3.14. Inclusion of GagM in prime affects serum neutralisation as measured by TZM-bl 
assay.  
Dotted black line represent assay detection limit (1/20 dilution). All data points below detection limit 
are plotted as 19. ID50 titres over time of individual animals with Tier 2, vaccine matched neutralisation 
titres against CAP256_SU pseudo-virions. The black arrow indicates low titre Tier 2 neutralisation 
titres after the second MVA boost in 3 out of 4 animals in the DDMMPP Env+GagM group, before any 
protein boosting.  
For the MMPPP regimen, the neutralisation assay was only performed after the second rMVA 
vaccine.  
 
after the second rMVA vaccine in all four groups (Table 3.4, MMPPP: post primes and 
DDMMPP: post MVA B2). When data of the groups within a regimen was combined 
(Env+GagM and Env alone), neutralisation titres after the second rMVA inoculation towards 
MW965.26 was significantly higher in the DDMMPP regimen compared to MMPPP (Student t 
test, p<0.01). The neutralising titres towards MW965.26 further increased in all four groups 
after protein boosting, where again after the first protein boost, these were significantly higher 
DDMMPP regimen compared to MMPPP (Student t test, p<0.05). DNA priming of the rMVA 
vaccine also improved the development of neutralising antibodies for tier 1B 1107356 
pseudovirions, which developed after the second MVA vaccine for the DDMMPP regimen and 
only after protein boosting for MMPPP. Most promising, neutralisation titres for vaccine 
matched Tier 2 neutralisation (autologous) towards CAP256_SU was observed in all four 
groups of rabbits as well. For the MMPPP regimen these neutralisation titres developed only 
after protein boosting and in 5 out of 9 animals after the final protein boost. CAP256_SU 
neutralisation titres were in general low (<1:105), although one animal showed consistently 
higher neutralisation response of above 1 in 300 after the second and third protein boost. DNA 
priming clearly increased the autologous Tier 2 neutralisation response in an animal. Although 
almost a similar number of rabbits developed neutralising antibodies for CAP256_SU (6 out 
of 10), titres were clearly higher, with four animals having titres above the threshold required 
for 50% protection (1 in 105) in a NHP model [147]. Furthermore, in three rabbits this 
neutralisation response already developed after the second rMVA vaccine. 
In depth analysis of the autologous Tier 2 neutralisation response comparing the groups 
receiving Env+GagM to those administered with Env alone revealed several exciting 
observations. First, more animals developed autologous Tier 2 neutralisation when Gag was 
included in the vaccines, with 3 out of 5 for MMPPP Env+GagM (60%) compared to 2 out of 4 
for Env alone (50%). This was even more pronounced for the DDMMPP regimen with 4 out of 
5 (80%) for Env+GagM compared to 2 out of 5 for Env alone (40%) (Figure 3.14). Furthermore, 
with Gag inclusion into the MMPPP or DDMMPP regimen, 5 out of 7 animals (rabbits 6526, 
6530, 6826, 6827 and 6830) with autologous Tier 2 neutralising antibodies developed these 
at an earlier time point compared to animals which received Env alone (rabbits 6047, 6048, 
6843 and 6848). For MMPPP Env+GagM this neutralisation appeared after the first protein for 
both animals whereas for DDMMPPP Env+GagM in 3 out of 4 rabbits Tier 2 neutralisation of 
CAP256_SU developed without a protein boost, after the second rMVA inoculation (Figure 
3.14, indicated with arrow). 
As mainly animals from the DDMMPP regimen showed autologous Tier 2 neutralisation titres 
above 1:105, the week 30 sera from these six rabbits were tested against a global panel of 
ten Tier 2 HIV-1 Env pseudoviruses. Three out of 6 animals developed a low titre neutralisation 
response against Clade A 398F1, ranging between 1:20-29 (Table 3.5). 
Table 3.5. Week 30 serum neutralisation against global panel for DDMMPP rabbit experiment 
as measured by TZM-bl assay.  
Week 30 sera from immunised animals were assessed for neutralising activity (ID50) against a global 
panel of Tier 2 Env pseudotyped virions.  
The 50% neutralisation titres are color-coded to reflect their potency range as indicated.  
Titres below 20 are considered negative. 
 
 
The same sera that were tested against the global Tier 2 panel were used to investigate the 
possible neutralisation site within the Env sequence. A K169E mutation within CAP256_SU 
X1632 398F1 25710 BJX2000 CE0217 CE1176 CH119 CNE8 CNE55 TRO.11 X2278 246F3
Rabbit Regimen G A C CRF07 C C CRF07 CRF01 CRF01 B B AC
6826 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6827 <20 21 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6830 <20 24 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6850 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6843 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
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Env leads to the loss of binding of the native-like Env trimer specific MAbs PG16 and CAP256 
VRC26.08 [167, 174, 252]. When sera were tested against these CAP256_SU K169E 
pseudovirions, no differences were observed compared to the CAP256_SU pseudovirion 
(Table 3.6), suggesting that the neutralisation response was directed towards a region outside 
the trimer apex of Env. In line with this, chimaeras formed by replacing the V1V2 region of two 
heterologous viruses, BG0505N332+ or CAP84, with that of CAP256_SU, were not 
neutralised, indicating that the Tier 2 NAbs elicited in this study are probably not targeting the 
V1V2 region. 
Table 3.6. Week 30 serum neutralisation against CAP256 Env K169E mutant for DDMMPP 
rabbit experiment as measured by TZM-bl assay.  
Week 30 sera from immunised animals positive for Tier 2 CAP256_SU neutralisation were assessed 
for neutralising activity (ID50) against CAP256_SU K169E or BG0505N332+ and CAP84 
pseudovirions with their V1V2 loop was replaced with that of CAP256_SU.  
The 50% neutralisation titres are color-coded to reflect their potency range as indicated.  
Titres below 20 are considered negative. 
     
 
3.4. Discussion 
Building on observations discussed in Chapter 2 where the adjuvant AlhydroGel induced a 
superior immune response with lectin affinity purified soluble CAP256 gp140-FL-IP (soluble 
Env (GNL)), here several experiments were performed where the protein vaccine was 
preceded by the DNA and/or recombinant MVA (rMVA) HIV-1 vaccines to test whether this 
would improve the immunogenicity and the longevity of this soluble Env protein vaccine. Both 
DNA and rMVA vaccines were characterised in vitro before subsequent animal testing. For 
DNA vaccines a backbone was used which was shown to elicit improved immunogenicity in 
mice and to allow significant dose sparing due to a novel enhancer element from porcine 
circovirus type 1 [299, 413]. The rMVA vaccines used in this study are able to actively infect 
certain lines of mammalian cells in vitro, whilst being replication incompetent in vivo: in either 
BG505N332 CAP84
Rabbit Regimen 2nd prot 3rd prot 2nd prot 3rd prot 2nd prot 2nd prot
6526 59 23 37 43 NT NT
6530 54 48 33 56 NT NT
6049 <20 39 NT <20 NT NT
6826 1295 N/A 1495 N/A <20 <20
6827 338 N/A 215 N/A <20 <20
6830 359 N/A 306 N/A <20 <20
6850 37 N/A 45 N/A <20 <20
6047 <20 28 NT 22 NT NT
6048 333 333 394 350 NT NT
6843 102 N/A 141 N/A <20 <20
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case, this will result in expression of exogenous genes present in MVA. Therefore, rMVA can 
induce both a humoral and cellular response and activate both CD4+ and CD8+ T-cells [315]. 
For both DNA and recombinant MVA vaccines, the CAP256 gp160 gene was truncated to 
gp150 (AA 730), thereby truncating most of the gp41 cytoplasmic tail while retaining the 
transmembrane domain, and improving expression and genetic stability [440]. The other 
modifications present in the soluble Env protein vaccine were retained, with the furin cleavage 
site replaced with two glycine-serine based repeats (GGGGS) to form a flexible linker (FL) 
[383, 384] and an I548P mutation equivalent to the I559P in the SOSIP trimers introduced to 
stabilise trimerisation of gp41 [374]. The vaccines generated with this insert were named 
pMExT gp150-FL-IP (DNA Env) and recombinant MVA gp150-FL-IP (rMVA Env). For both 
DNA and rMVA vaccines, subtype C mosaic Gag (GagM) was either co-expressed (DNA 
vaccine pTJDNA4, also in pTHpCapR backbone) or Env was targeted into rMVA GagM 
(abbreviated to DNA or rMVA Env+GagM). It was anticipated that inclusion GagM could 
potentially induce virus-like particle (VLP) formation in vivo as was shown in this project in 
vitro. This could lead to presentation of Env to the immune system in its natural membrane-
bound state in particles, which has been shown to lead to increased immunogenicity [442-
445]. Furthermore, the GagM, which was designed in silico to maximise potential T-cell 
epitopes, elicited an improved cell mediated immune response as compared to a natural Gag 
in mice and was therefore predicted to do the same in rabbits [272, 413, 414]. 
3.4.1 Env expressed from DNA and rMVA HIV-1 vaccines can take on a native-like 
conformation 
For DNA and rMVA vaccines, live-cell staining experiments were performed to identify the 
presence of epitopes recognised by broadly neutralising epitopes in Env. Although some 
epitopes characteristic of misfolded Env trimers were detected when Env was expressed from 
rMVA Env+GagM or DNA Env in HeLa cells as judged by positive signals for bnAbs F105 and 
447-52D, the broadly neutralising epitopes for the V2-superglycan (MAbs PGT128 and 
PGT135), the CD4-binding site (MAb VRC01) and V1V2 glycan (MAb PG9) were present as 
well. More importantly, clear fluorescent signals were detected for PG16, PGT145 and 
CAP256 VRC26.08, all bnAbs which specifically bind to Env in a native-like conformation. 
These observations are in line with data from Cappuci et al [343], where BG505 SOISP.664 
expressed from MVA or simian adenovirus resulted in expression of both native-like and 
misfolded trimers [343]. It should be emphasised that the live-cell staining used here is a 
qualitative assay, therefore developing a quantitative assay would greatly assist further 
characterisation of the DNA and rMVA HIV-1 vaccines. A fluorescence-activated cell sorting 
(FACS) based on this live-cell staining protocol could be considered. 
Compared to the Env protein vaccine used in Chapter 2, an additional round of purification 
was included where CAP256 soluble Env trimers were isolated from the lectin affinity-purified 
Env protein (soluble Env (GNL)) by size exclusion chromatography (SEC). These soluble Env 
trimers were mainly in a trimeric conformation as judged by molecular weight on Blue Native 
protein PAGE gels. However, when His-tagged soluble Env trimers were isolated by SEC, a 
full separation between trimers and dimers was not achieved. Despite this, soluble Env-His 
was tested for the presence of epitopes recognised by broadly neutralising epitopes in Env in 
an ELISA assay. Similar results were obtained as for the DNA and rMVA HIV-1 vaccines, 
where bnAb epitopes for V2-superglycan, the CD4-binding site (MAb and V1V2 glycan were 
present and ELISA signals were higher compared to soluble Env-His (GNL). Most 
encouragingly, ELISA signals for PG16 and CAP256 VRC26.08 were detectable, indicating 
that some of the soluble Env trimers were in a native-like conformation. However, clear ELISA 
signals were present as well for F105 and 447-52D, an indication of misfolded Env trimers. 
This was hardly surprising as Env-His dimers would have been present in the soluble Env-His 
trimer preparation. Therefore it is anticipated that the soluble Env trimers used as protein 
vaccine have an improved antigenic profile compared to the Env-His version considering the 
better BN-PAGE profile. However, additional purification by positive selection of native-like 
Env trimers using bnAbs PG16 or CAP256 VRC26.08 [371, 435] or removing misfolded trimers 
with F105 or 447-52D (negative selection) [385, 422] could be considered to improve the 
antigenic properties even further. Additional characterisation of the protein vaccine, based on 
for instance the bio-layer interferometry technology used in the Octet, could be considered as 
well. 
3.4.2 DNA priming improves the immunogenicity of a rMVA prime – protein boost 
HIV-1 vaccine regimen, including autologous Tier 2 neutralisation 
The DNA, rMVA and protein vaccines discussed above where subsequently tested in different 
heterologous vaccine platform regimens in rabbit immunogenicity studies. In two groups of 
animals, two rMVA vaccines (rMVA Env+GagM) were boosted with three trimeric, soluble Env 
protein vaccines, where group 1 received rMVA Env+GagM and group 2 rMVA Env (MMPPP). 
This was compared to two more groups where the same rMVA vaccines were primed with 
matching DNA vaccines (regimen DDMMPP). As DNA vaccines by themselves in general only 
lead to subtle and transient immune responses which are skewed towards a CD8+ rather than 
a CD4+ T-cell response [439], they are effective in priming a cellular immune response of viral 
vaccines and these heterologous vaccine regimens can lead to more balanced CD4+ and 
CD8+ T cell responses [446]. It has therefore been investigated in combination with rMVA in 
a number of studies [333, 335, 337, 339, 447], including from our group [334, 336, 354, 355, 
413]. 
Both MMPPP and DDMMPP regimens resulted in serum binding antibodies to CAP256 
soluble trimeric Env which could be detected after the first rMVA inoculation but not after DNA 
vaccines alone, and were boosted by the second rMVA. Although there was a trend with 
antibody titres increasing after each protein vaccine, this was not tested to be significant.  
Comparing both vaccine regimens, neutralisation titres for Tier 1A MW965.26 and Tier 1B 
6644 after the second rMVA inoculation were significantly higher for this DDMMPP regimen 
compared to MMPPP. In both regimens, Tier1B neutralisation of 6644 was observed after the 
second rMVA vaccine, but only in the DDMMPP regimen pseudovirions of 1107365 were 
neutralised at this time point. The most noteworthy difference between the two different 
regimes was in neutralisation titres for vaccine-matched Tier 2 CAP256_SU pseudovirions, 
which were clearly higher for DDMMPP (although failed to test significantly different), ranging 
between 1:54 and 1:1294 after the final protein boost. Tier 2 autologous neutralisation 
response rates were roughly similar between groups (DDMMPP 6/10 versus MMPPP 5/9). 
However, for the DDMMPP regimen, four animals had titres above the threshold required for 
50% protection (1 in 105) in a NHP model [147], compared to just one from the MMPPP 
regimen. Encouragingly as well for the DDMMPP regimen, Tier 2 neutralisation had developed 
after the first protein vaccine for all animals, whereas for the MMPPP some animals only 
developed low neutralisation titres after the third protein boost.  
The improvement in Tier 2 neutralisation when the rMVA vaccines are primed with matching 
DNA vaccines correlates with other studies which have shown that DNA primes a good 
humoral response [380, 448]. The addition of a DNA prime to MVA vaccination regimens also 
increases the magnitude and quality of T cell responses [347, 448, 449]. Addition of DNA-C 
priming in the EV01 Phase I Trial increased IgG antibody responses against Env from 27% in 
the group vaccinated with NYVAC alone to 75% in the DNA + NYVAC group [449]. The DNA 
prime also significantly boosted the T cell responses. The effectiveness of heterologous 
vaccines regimens is further emphasised by a study from Capucci et al. [343], where three out 
of four rabbits immunised with the simian adenovirus vaccine, followed by MVA and then 
ISCOMATRIXTM-adjuvanted BG505s trimer, developed autologous Tier 2 Nabs. 
The antibody lineage which developed into broadly neutralising antibodies in donor CAP256, 
where this Env sequence was taken from, was directed against the trimer apex (V1V2-loop) 
[425]. The CAP256_SU Tier 2 neutralisation observed in this DDMMPP experiment is most 
likely targeted outside of this region, as no differences were observed towards the 
neutralisation of CAP256_SU K169E mutant (where bnAb binding of PG16 and CAP256-
VRC26.08 is lost [94, 167, 174]). Similarly, no neutralisation of pseudorivrions BG505N332+ 
or CAP84, which both contain the CAP256_SU VIV2 loop, was seen. Further characterisation 
of the site of neutralisation would be informative, and showing that the site of neutralisation is 
similar between animals would build confidence that CAP256_SU Env is a suitable sequence 
for HIV-1 vaccines. Although it appears that Tier 2 neutralisation is outside the V1V2-loop, 
some low level Tier 2 cross-neutralisation was observed against 398F1. The V3-loop appears 
to be best conserved between CAP256_SU and 398F1 after aligning both Env sequences 
(data not shown), which possibly gives a clue towards the neutralisation epitope. It would be 
interesting to investigate for the 398F1 Env sequence if neutralisation is targeted to the same 
region as for CAP256_SU. However, the low neutralisation titres for 398F1 might be prohibitive 
for this analysis. 
3.4.3 Inclusion of mosaic Gag in DNA and rMVA prime vaccines improves 
autologous Tier 2 neutralisation dynamics 
For two different rabbit vaccine regimens, DNA and rMVA vaccines for Env were combined 
with HIV-1 subtype C mosaic Gag (GagM ) with the aim of inducing VLP formation in vivo, as 
was shown in this project in vitro. In this way, Env would be presented to the immune system 
in its natural membrane-bound state in particles, which has shown to lead to increased 
immunogenicity [442, 443, 445, 450]. Although binding antibodies to soluble Env or scaffolded 
CAP256 V1V2-loop protein were similar for groups receiving Env and Env+GagM, Tier 2 
neutralisation was positively affected by the inclusion of Gag into the HIV-1 vaccine of MMPPP 
and DDMMPP regimens. While it is difficult to conclude that Gag increases Tier 2 
neutralisation titres, the dynamics of Tier 2 neutralisation development were changed, with a 
clear increase in the number of animals where neutralisation is induced. For the majority of 
animals this neutralisation developed at an earlier time point compared to those vaccinated 
with Env alone. Possibilities are that Env stabilisation and presentation in a more native-like 
membrane-bound state on Gag VLPs, and/or the adjuvanting properties of the Gag VLPs, 
might underlie this phenomenon. Tong et al. [405] showed that the surface of HIV-1 derived 
VLPs often contain uncleaved gp160 and gp41 stumps, that promote the development of non-
neutralising responses. The removal of these non-functional Envs with protease treatment 
resulted in VLPs that were better able to induce Tier 2 NAbs [405, 451]. As the Env used in 
this paper contains a flexible linker between the gp120 and gp41 there is no necessity for 
cleavage, and thus it is highly unlikely that there will be any exposed gp41 stumps on the 
surface of our VLPs. Ingale et al. [389] showed that SOSIP or NFL trimers presented on the 
surface of nanoparticles were better at activating germinal centre B cells and inducing B cell 
receptor signalling and activation than soluble Env, further supporting the use of a particle-
based HIV vaccine. The Env presented on the surface of these nanoparticles also showed a 
trend towards eliciting better neutralising antibody responses compared to the soluble Env 
[389]. This is a possible mechanism underlying the improved response in with the DNA and 
rMVA Env+GagM priming, where this B-cell response is triggered by Env incorporated in Gag 
VLPs. 
Several studies in which Gag was included in the vaccine regimen point towards the value of 
heterologous vaccine strategies. In a non-human primate (NHP) model, DNA and rMVA 
vaccines expressing Env-Gag VLPs were moderately successful in generating a low 
autologous Tier 2 neutralisation response when used in a DNA prime, rMVA boost and 
rMVA+gp120 protein boost regimen [346]. Work at the Emory Vaccine Center by Amara et al., 
has shown the strength of VLP production from DNA prime – MVA boost (DDMM) regimens 
by inducing robust systemic cellular and humoral immune-responses in NHPs against HIV/SIV 
[445, 452-456]. Encouragingly, these DNA prime – MVA boost regimens resulted in delayed 
acquisition in macaques after SIV challenge [457, 458]. Inclusion of a gp140 protein vaccine 
in the second MVA inoculation improved antibody response towards Env [459]. Similar results 
were obtained when gp140 protein or Gag VLPs containing Env vaccines were used to boost 
DDMM regimens [345, 460, 461], although this might not necessarily improve protection 
against HIV-1 acquisition [461]. Furhtermore, subtle Tier 2 neutralisation was reported as well 
in NHPs when a DNA prime- rMVA boosting regimen, containing gp160 and Gag in the DNA 
vaccine and gp140 and Gag for the rMVA vaccine, was used [462]. A group receiving gp120 
protein at the same time as the rMVA vaccine performed best in this particular study. The case 
for heterologous prime-boost regimens is further strengthened by work in macaques by the 
Barouch group, who showed that adeno virus priming followed by rMVA boosting of bivalent 
M mosaic Env/Gag/Pol antigens vaccines is effective in generating low Tier 2 neutralisation 
response and protection in SHIV challenge models [463]. These studies, together with the 
data presented in this thesis, emphasises that heterologous prime-boost regimens could 
potentially lead to more immunogenic HIV-1 vaccines.  
It should be emphasised that it is complicated to directly compare the different studies as 
different antigens are used (such as BG505, ConM, ConS, CAP256 for these studies), Env 
length (gp160, gp150, gp140), Env mutations (such as SOSIP, stabilising mutations, deleted 
or optimised furin cleavage site and flexible linker), vaccine platforms (DNA, rMVA, adeno 
virus, protein and different heterologous combinations of these) and animal models (rabbit, 
guinea pig, macaques). 
Finally, compared to the protein vaccine used in Chapter 2, additional purification of soluble 
Env by isolating the trimeric fraction using SEC might have been another important factor 
driving the induction of autologous Tier 2 neutralisation. However, it should be emphasised 
that under the right conditions where Env and GagM were included in the DNA and rMVA 
vaccine, Tier 2 neutralisation was already observed after the second rMVA vaccine and was 
further boosted by the protein vaccines, suggesting that the combined effect of all three 
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Recently there is an increased interest in particulate vaccine designs for displaying Env in 
dense arrays. These can take the form of self-assembling protein nanoparticles such as virus-
like particles (VLPs), those which use proteins scaffolds such as the popular protein ferritin, 
or synthetic nanoparticles including lipid nanoparticles/liposomes, silica nanoparticles and 
particles based on polymers [401, 402]. Interestingly, the protein vaccines currently licensed 
for hepatitis B and human papillomavirus are VLP-based vaccines [403, 404]. One of the 
main objectives of particulate Env vaccines is better direct B-cell activation, where the 
repetitive display of high density Env trimers would probably improve B cell receptor (BCR) 
cross-linking and could potentially compensate for low affinity antigen-BCR interactions 
between Env and naïve B-cells [402, 405]. 
In Chapter 3, an approach was presented in which CAP256 gp150-FL-IP (Env) was displayed 
on Subtype C mosaic Gag (GagM) VLPs from HIV-1 DNA and MVA vaccines. When these 
Env+GagM HIV-1 vaccines were tested in immunogenicity studies in rabbits using different 
heterologous HIV-1 vaccine platforms, superior autologous Tier 2 neutralisation of 
CAP256_SU pseudovirions was observed in a regimen of 2x DNA, 2x MVA and 2x protein 
vaccines (DDMMPP) compared to Env without GagM vaccines or a regimen without HIV-1 
DNA vaccines (MMPPP). However, as the Env spike density on the native HIV-1 virion is 
relatively low when compared to other viruses [464], this could very well also be the case for 
these VLPs. Other groups have tried to improve spike density by replacing the transmembrane 
domain (TM) and cytoplasmic tail (CT) of gp41 with the corresponding elements from 
glycoproteins from other viruses. An increase in spike density of Env chimaeras resulted when 
the TM plus CT of glycoproteins from Epstein Barr virus, mouse mammary tumour virus 
(MMTV), baculovirus gp64 and HA from influenza A virus were used [399, 418-420, 465]. 
Therefore, in work reported in this chapter, an effort was made to improve the spike density 
on VLPs and the plasma membrane by generating chimaeric constructs between HIV-1 Env 
and the haemagglutinin stalk domain from influenza A, and to investigate if this would improve 
the spike density of this chimaeric construct on both the plasma membrane and VLPs 
compared to CAP256 gp150-FL-IP. Two constructs were designed, where either the whole 
HIV-1 gp41 was replaced with influenza haemagglutinin HA2 (CAP256 gp120HA2-FL-IP) or 
only the TM and CT of gp41 were substituted with the corresponding domain of HA2 (CAP256 
gp120HA2tr-FL-IP) (collectively named Env:HA2 chimaeras). One of the driving reasons for 
the selection of HA2 to generate these Env:HA2 chimaeras over the other glycoproteins 
mentioned above has been that, depending on the expression platform, these chimaeric 
proteins can assemble into particles without the need of Gag or other structural viral proteins 
[421]. After in vitro characterisation, the intent was that both Env:HA2 chimaeras would be 
used in DNA and MVA vaccines in combination with GagM for immunogenicity testing in rabbits 
using the DDMMPP regimen. 
4.2 Material and methods 
Refer to Sections 2.2 and 3.2 for methods common to all investigations. 
4.2.1 Design of CAP256 Env and Env:HA2 chimaeric constructs 
The sequence of the CAP256_SU gp160 (clone CAP256.206sp.032.C9) has been previously 
described (GenBank: KF241776.1) [167]. The Env sequence was altered as follows: the native 
leader (signal peptide) was removed, the furin cleavage site was replaced with two glycine-
serine based repeats (GGGGS) to form a flexible linker (FL) [383, 384] and an I548P mutation 
equivalent to the I559P in the SOSIP trimers was introduced to stabilize trimerisation of gp41 
[374]. Finally, the sequence was truncated to gp150 (AA 730) for MVA and DNA vaccines to 
increase expression and stability [440], thus generating gp150-FL-IP. Two different chimeras 
were generated in which either the whole of HIV-1 gp41 was replaced with the corresponding 
influenza HA2 stalk (gp120HA2-FL), or the ectodomain of gp41 including the I559P mutation 
was retained, and only the transmembrane domain and cytoplasmic tail of HA2 was used 
(gp140HA2tr-FL-IP). The HA2 stalk sequence was based on the influenza A H5N1 strain 
(REFSEQ: accession NC_007362.1). For all three constructs, any potential poxvirus 
termination signals (TTTTTNT) were removed from the coding sequence and a poxvirus 
termination signal (TTTTTCT) was added directly after the STOP codon (TGA) of the Env 
gene. The Env sequences were human codon optimised and synthesised by GenScript 
(Nanjing). For the Env:HA2 chimaeric constructs, only the C-terminal portion after the flexible 
linker (FL) was ordered for subsequent subcloning behind gp120-FL. 
4.2.2 Generation of DNA Env and Env:HA2 chimaeric vaccines 
The mammalian expression plasmid pMExT CAP256 gp150-FL-IP described in Chapter 3 
was used as a backbone for generating the Env:HA2 chimaeras. A unique, in-frame BamHI 
restriction site was introduced into gp150 at the C-terminal end of the flexible linker (FL), which 
allowed the exchange of gp41 with the influenza HA2 stalk or ectodomain of gp41 fused to the 
HA2 transmembrane domain and cytoplasmic tail using the BamHI and EcoRI sites thereby 
generating pMExT CAP256 gp120HA2-FL and pMExT CAP256 gp140HA2tr-FL-IP 
respectively (Figure 4.1A-C). After verification and characterisation (see Section 3.2.7), the 
DNA Env:HA2 chimaeric vaccines were synthesised by Aldevron (Fargo) for immunisation 
experiments. These DNA vaccines will be abbreviated in this chapter as outlined in Table 4.1. 
 
A) pMExT CAP256 gp150-FL-IP 
 
B) pMExT CAP256 gp120HA2-FL 
 
C) pMExT CAP256 gp140HA2tr-FL-IP 
 
Figure 4.1 Plasmid map of DNA vaccines 
expressing CAP256 Env and Env:HA2 
chimaeras. 
(A-C) Amp(R): ampicillin resistance gene for 
bacterial selection. ColE1: bacterial origin of 
replication. Mammalian expression of CAP256 
gp150-FL-IP, gp120HA2-FL and gp140HA2tr-FL-
IP is driven by a promoter containing a porcine 
circovirus enhancer (pCAP) in the reverse 
orientation, the essential component of the CMV 
promoter (pCMV core) and the non-essential part 
of the CMV promoter (pCMV minor) for maximal 
expression. Arrows indicate the direction of all 





Table 4.1 Abbreviations for Env and Env:HA2 chimaeric DNA vaccines 
Abbreviation Env insert Mosaic Gag co-expression 
DNAC5 CAP256 gp150-FL-IP x 
DNAGC5 CAP256 gp150-FL-IP Yes 
DNAC2 CAP256 gp120HA2-FL x 
DNAGC2 CAP256 gp120HA2-FL Yes 
DNAC4 CAP256 gp140HA2tr-FL-IP x 
DNAGC4 CAP256 gp140HA2tr-FL-IP Yes 
DNA GagM x Yes 
 
4.2.3 CAP256 Env transfer vector for generating recombinant MVA 
A transfer vector was created where in between overlapping flanks of the MVA G1L–I8R locus 
a selection cassette containing the eGFP gene under the control of the vaccinia virus (VACV) 
p7.5 promoter and K1L gene under the VACV pSS promoter were inserted to form the plasmid 
Shuttle and Selection for Pox Expression (pSSPEx) (Figure 4.2A). Similar as to CAP256 
gp150-FL-IP (Chapter 3), CAP256 gp120HA2-FL and CAP256 gp140HA2tr-FL-IP, including 
the tPA leader, were subcloned using HindIII and EcoRI sites from the pMExT DNA vectors 
downstream of the VACV mH5 promoter to generate pSSPEx CAP256 gp120HA2-FL and 
pSSPEx CAP256 gp140HA2tr-FL-IP (Figure 4.2B+C). 
A) pSSPEx 
 
B) pSSPEx CAP256 gp120HA2-FL 
 
 
C) pSSPEx CAP256 gp120HA2tr-FL-IP 
 
Figure 4.2. Plasmid map of CAP256 Env 
vectors.  
(A-C) Transfer vector for generating recombinant 
MVA. CmpR: chloramphenicol resistance gene 
for bacterial selection. The eGFP gene is driven 
by VACV promoter p7.5. The positive selection 
marker K1L is expressed from the VACV 
promoter pSS. PEPV DR: penguin pox direct-
repeat peptide, not expressed. G1L and I8R 
flanks: portions of MVA G1L and I8R open 
reading frames. Arrows indicate the direction of 
all promoters and transcripts. TPA leader: human 
tissue plasminogen activator leader sequence. 
(B+C) Transcription of Env:HA2 chimaeras is 
from the modified VACV H5 promoter (mH5). All 
transcripts include a 3` pox transcriptional 
termination signal (Pox terminator). 
 
4.2.4 Generation of rMVA GagM CAP256 Env:HA2 chimaeras 
For Env:HA2 chimaeras, recombinant MVA (rMVA) vaccines were only constructed in the 
rMVA GagM background [413, 414]. The rMVA vaccines rMVA GagM CAP256 gp120HA2-FL 
and rMVA GagM CAP256 gp140HA2tr-FL-IP were generated and grown to high titre stocks as 
described in Section 3.2.5. Both Env:HA2 chimaeric vaccines were verified and characterised 
as described in Section 3.2.8. These rMVA vaccines will be abbreviated in this chapter as 
outlined in Table 4.2. 
Table 4.2 Abbreviations for Env and Env:HA2 chimaeric DNA vaccines 
Abbreviation Env insert Mosaic Gag present 
MVAC5 CAP256 gp150-FL-IP x 
MVAGC5 CAP256 gp150-FL-IP Yes 
MVAGC2 CAP256 gp120HA2-FL Yes 
MVAGC4 CAP256 gp140HA2tr-FL-IP Yes 
MVA GagM x Yes 
wtMVA x x 
 
4.2.5 Verification and characterisation of DNA and rMVA vaccines 
In addition to the assays outlined in Section 3.2.7 and 3.2.8 for the verification and 
characterisation of the Env and Env:HA2 chimaeric DNA and rMVA vaccines, a FACS assay 
was adapted from Samal et al. 2019, to quantify the presence of Env bnAb epitopes after 
expression of the Env and DNA Env:HA2 chimaeric vaccines in HEK293T cells [466]. For this, 
T75 flasks, ~80% confluent with HEK293T cells, were transfected with 30µg of Env or Env:HA2 
chimaeric DNA vaccines using 90µl polyethyleneimine-branched (PEI). Three days post 
infection, completely confluent cell layers were harvested in PBS using a cell-scraper. All 
subsequent steps were performed at room temperature. First, harvested cells were washed 
three times with Buffer-1 (DMEM+5% FCS) by spinning cells down for four minutes at 475g. 
After reconstitution of the cells in the pellet after the final spin using Buffer-1, cells were divided 
between 12 wells in a 96-well round bottom plate and incubated with bnAbs at a final 
concentration of 10µg/ml) for 60 minutes. Cells were washed with Buffer-1 three times by 
spinning the 96-well plate for four minutes at 475g each time and were subsequently incubated 
with a 1:500 dilution of anti-Human IgG-Cy3 (Fc specific) antibody in Buffer-1 for one hour. 
Cells were then washed three times (as above) but with Buffer-2 (5% FCS in PBS) before 
fixing in Buffer-2 + 0.5% formaldehyde and subsequent analysis on a FACS Canto II Analyzer 
(BD Biosciences, Sunnyvale) which was programmed to measure FSC (forward scatter), SSC 
(side scatter), and Cy3 intensity. For each well, 100 000 cells were acquired in BD FACS Flow 
buffer as the sheath fluid. Data were analysed in the FlowJo software where cell gating cell 
was used to avoid cellular debris and calculate the mean fluorescent intensity (MFI) of Cy3. 
For each bnAb, untransfected cells were used as a control to determine the Cy3 negative and 
positive cell populations after forward and side scatter correction. To compare the gp150 and 
chimeric envelope constructs, an Env score for each bnAb was calculated based on the mean 
Cy3 fluorescent intensity (MFI) post FSC and SSC correction:  
𝐸𝑛𝑣 𝑠𝑐𝑜𝑟𝑒 =
(𝑀𝐹𝐼 𝑏𝑛𝐴𝑏 × 𝐶𝑦3 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠)
(𝐶𝑦3 𝑝𝑜𝑠𝑖𝑡𝑖𝑣𝑒 + 𝑛𝑒𝑔𝑎𝑡𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠)
 
The same anti-Env human bnAbs (PG9, PG16, PGT128, PGT135, PGT145, CAP256 
VRC26.08, VRC01, 10E8 F105 and 447-52D) as tested in the live-cell staining were used for 
these experiments. The following controls were included in the FACS assay: 1) untransfected 
cells + bnAbs + anti-Human IgG-Cy3 (used for correction as described above), 2) transfected 
and untransfected cells, incubated with only anti-Human IgG-Cy3, and 3) transfected and 
untransfected cells alone. This FACS assay was only performed for DNA vaccines (without 
GagM co-expression) as rMVA vaccines all expressed eGFP and the FACS Canto II Analyzer 
could not distinguish eGFP from Cy3 signals.  
Virus-like particles from the different Env and Env:HA2 chimaeric DNA or MVA vaccines were 
isolated from HEK293T cells using OptiPrep gradient centrifugation as outlined in Sections 
3.2.7 and 3.2.8. VLPs from the different HIV-1 vaccines were run on SDS-PAGE and blotted 
onto PVDF membranes. Detection of Env was performed using goat α-HIV 1 gp120 antibody 
(5000-0557, Bio-Rad, Hercules) allowing for direct comparison of Env and Env:HA2 chimaeras 
incorporation into Gag-VLPs. Mosaic Gag was detected using goat α-HIV 1 p24 (Gag) (4999-
9007, Bio-Rad, Hercules). After detection with a mouse monoclonal α-goat/sheep IgG-alkaline 
phosphatase (AP) GT34 (Sigma, St Louis), blots were imaged on a Gel Doc XR+ (Bio-Rad, 
Hercules) and densitometry was performed with Image Lab 5.2.1 (Bio-Rad, Hercules), which 
was used to calculate Env:Gag ratios. The data was normalised to the average Env:Gag ratio 
for CAP256 gp150-FL-IP + GagM (=1). The data was a combination of 3 independent 
experiments from MVA HIV-1 vaccines and 1 experiment from DNA HIV-1 vaccines (n=4). 
4.2.6 Rabbit immunisation comparing heterologous vaccine platforms 
Female New Zealand white rabbits were housed in the Research Animal Facility in the Faculty 
of Health Sciences at the University of Cape Town. All the animal procedures were approved 
by the UCT Animal Research Ethics Committee (UCT AEC 14-030 & UCT AEC 015/051) and 
performed by trained animal technologists Rodney Lucas and Inge Botes. The rabbits were 
monitored daily for any signs of pain, discomfort or stress and were weighed weekly. 
Three groups of 5 rabbits were selected to compare rMVA vaccines Env + GagM or Env:HA2 
chimaeras + GagM with matching DNA vaccine priming followed by soluble, trimeric Env 
boosting (see Table 4.3 for groups). All groups received 100µg pTJDNA4 (GagM) combined 
with either 100µg pMExT CAP256 gp150-FL-IP (group 1), pMExT CAP256 gp120HA2-FL 
(group 2) or pMExT CAP256 gp140HA2tr-FL-IP (group 3). Concentration of all DNA vaccines 
was 1mg/ml in PBS. Primes were administered intramuscularly in the hind leg at week 0 and 
4. At week 8 and 12, all groups received vaccine matched rMVA boosts. Groups 1 received 
108 pfu in 500µl PBS + 10% glycerol rMVA GagM CAP256 gp150-FL-IP, group 2 received 108 
pfu in 500µl PBS + 10% glycerol rMVA GagM CAP256 gp120HA2-FL and group 3 received 108 
pfu in 500µl PBS + 10% glycerol rMVA GagM CAP256 gp140HA2tr-FL-IP. These rMVA boosts 
were administered intramuscularly in the hind leg. Finally, all rabbits received 40µg of CAP256 
soluble, trimeric Env protein in 500µl 1:1 (v/v) AlhydroGel® at week 20 and 28 to boost the 
immune response. This experiment is abbreviated as DDMMPP. Animals were not sacrificed 
at week 39 as they were entered into a longitudinal study (not discussed in this dissertation). 
In group 3, one rabbit died after the first DNA inoculation due to unrelated causes. The data 
from group 1 is the same as used for Chapter 3. 
Table 4.3. Groups of rabbits comparing Env to Env:HA2 chimaeras 
 
4.2.7 Rabbit sera characterisation 
To assess Env or CAP256_SU V1V2-loop binding antibodies titres in rabbit sera, ELISA were 
performed as described in Section 3.2.10. However, ELISA data was fitted to a non-linear 
regression curve (log(agonist) vs. response – variable slope) in GraphPad Prism 5.0 . Antibody 
end-point titres (X) were calculated from the model used in the software for fitting: 
𝑇𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑌) = 𝐶𝑢𝑟𝑣𝑒 𝑚𝑖𝑛 (
𝐶𝑢𝑟𝑣𝑒 max − 𝐶𝑢𝑟𝑣𝑒 𝑚𝑖𝑛
1 + 10((𝐿𝑜𝑔𝐸𝐶50−𝑋) × 𝐻𝑖𝑙𝑙 𝑆𝑙𝑜𝑝𝑒
) 
Where the threshold (Y) for each time point was set as: 
𝑇𝑟𝑒𝑠ℎ𝑜𝑙𝑑 (𝑌) = 𝑤𝑒𝑒𝑘 0 𝐶𝑢𝑟𝑣𝑒 min + (2 × 𝑠𝑡𝑎𝑛𝑑𝑎𝑟𝑑 𝑒𝑟𝑟𝑜𝑟 𝑤𝑒𝑒𝑘 0 𝐶𝑢𝑟𝑣𝑒 min)  
Data were plotted as the mean +/- SEM for the whole group 
DNA rMVA gp140-FL-IP wk 0 wk 4 wk 8 wk 12 wk 20 wk 28
RB6826 1 gp150 + GagM gp150 + GagM AlhydroGel (1:1)      
RB6827 1 gp150 + GagM gp150 + GagM AlhydroGel (1:1)      
RB6828 1 gp150 + GagM gp150 + GagM AlhydroGel (1:1)      
RB6830 1 gp150 + GagM gp150 + GagM AlhydroGel (1:1)      
RB6850 1 gp150 + Gag
M gp150 + GagM AlhydroGel (1:1)      
RB6832 2 gp120HA2 + Gag
M gp120HA2 + Gag
M AlhydroGel (1:1)      
RB6833 2 gp120HA2 + Gag
M gp120HA2 + Gag
M AlhydroGel (1:1)      
RB6834 2 gp120HA2 + Gag
M gp120HA2 + Gag
M AlhydroGel (1:1)      
RB6835 2 gp120HA2 + Gag
M gp120HA2 + Gag
M AlhydroGel (1:1)      
RB6836 2 gp120HA2 + Gag
M gp120HA2 + Gag
M
AlhydroGel (1:1)      
RB6838 3 gp140HA2tr + Gag
M gp140HA2tr + Gag
M AlhydroGel (1:1)      
RB6839 3 gp140HA2tr + Gag
M gp140HA2tr + Gag
M AlhydroGel (1:1)      
RB6840 3 gp140HA2tr + Gag
M gp140HA2tr + Gag
M AlhydroGel (1:1)      
RB6842 3 gp140HA2tr + Gag
M gp140HA2tr + Gag
M AlhydroGel (1:1)      
RB6849† 3 gp140HA2tr + Gag
M gp140HA2tr + Gag
M
AlhydroGel (1:1)      
† Died of unrelated causes
Protein boost
animal group
Vaccine Prime rMVA boost
Rabbit sera from different time points were tested for the ability to inhibit Env-pseudotype 
virions to enter a reporter cell line as described in Section 3.2.10. The following Env-
pseudotyped viruses (MW965.26, 6644, 1107356, CAP256_SU, CAP256_SU K169E or 
BG0505N332+/CAP256_SU V1V2-loop and CAP84/CAP256_SU V1V2-loop) were assayed.  
All neutralisation assays were performed by Professor Lynn Morris’s group at the Centre for 
HIV and STIs, National Institute for Communicable Diseases of the National Health Laboratory 
Service, Johannesburg, South Africa. 
4.2.8 Statistical analysis 
All statistical analysis was performed in GraphPad Prism 5.0 (GraphPad Software, San Diego) 
and tests are indicated in results and/or corresponding figure legend. 
4.3 Results 
4.3.1 CAP256 Env immunogens 
It is well established that the Env spike density on the HIV-1 virion is relatively low when 
compared to other viruses [464]. It has previously been shown that substituting the 
transmembrane domain and cytoplasmic tail of gp41 with the corresponding elements of the 
hemagglutinin stalk from influenza A improves the spike density of this chimaeric construct on 
both the plasma membrane and virus-like particles (VLPs) [399]. Therefore, two chimaeric 
constructs were designed based on the modified CAP256 gp150-FL-IP characterised in 
Chapter 3, in which either the whole of HIV-1 Env gp41 was replaced with that of the influenza 
viral hemagglutinin stalk (HA2) or the ectodomain of gp41 was retained while introducing the 
HA2 transmembrane and cytoplasmic tail section, thus generating gp120HA2 and gp140HA2tr 
respectively (Figure 4.3A). DNA and rMVA vaccines were made for both chimaeric constructs. 
The Env protein vaccine used in this chapter is same as described in Chapter 3: that is, 
CAP256 soluble trimeric Env (Figure 4.3A). 
4.3.2 Transient expression of CAP256 Env:HA2 chimaeras from DNA vaccines 
As described in Chapter 3, HIV-1 subtype C mosaic Gag (pTJDNA4) was co-expressed with 
the aim of inducing the formation of VLPs. To test the Env and Env:HA2 chimaeric vaccines 
for in vitro expression and cellular secretion of transgenes, HEK293T cells were transiently 
transfected with pTJDNA4 + pMExT CAP256 gp150-FL-IP (DNAGC5, see Table 4.1), pMExT 
CAP256 gp120HA2-FL (DNAGC2) or pMExT CAP256 gp140HA2tr-FL-IP (DNAGC4). Env and 
Gag could be detected by western blotting in the cell media 72 hours after transfection (Figure 
4.3B), indicating that both Env and Gag were secreted. A non-specific band just below that of 





Figure 4.3 Design of CAP256 Env and 
Env:HA2 chimaeric vaccine inserts and 
characterisation of in vitro expression 
from DNA vaccines. 
(A) Schematic representations comparing 
wild type Env and Env:HA2 chimaeras used in 
DNA and rMVA vaccines. The Env sequence 
was truncated to amino acid 730 to improve 
transgene stability, while containing further 
modifcations where the wild type signal 
peptide (HIV-1 SP) was replaced with the 
human tissue plasminogen activator (TPA), 
the furin cleavage site with a flexible linker 
(FL) sequence and an I559P mutation was 
introduced (gp150-FL-IP). The whole of Env 
gp41 was replaced with that of influenza HA2, 
losing the I559P mutation, thus generating 
gp120HA2-FL-IP. Or only the  
transmembrane domain (TM) and cytoplasmic tail of HIV-1 gp41 was substituted for the 
corresponding elements from influenza HA2, retaining the I559P mutation, thus generating 
gp140HA2tr-FL-IP.  
(B) Co-expression of mosaic Gag (DNA GagM, pTJDNA4), and pMExT CAP256 gp150-FL-IP 
(DNAGC5), gp120HA2-FL-IP (DNAGC2) or gp140HA2tr-FL-IP (DNAGC4) DNA vaccines led to 
secretion of both Env (top) and Gag (bottom) into the media of HEK293T cells as detected by western 
blotting. An a-specific band just below that of Gag was detected in all samples, including in the empty 
vector control (pMExT) (indicated with *), whereas the specific band was present in all other samples, 
including pTJDNA4 alone. 
 
The Env and Env:HA2 chimaeric DNA vaccines by themselves were further characterised for 
the presence of a select list of Env bnAbs epitopes upon expression (Table 1.1) using a live 
cell staining protocol in HeLa cells. Using this method, only Env present on the plasma 
membrane would be detected and therefore be a suitable indication of the antigenic properties 
of the natively expressed (non-denatured) Env trimer. Cells expressing Env were positively 
identified with a rabbit α-Env polyclonal antibody after staining with the different bnAbs. 
Binding was observed for all epitopes tested for CAP256 gp150-FL-IP (DNAC5) and CAP256 
gp140HA2tr-FL-IP (DNAC4), but not gp120HA2-FL (DNAC2) (Table 4.4, Figure 4.4 and 
Appendix D).  
Table 4.4. Live cell staining using bnAbs in HeLa cells transfected with HIV-1 DNA vaccines 
 
 
As expected, no binding of bnAb 10E8 was observed for DNAC2, as the MPER domain of 
HIV-1 Env was replaced with that of influenza HA2, whereas the MPER epitope was detected 
for DNAC5 and DNAC4. All other, non native-like trimer epitopes were present for all three 
DNA constructs: the V3-glycan supersite (bnAbs PGT128 and PGT135), the CD4-binding site 
(VRC01) and the V2-glycan (PG9). Although some signal was also detected with the bnAbs 
F105 and 447-52D, suggesting that some of the Env expressed from the DNA vaccine was 
misfolded. Interestingly, as with bnAb10E8, bnAbs recognising native-like Env trimers (PG16, 
PGT145 and CAP256 VRC26.08) also failed to bind to DNAC2 but had very clear signal for 
DNAC5 and DNAC4 (Table 4.4 and Figure 4.4). This result implies that only gp150-FL-IP and 
the Env:HA2 chimaera where only a short portion of Env is replaced with that of influenza HA2 
(gp140HA2tr-FL-IP) can induce native-like Env trimers, whereas when gp41 is completely 
replaced with HA2 (gp120HA2-FL) mainly misfolded Env trimers are formed. Only 
immunofluorescence for bnAbs was observed in cells that were positive for the rabbit α-Env 
polyclonal antibody (as assessed by FITC signal), indicating the specificity of the bnAb live-
cell staining. However, especially for PGT145, PG16 and CAP256 VRC26.08, bnAb signals 
were not detected in all cells positive for Env expression.  
 
 
Antibody Neutralisation Epitope DNAC5 DNAC2 DNAC4
PGT128 Broad V3-glycan supersite x   
PGT135 Broad V3-glycan supersite x   
447-52D Narrow V3 x   
VRC01 Broad CD4 binding-site x   
F105 Narrow CD4 binding-site x   
PG9 Broad V2-glycan x   
PG16 Broad V2-glycan Yes   
PGT145 Broad V2-glycan Yes   
CAP256 VRC26_08 Broad V2-glycan Yes   
10e8 Broad MPER x   
Native-like 
trimer
Live cell mapping DNA
A) DNAC5 PG16 
 
B) DNAC5 PGT145 
 
C) DNAC5 VRC26_08 
 
D) DNAC2 PG16 
 
E) DNAC2 PGT145 
 
F) DNAC2 VRC26_08 
 
G) DNAC4 PG16 
 
H) DNAC4 PGT145 
 
I) DNAC4 VRC26_08 
 
J) DNAC5 10E8 
 
K) DNAC2 10E8 
 
L) DNAC4 10E8 
 
Figure 4.4. Live cell staining using bnAbs recognising native-like Env trimers or MPER domain 
in HeLa cells transfected with HIV-1 DNA vaccines.  
(A-L) HeLa cells transfected with pMExT CAP256 gp150-FL-IP (DNAC5) and gp140HA2tr-FL-IP 
(DNAC4) and gp120HA2-FL (DNAC2) were visualised by their Env expression using a rabbit α-Env 
polyclonal and α-rabbit IgG-FITC (RB). The bnAbs PG16, PGT145, CAP256 VRC26.08 and 10E8 
were detected with anti-human IgG-Cy3 (HMAb). The bnAb epitopes for native-like trimers (PG16, 
PGT145, and CAP256 VRC26.08) or the MPER (10E8) are present for DNAC5 and DNAC4 but not 
DNAC2. Overlapping signal between the rabbit α-Env polyclonal and bnAbs appears as yellow. Bar 
represents 20µm. 
 
With the bnAb live-cell staining being a qualitative assay, a fluorescence-activated cell sorting 
(FACS) experiment in HEK293T cells was performed for a quantitative measure of the bnAb 
epitopes present in Env or Env:HA2 chimaeras (Figure 4.5). The results presented for the 
FACS assay are expressed as the Env score which better represents the data, as it takes into 
account the number of cells with a positive and negative signal for bnAb binding (see Section 
4.2.5). Similar to the live-cell staining, for DNAC2 almost no signal is detectable for the MPER 
bnAb 10E8 or the bnAbs selective for native-like Env trimers (PG16, PGT145 and CAP256 
VRC26.08). For DNAC5 and DNAC4, the Env score for all three native-like V2 trimer apex 
bnAbs (PG16, PGT145 and CAP256 VRC26.08) is lower compared to none native-like trimer 
epitopes of the V3-glycan supersite (bnAbs PGT128 and PGT135), the CD4-binding site 
(VRC01) and the V2-glycan (PG9). However, almost 20% of Env is in a native-like state for 
DNAC5 and DNAC4 when the Env score for PG16, PGT145 or CAP256 VRC26.08 is 
normalised to VRC01. There are no obvious differences between DNAC5 and DNAC4, 
however there is a trend towards higher Env scores for DNAC5 for all bnAb epitopes apart 
from F105 and 447-52D, which are indicative of misfolded Env trimers. Interestingly, for the 
latter two bnAbs, the highest Env scores are observed for DNAC2. Combined with the 
extremely low Env scores for PG16, PGT145 and CAP256 VRC26.08 this suggests that 
expression of DNAC2 leads to a high percentage of misfolded Env trimers. Furthermore, this 
data would also suggest the Env:HA2 chimaeras fail to improve the spike density on the 
plasma membrane as this would have been reflected in higher Env scores. In general, Env 
scores are highest for DNAC5: the highest Env score for all bnAbs (10E8) is for DNAC5 and 
the sum of all Env scores is highest for DNAC5. 
 
Figure 4.5 FACS based assay to quantify the presence of Env bnAb epitopes from Env and 
Env:HA2 chimaeric DNA vaccines.  
Env expression on the cell membrane of HEK293T cells transfected with CAP256 gp150-FL-IP 
(DNAC5) and CAP256 gp140HA2tr-FL-IP (DNAC4) and gp120HA2-FL (DNAC2) was quantified by 
bnAbs for V3-glycan supersite (bnAbs PGT128 and PGT135), the CD4-binding site (VRC01), the V2-
glycan (PG9) and trimers (PG16, PGT145 and (CAP256) VRC26.08) or non-NAbs F105 and 447-
52D in a FACS assay. Env scores +/- SEMs (based on cells positive for Cy3, n=1 experiment) 
 











































4.3.3 Construction and characterisation of rMVA vaccines expressing Env 
4.3.3.1 Verification of the integrity of rMVA vaccines 
Recombinant MVA expressing GagM and the two different Env:HA2 chimaeras were generated 
similarly as was described for rMVA GagM + CAP256 gp150-FL-IP in Section 3.3.2 (Figure 
4.6 for targeting strategy), resulting in MVAGC2 (expressing GagM + CAP256 gp120HA2-FL) 
and MVAGC4 (expressing GagM + CAP256 gp140HA2tr-FL-IP) (Table 4.2). Single clones for 
both MVA vaccines were selected from RK13 cells and expanded to high titres stocks 
(MVAGC2 = 2.0*109; MVAGC4 = 1.9*109) in RK13 cells. To test for correct integration and 
stability of Env in the I8R-G1L locus, PCRs were carried out on DNA isolated from RK13 cells 
infected with the high titre stocks rMVA using a primer upstream of the VACV mH5 promoter 
and a reverse primer within the G1L locus but outside the G1L recombination flank in pSSPEx. 
These PCR products were subsequently sequenced to check for possible mutations. The 
sequence was exactly as predicted for both recombinant MVA vaccines indicating correct 
integration of Env:HA2 chimaeras into the MVAGC2 or MVAGC4 vaccines (data not shown). 
In a similar fashion, the 5’ and 3’ arms of GagM were verified as well (data not shown). 
 
Figure 4.6. Targeting strategy for the generation of recombinant MVA expressing Env and 
Env:HA2 chimaeras.  
Schematic representation of targeting CAP256 gp150-FL-IP, gp120HA2-FL or CAP256 gp140HA2tr-
FL-IP into the I8R-G1L locus of the MVA GagM pox genome. Triangles indicate direction of open-
reading frames. Expression of Env or Env:HA2 chimaeras is driven by the VACV mH5 promoter 
 
.3.3.2 Expression of Env by rMVA vaccines 
To assess for in vitro expression of the recombinant antigens, HEK293T cells were infected 
with Env and Env:HA2 chimaeric MVA vaccines; namely MVAGC5, MVAGC2 and MVAGC4. 
Similar to the DNA vaccines, Env and Gag could be detected by western blotting in the cell 
media 48 hours after infection (Figure 4.7A), indicating that both Env and Gag were secreted. 
Again, a non-specific band just below that of Gag was observed in all samples, including the 
empty vector control (indicated with *). Furthermore, immunofluorescent staining and confocal 
imaging of infected cells showed expression and co-localisation of Gag and Env for all three 











Figure 4.7. Characterisation of in vitro expression of MVA Env and 
Env:HA2 chimaeric vaccines.  
(A) Both Env and Gag could be detected in media from HEK293T cells 
infected with MVA GagM + CAP256 gp150-FL-IP (MVAGC5), + 
gp120HA2-FL-IP (MVAGC2) or + gp140HA2tr-FL-IP (MVAGC4) 
whereas only Gag was detected for MVA GagM (GagM). An a-specific 
band just below that of Gag was detected in all samples, including wild 
type MVA (wtMVA) (indicated with *). 
 (B-E) Confocal imaging (maximum intensity projections) showing co-
localisation of Gag and Env within HEK293T cells after infection with 
with MVAGC5 (B), MVAGC2 (C) and MVAGC4 (D). (E) No Env or Gag 
immunofluorescent signal in uninfected control cells.  
Pseudo-colouring for Cy3 is in red (Gag) and Alexa 647 in green (Env).  
Scale bar=10μm. 
 
Env and Env:HA2 chimaeric MVA vaccines, (MVAGC5, MVAGC2 and MVAGC4) were 
characterised for the presence of bnAb epitopes upon infection of HeLa cells in similar 
experiments as for the DNA vaccines, resulting in a very comparable outcome. The same 
bnAb epitopes, recognising native-like Env trimers (PG16, PGT145 and CAP256 VRC26.08) 
or the MPER domain (10E8) were undetectable for MVAGC2 (Table 4.5, Figure 4.8 and 
supplement E). All other, non native-like trimer epitopes were present for all three MVA 
vaccines, the V3-glycan supersite (bnAbs PGT128 and PGT135), the CD4-binding site 
(VRC01), and the V2-glycan (PG9). Although some signal was detected as well with the bnAbs 
F105 and 447-52D, suggesting that some of the Env expressed from the Env and Env:HA2 
chimaeric vaccines was misfolded. However, for MVAGC5 and (although fainter) MVAGC4, 
bnAbs recognising native-like Env trimers (PG16, PGT145 and CAP256 VRC26.08) were 
detected, suggesting that only these two HIV-1 MVA vaccines can induce native-like Env 
trimers. Infected HeLa cells were identified by the presence of an eGFP signal, expressed 
from the recombinant MVA. 
Table 4.5. Live cell staining using bnAbs in HeLa cells infected with HIV-1 MVA vaccines 
 
 
4.3.4 Virus-like particle formation from Env:HA2 chimaeric DNA and rMVA vaccines 
As shown for DNAGC5 and MVAGC5 (Chapter 3 and Figure 4.9+10), expression of the 
Env:HA2 chimaeras from DNAGC2, DNAGC4 (both Figure 4.9), MVAGC2 or MVAGC4 (both 
Figure 4.10) resulted in the formation of VLPs as observed by electron microscopy (EM). A 
small number of VLPs were measured using the EM imaging software and with data combined 
from both DNA and MVA, no significant differences in VLP diameter was observed between 
the different Env and Env:HA2 chimaeric constructs or to Gag alone (One-way ANOVA) 
(Figure 4.11D).  
When VLPs resulting from expression of Env and Env:HA2 from chimaeric DNA or MVA 
vaccines were isolated from the media of HEK293T cells by a two-step OptiPrep gradient 
centrifugation protocol, both Gag and Env were present as confirmed with western blotting of  
Antibody Neutralisation Epitope MVAGC5 MVAGC2 MVAGC4
PGT128 Broad V3-glycan supersite x   
PGT135 Broad V3-glycan supersite x   
447-52D Narrow V3 x   
VRC01 Broad CD4 binding-site x   
F105 Narrow CD4 binding-site x   
PG9 Broad V2-glycan x   
PG16 Broad V2-glycan Yes   
PGT145 Broad V2-glycan Yes   
CAP256 VRC26_08 Broad V2-glycan Yes   
10E8 Broad MPER x   
Native-like 
trimer
Live cell mapping rMVA
 
Figure 4.8. Live cell staining using bnAbs recognising native-like Env trimers or MPER domain 
in HeLa cells infected with HIV-1 MVA vaccines.   
HeLa cells infected with MVA GagM plus CAP256 gp150-FL-IP (left column), gp120HA2-FL (middle 
column), or gp140HA2tr-FL-IP (right column) were identified by eGFP expression from MVA (MVA). 
The bnAbs PG16 (1st row), PGT145 (2nd row), CAP256 VRC26.08 (3rd row) and 10E8 (4th row) were 
detected with anti-human IgG-Cy3 (Env). The bnAb epitopes for native-like trimers (PG16, PGT145, 
and CAP256 VRC26.08) or the MPER (10E8) are present for MVAGC5 and MVAGC4 but not 
MVAGC2. Because of the low signal, cells infected with MVA GagM + gp140HA2tr-FL-IP positive for 
10E8 are indicated with *. Bar represents 20µm. 
 
samples from the only visible band (~45mm from the bottom) isolated from the second 
OptiPrep gradient, suggesting Env inclusion into Gag VLPs (Figure 4.11A+B). Encouragingly, 
no Env band was observed in the equivalent band isolated from DNA or rMVA vaccines 









Figure 4.9. In vitro Gag VLP formation from RK13 cells transfected with Env and Env:HA2 DNA 
vaccines. 
(A-D) Electron microscopy images showing in vitro formation of VLPs from the different DNA 
vaccines. Examples of VLPs are indicated with  and VLP budding events with *. (A) DNAGC5, (B) 
DNAGC2 and (C) DNAGC4. No VLP-like structures could be detected in the empty vector control 
(D). 
 
this was repeated three times, whereas for the matching DNA vaccines this was performed 
once. These blots were used for densitometry and to calculate Env:Gag ratios as a measure 
for Env spike density on the isolated VLPs, with the average signal for Gag+gp150 (GC5) set 
as 1. Surprisingly, no significant differences between Env (GC5) and the Env:HA2 chimaeras 
(GC2 and GC4) were detected (One-way ANOVA) (Figure 4.11C). If anything, there is a trend 
towards higher Env spike density for gp150 rather than the Env:HA2 chimaeras. 
4.3.5 Immunogenicity studies in rabbits comparing Env and Env:HA2 chimaeric 
DNA and MVA based vaccines 
To investigate how the in vitro characteristics of the three Env and Env:HA2 chimaeric DNA 
and MVA vaccines translates into in vivo immunogenicity, three group of rabbits were 
inoculated using the regimen optimised in Chapter 3 of two DNA vaccines, followed by two 









Figure 4.10. In vitro Gag VLP formation from RK13 cells infected with Env and Env:HA2 rMVA 
vaccines.  
(A-C) Electron microscopy images showing in vitro formation of VLPs from the different rMVA 
vaccines. Examples of VLPs are indicated with  and VLP budding events with *. (A) MVAGC5, (B) 
MVAGC2 and (C) MVAGC4.  
The dotted line in (B) approximately delineates the extracellular compartment with VLPs on the left 
from the cell on the right containing mature MVA particles.  
(D) No VLP like structures could be detected in MVAC5 (Env alone).  
 
adjuvanted in AlhydroGel (DDMMPP) (Table 4.3, Figure 4.12). Data for the rabbits receiving 
DNA and MVA vaccines containing Env+GagM (GagM+gp150) is the same data as presented 
in Chapter 3.  
Serum was taken at regular intervals and tested in a soluble, trimeric Env binding ELISA as 
described before (Section 3.3.5). Again, Env-binding antibodies only developed after 
administration of rMVA vaccines (Figure 4.13A). No differences were observed in the  
development of α-Env binding antibodies over time between the group receiving GagM +Env 
(GagM+gp150) as DNA and MVA vaccines or the two groups inoculated with GagM+Env:HA2 
chimaeric DNA and MVA vaccines (GagM+gp120HA2 or GagM+gp140HA2tr) (Two-way 
ANOVA). Similarly, for all three groups, α-Env binding antibody titres peaked after every rMVA 









Figure 4.11. Env inclusion into Gag-VLPs from Env + GagM DNA and rMVA vaccines.   
(A+B) Env (top) and Gag (bottom) could be detected by western blotting in VLPs isolated from the 
second OptiPrep gradient when both GagM and Env were co-expressed from DNA (A) and rMVA (B) 
Env and Env:HA2 vaccines. Likewise, VLPs containing Gag only are detected from DNA or rMVA 
GagM. Whereas no Gag or Env signal was detected for cells alone, DNA or rMVA Env vaccines or 
wildtype MVA.  
(C) No significant differences in relative Env:Gag ratios between Env and the Env:HA2 chimaeric 
vaccines (n=4; One-way ANOVA) as measured by densitometry of western blot signals from isolated 
VLPs.  
(D) Similarly, inclusion of Env and Env:HA2 chimaeras has no effect on VLP size (One-way ANOVA). 
Data combined from EM pictures of DNA and MVA HIV-1 vaccines.  
 
either of the two protein boosts (Two-way ANOVA). These α-Env binding antibodies appear 
to reach a titre within the serum which cannot be improved upon. Serum from all three groups 
were tested in a binding ELISA against the autologous CAP256 SU V1V2 loop at week 14 










































Figure 4.12. Rabbit immunisation regimens.  
Immunisation protocol for the three different groups. with matching DNA and MVA vaccines (GagM 
+ gp150-FL-IP, GagM + gp120HA2-FL or GagM + gp140HA2tr-FL-IP). Animals in all groups received 






Figure 4.13. Env binding ELISAs of rabbit sera.  
(A) Time course depicting binding of rabbit sera to soluble, trimeric CAP256 Env as measured by 
ELISA. Endpoint titre was plotted as 10 when no ELISA signal was observed.  
(B) CAP256 V1V2 loop scaffold binding ELISA of rabbit sera post second MVA or post final protein . 
This binding ELISA was negative for week 0.  
Groups identified as DNA and matching MVA vaccine (GagM+gp150, GagM+gp120HA2 and 
GagM+gp140HA2tr). 
All data are presented as group averages +/- SEMs. 
 
point titres of the sera could be detected between the different groups (GagM+gp150, 
GagM+gp120HA2 or GagM+gp140HA2tr) or between week 14 and 30 (Two-way ANOVA). 
When these rabbit sera were tested for neutralizing activity (ID50) against a panel of Env-
pseudotyped virions, neutralisation of Tier 1A MW965.26 can already be observed after the 
first rMVA inoculation with no clear differences between the different GagM plus Env or 
Env:HA2 chimaeric DNA and MVA vaccines (Table 4.6). These neutralisation titres 
significantly increased after the second rMVA inoculation (all groups/rabbits combined, 
Student t-test, p<0.001). At this same time point, most animals developed Tier 1B 
neutralisation for Tier 1B 6644 and some towards Tier 1B 1107365. Protein boosting failed to 
enhance these Tier 1A and 1B neutralisation titres, but the patterns appear very similar 
between the different GagM plus Env or Env:HA2 chimaeric DNA and MVA vaccines. 
Encouragingly, neutralisation titres for vaccine matched Tier 2 neutralisation towards 
CAP256_SU were observed, ranging between 1:44 and 1:1294 after the final protein boost  
DDMMPP wk0 min+2xSE
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Table 4.6. Serum neutralisation from rabbits vaccinated with different adjuvants as measured by TZM-bl assay.  
Sera from immunised animals were assessed for neutralising activity (serum dilution required for a 50% reduction in entry of the 
infecting virus into a reporter cell line (ID50) against a panel of Env-pseudotyped virions at different time points. The 50% 
neutralisation titres are color-coded to reflect their potency range as indicated. Pre-bleeds (pre) was taken at week 0. All other bleeds 
were taken 2 weeks after the indicated vaccine, abbreviated as M1: first MVA, M2: second MVA, P1: first protein and P2: second 
protein. The pre-bleeds and MuLV control for all rabbits and time points were negative in this assay. As the Env binding ELISA was 
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Regimen Rabbit pre M1 M2 P1 P2 pre M1 M2 P1 P2 pre M1 M2 P1 P2 pre M1 M2 P1 P2 pre-wk30
6826 <20 195 3426 5286 7840 <20 <20 85 45 170 <20 <20 32 <20 29 <20 <20 70 486 1294 <20
6827 <20 119 3892 14601 2748 <20 <20 120 196 104 <20 <20 35 <20 <20 <20 <20 53 519 174 <20
6828 <20 81 7239 664 4348 <20 <20 172 20 136 <20 <20 62 <20 21 <20 <20 <20 <20 <20 <20
6830 <20 108 12641 20778 3920 <20 <20 299 172 143 <20 <20 40 <20 <20 <20 <20 60 332 296 <20
6850 <20 <20 1999 1987 787 <20 <20 78 40 41 <20 <20 <20 <20 <20 <20 <20 <20 32 54 <20
median <20 108 3892 5286 3920 <20 <20 120 45 136 <20 <20 35 <20 <20 <20 <20 53 332 174 <20
6832 <20 <20 470 3594 1115 <20 <20 <20 30 <20 <20 <20 21 <20 <20 <20 <20 <20 <20 <20 <20
6833 <20 166 82 96 211 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6834 <20 36 42 305 148 <20 <20 <20 21 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20
6835 <20 25 2410 1050 3680 <20 <20 130 74 83 <20 <20 <20 <20 23 <20 <20 <20 <20 <20 <20
6836 <20 35 8193 6134 1786 <20 <20 595 175 158 <20 <20 47 <20 <20 <20 <20 <20 <20 <20 <20
median <20 40 502.3 925 745 <20 <20 56 43 39 <20 <20 23 <20 <20 <20 <20 <20 <20 <20 <20
6838 <20 97 1060 6524 3235 <20 <20 113 154 113 <20 <20 <20 <20 25 <20 <20 <20 <20 <20 <20
6839 <20 53 578 8835 2578 <20 <20 32 262 89 <20 <20 <20 24 <20 <20 <20 <20 242 151 <20
6840 <20 44 101 384 298 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 <20 103 44 <20
6842 <20 87 NT 5783 2816 <20 <20 NT 112 128 <20 <20 NT <20 <20 <20 <20 NT 171 220 <20
median <20 67 395.5 3364 1626 <20 <20 41 96 70 <20 <20 <20 <20 <20 <20 <20 <20 95 72.6 <20
ID50 after:
Clade C Tier 1A
MW965.26
Clade C Tier 1B Clade C Tier 1B
ID50 after: ID50 after: ID50 after:













 (Table 4.6). These Tier 2 neutralisation titres for CAP256_SU are above the threshold 
required for 50% protection (1 in 105) in a NHP model [147] in 5 out of 7 animals. Interestingly, 
there is a complete lack of any Tier 2 neutralisation for the group receiving gp120HA2tr as part 
of the DNA and MVA vaccines. Whereas it appears the Env:HA2 chimaera gp140HA2tr-FL-IP 
fails to improve immunogenicity over gp150-FL-IP, including Tier 2 neutralisation. 
The week 30 sera from  seven rabbits that showed Tier 2 neutralisation against CAP256_SU 
were tested against a global panel of ten Tier 2 HIV-1 Env pseudoviruses. Five out of 7 animals 
developed a low titre neutralisation response against Clade A 398F1 (ranging between 1:20-
29) (Table 4.7). 
Table 4.7. Week 30 serum neutralisation against global panel for DDMMPP rabbit experiment 
as measured by TZM-bl assay.  
Week 30 sera from immunised animals were assessed for neutralising activity (ID50) against a global 
panel of Tier 2 Env pseudotyped virions.  
The 50% neutralisation titres are color-coded to reflect their potency range as indicated.  
Titres below 20 are considered negative. 
 
 
The same sera that were tested against the global Tier 2 panel was used to investigate the 
possible neutralisation site within the Env sequence. A K169E mutation within CAP256_SU 
Env leads to the loss of binding of the native-like Env trimer specific MAbs PG16 and CAP256-
VRC26.08 [167, 174, 252]. When sera were tested against these CAP256_SU K169E 
pseudovirions, no differences were observed compared to the CAP256_SU pseudovirion 
(Table 4.8), suggesting that the neutralisation response was directed towards a region outside 
the trimer apex of Env. In line with this, chimaeras formed by replacing the V1V2 region of two 
heterologous viruses, BG0505N332+ or CAP84, with that of CAP256_SU, were not 
neutralised, indicating that the Tier 2 NAbs elicited in this study are probably not targeting the 
V1V2 region. 
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Table 4.8. Week 30 serum neutralisation against CAP256 Env K169E mutant for DDMMPP 
rabbit experiment as measured by TZM-bl assay.  
Week 30 sera from immunised animals positive for Tier 2 CAP256_SU neutralisation were assessed 
for neutralising activity (ID50) against CAP256_SU K169E or BG0505N332+ and CAP84 
pseudovirions with their V1V2 loop was replaced with that of CAP256_SU.  
The 50% neutralisation titres are color-coded to reflect their potency range as indicated.  
Titres below 20 are considered negative. 
     
 
4.4 Discussion 
In Chapter 3, a regimen of two HIV-1 DNA vaccines followed by two recombinant HIV-1 MVA 
vaccines and boosted with two CAP256 soluble, trimeric Env protein vaccines, led to superior 
immune responses, including autologous Tier 2 neutralisation. This was especially true when 
CAP256 gp150-FL-IP and subtype C mosaic Gag were included in the DNA and MVA 
vaccines, possibly due to the formation of Gag virus-like particles (VLPs) in vivo as was shown 
previously in vitro. For work reported in this chapter, an effort was made to improve this spike 
density on VLPs and the plasma membrane by generating chimaeric constructs between HIV-
1 Env and the HA stalk from influenza A, as it had  previously been shown that substituting 
the transmembrane domain and cytoplasmic tail of gp41 with the corresponding elements of 
the HA stalk improved the spike density of this chimaeric construct [399]. Two different 
constructs were generated, based on CAP256 gp150-FL-IP, in which either the whole of HIV-
1 Env gp41 was replaced with that of the influenza viral stalk domain (HA2) (gp120HA2), or the 
ectodomain of gp41 was retained while introducing the HA2 transmembrane and cytoplasmic 
tail section (gp140HA2tr). 
No differences in in vitro expression levels of gp150 Env and Env:HA2 chimaeras from DNA 
and rMVA vaccines were observed. VLP formation was verified from both platforms by 
electron microscopy when GagM was co-expressed, and no major differences in VLP 
morphology or diameter were apparent between Env and Env:HA2 chimaeras. Surprisingly, 
when the above VLPs were isolated by OptiPrep density centrifugation, no differences in 
Env:Gag protein ratios between Env and Env:HA2 chimaeras were observed. Similarly, Env 
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scores of Env bnAb binding in a FACS assay were similar or on the whole better for gp150 
Env compared to Env:HA2 chimaeras. This would all suggest that the Env:HA2 chimaeras 
vaccines tested here failed to enhance surface Env spike density in contrast to what has been 
described before by Wang et al., 2007 [399]. However, this might have been influenced by 
several differences in construct design (Table 4.9). For instance, Wang et al. used different 
signal peptides for the chimaeric Env construct compared to gp160, which might have affected 
Env trafficking to the plasma membrane [416, 417]. Furthermore, the furin cleavage site 
present in gp160 was removed for the chimaeric construct, which means that subsequent 
shedding of gp120 from gp41 for the gp160 control might have skewed the data in the study 
by Wang et al. For the experiments reported in this chapter, replacement of the signal peptides 
with the tPA leader and of the furin site with a flexible linker were performed for both Env and 
the Env:HA2 chimaeras, which might have improved the spike density of Env as well. Finally, 
for the experiments in this chapter, Env was truncated to gp150, which should have improved 
expression compared to the gp160 used by Wang et al., 2007 [399, 400]. Moreover, the use 
of a different Env in this work may also have been a factor. In summary, all the modifications 
which were introduced to CAP256 gp150-FL-IP might have led to much higher Env levels on 
the plasma membrane which then could be recruited into VLPs, thereby substantially 
increasing Env spike density as compared to the Con-S gp160 used by Wang et al., 2007 
[399]. Experiments comparing the unmodified CAP256_SU gp160 sequence to the gp150-FL-
IP used here will be very informative to assess if all the modifications to Env led to 
improvement of spike density. Furthermore, other transmembrane domain plus cytoplasmic 
tail regions of of viral glycoproteins such as Epstein Barr and mouse mammary tumour viruses 
and of baculovirus gp64 have also been shown to be effective in increasing Env spike density, 
and might be worth pursuing [399, 418-420, 465].  
Of more concern than effects on Env spike density was the effect the Env:HA2 chimaeras had 
on the presentation of Env bnAb epitopes, as observed in both qualitative live-cell staining 
assays and a quantitative FACS assay. In the most extreme case, no native-like Env trimers 
were observed for gp120-HA2–FL as assessed with bnAbs PG16, PGT145 and CAP256 
VRC26.08. Furthermore, the highest Env scores for bnAbs F105 and 447-52D were observed 
for this chimaeric construct, indicating that expression of gp120HA2 led to highest percentage 
of misfolded Env trimers, or potentially of the trimer dissociating into dimers and monomers. 
Although the overall picture for gp140HA2tr-FL-IP appeared better, Env scores for bnAbs 
PG16, PGT145 and CAP256 VRC26.08 were comparable to gp150-FL-IP, higher Env scores 
were observed for bnAbs F105 and 447-52D, again indicating more Env was in a less optimal 
conformation compared to gp150-FL-IP. It should be noted as well that for all Env and Env:HA2 
chimaeric DNA and rMVA vaccines, some misfolded Env was expressed judged by the binding  
Table 4.9 Env and Env:HA2 chimaeric construct characteristics.  
The different features between the Env control and Env:HA2 chimaeras used by Wang et al., 2007 [399] 
and in this thesis. Key differences within the manuscript of Wang et al., paper [399] are highlighted in 
bold italics, whereas between those experiments and here in this chapter are underlined in bold. 
 
 
of MAbs F015 and 447-52D. This is in line with data from Cappuci et al [343], who showed 
that BG505 SOISP.664 expressed from MVA or simian adenovirus results in expression of 
both native-like and misfolded trimers [343]. Unfortunately, the chimaeric constructs using 
Epstein Barr, MMTV or baculovirus gp64 were never as thoroughly characterised and it is 
unknown if these chimaeric constructs can fold into a native-like like Env trimer, although these 
increased the Env spike density [399, 418-420, 465]. Subsequent in vivo testing of the 
chimaeric Env construct using either the transmembrane domain plus the cytoplasmic tail of 
MMTV baculovirus gp64 resulted in very disappointing neutralisation titres in HIV-1 
pseudovirion neutralisation assays, without any autologous Tier 2 neutralisation titres [419, 
420]. Therefore, before considering using Env chimaeras as HIV-1 vaccines, the presence of 
bnAb epitopes and especially those recognising the native-like trimer should be assessed. 
A high fraction of misfolded Env of gp120-HA2–FL from DNA and MVA vaccines in vitro seems 
to correlate to the immunogenic properties of the corresponding DNAGC2 and MVAGC2 
vaccines in rabbits. Although Env-binding antibodies to CAP256 Env trimers or the V1V2-loop 
are unaffected, HIV-1 pseudovirion neutralisation is clearly affected, with 0 out of 5 animals 
developing autologous Tier 2 neutralisation. In comparison, 4 out of 5 animals from the gp150-
FL-IP (DNAGC5 and MVAGC5) group developed these Tier 2 neutralising antibodies, with 
three rabbits already showing Tier 2 neutralisation after the second MVA vaccine. As for 
Env Chimaera Env Chimaera 1 Chimaera 2
HIV-1
Length gp160 gp145 gp150 gp120 gp140
Signal peptide Native Chitinase
Furin site Yes No, fused
Fusion peptide Yes No
gp41 HIV-1 gp41 ecto Yes No, HA2 gp41 ecto
TM HIV-1 HA2 HIV-1 HA2 HA2
Cytoplasmic tail HIV-1 HA2 HIV-1, truncated HA2 HA2
I559P
Influenza A
Codon optimised ? Yes
Expressed in
Yes
HA2 from H3N2 strain HA2 from H5N1 strain
Insect cells Mammalian cells
Yes
YesNo






animals inoculated with gp140HA2tr-FL-IP (DNAGC4 and MVAGC4), in 3 out of 4 rabbits 
autologous Tier 2 neutralisation was observed. This underlines the requirement of HIV-1 
vaccines to present at least some of the Env antigen as a native-like trimer, as suggested from 
literature [277, 388]. 
Although the autologous Tier 2 neutralisation response in the gp150-FL-IP group is almost 
identical to the gp140HA2tr-FL-IP group, for the latter this developed on a delayed time scale 
and was only induced after inoculation with a soluble trimeric Env protein boost. As with the 
in vitro characteristics, the immunogenic properties of gp140HA2tr-FL-IP in vivo are nearly, but 
just not as good compared to gp150-FL-IP. This indicates that future research should be 
focussed on vaccines containing gp150 inserts rather than Env:HA2 chimaeras for the vaccine 






CHAPTER 5: CONCLUDING REMARKS 
Global awareness campaigns about HIV-1/AIDS and HIV-1 prevention combined with huge 
efforts to improve accessibility to antiretroviral therapy, both as a prophylactic measure and to 
prevent disease progression, have resulted in a dramatic decrease in newly infected 
individuals and AIDS-related deaths [31, 197, 467-469]. It appears that the HIV-1/AIDS 
pandemic is slowing down, but unfortunately current predictions are that the 2020 UNAIDS 
goals (90-90-90 targets, where 90% of people living which HIV-1 are diagnosed as such, from 
which 90% will receive sustained antiretroviral therapy, resulting in viral suppression in 90% 
of these individuals by 2020) will not be reached, leading to higher new HIV-1 infection and 
AIDS-related death rates than was aimed for under these goals [31]. These numbers are still 
staggering, with data showing that 1.7 million [1.4 million–2.3 million] new infections and 770 
000 [570 000–1.1 million] AIDS-related deaths were predicted for 2018 [31]. Therefore a 
prophylactic vaccine, even when only partially protective, would be a significant step forward 
in tackling the pandemic [223]. Furthermore, developing countries, especially those situated 
in eastern and southern Africa, carry the largest burden of people living with HIV, new HIV 
infections and deaths from AIDS [30-32]. With this in mind, the South African Medical 
Research Council (SAMRC) in association with the Department of Science & Technology 
(DST) extended a call for pre-clinical HIV-1 vaccine research under The Strategic Health 
Innovation Partnerships (SHIP) and funded the project ‘Novel HIV Vaccine Candidates for 
South Africa’ led by Professor Anna-Lise Williamson.  
This SHIP project required extensive tool, capacity and infrastructure development, with a 
large part of this work being presented in this thesis. For my project, the remit was further 
narrowed down to the development of an HIV-1 subtype C vaccine for sub-Saharan Africa 
eliciting high-titre antibody responses to HIV-1 envelope glycoproteins (Env) [26-29]. 
Therefore, an Env sequence was chosen from the Centre for the AIDS Programme of 
Research in South Africa (CAPRISA) 002 acute infection cohort [167, 174]. This particular 
virus was the superinfecting virus (SU) from participant CAP256 who developed broadly cross-
neutralising antibodies targeting the V1V2 loop 15 weeks after the second viral infection event. 
Furthermore, the CAP256_SU virus was shown to be sensitive to a range of broadly 
neutralising antibodies (bnAbs) targeting different epitopes within the Env sequence [167]. 
Consequently, this Env sequence has the potential not only to induce high-titre antibodies 
towards Env, but also to elicit neutralising antibodies in animal models. Based on the work 
reported in this thesis, further Env vaccines have been or are under development such as for 
Env Du151, a sequence from a South African cohort with the closest resemblance to the South 
African consensus sequence, and subtype C mosaic Env sequences [272, 470]. 
With the development and characterisation of the DNA and especially the MVA vaccines being 
more time consuming, the first vaccine I made was a lectin affinity purified soluble Env protein 
vaccine from the media of HEK293T cells. Initially characterised and used as a protein vaccine 
(Env (GNL)) without further refinement, the development of a stable cell line in HEK293 cells 
and subsequent repeat harvesting from the same culture flasks increased yields enough to 
implement a second layer of purification in which the trimeric Env fraction as adjudged by 
molecular weight was isolated using size exclusion chromatography (SEC). However, to be 
able to assess the folding of Env by the presence of Env bnAb epitopes, a stable cell line 
expressing a His-tagged version of Env had to be created. This allowed for coupling of Env to 
nickel coated plates for ELISA assays, compared to where Env was directly bound to plates, 
or trapping Env using lectin coated plates which both led to distorted ELISA results (data not 
shown). As was to be expected, the in vitro immunogenic properties of the Env trimers were 
clearly improved over Env (GNL), when a His-tagged version was used in a Env bnAb ELISA 
assay, with low signals for PG16 and CAP256 VRC26.08 which selectively bind the native-
like Env trimers only. The Env trimers used as protein vaccine will potentially display a better 
immunogenic profile as the His-tag affected the Env trimer formation to the extent that SEC 
purification was ineffective in completely separating Env trimers from dimers. A bio-layer 
interferometry based assay, such as can be performed on an Octet, could be considered as a 
replacement for the His-tag ELISA. Although this assay would require more Env protein, the 
bnAbs could be trapped on for instance protein A probes before binding of soluble trimeric 
Env can be measured, thereby circumventing the need for a tag for trapping Env. 
The Env (GNL) protein vaccine was subsequently used in the first animal study to investigate 
the modulatory effects of adjuvants to improve the immune response of the vaccine. The same 
protein was also used to successfully develop an Env binding ELISA assay, which allowed 
measuring α-Env binding antibodies in rabbit sera. In our experiments, the aluminium based 
adjuvant AlhydroGel (same formulation as alum) performed significantly better than AddaVax 
(similar to MF59) [366], both for inducing α-Env binding antibodies and for developing an HIV-
1 pseudovirion neutralisation response, with the caveat that these were only Tier 1A and 1B 
responses. Based on these results, AlhydroGel was selected as the adjuvant for all further 
protein vaccines in rabbits. Considering these results, hopefully the reason for a lack of 
vaccine efficacy in HVTN 702 clinical trial is something different than the switch from alum, as 
used in the partially successful predecessor study RV144, to MF59 [234, 258, 268-270]. 
However, data from Phase I studies in southern Africa seem to indicate slightly better immune 
responses when the vaccine regimen from RV144 trial was used (HVTN 097), compared to 
those of HVTN 702 (HVTN 100) [268, 271]. 
The SEC purified soluble Env trimers were used as protein vaccine and bait for binding ELISAs 
in the remaining animal experiments described in this thesis, where it was employed as a 
booster vaccine of MVA inoculations. Going forward, further purification of the protein vaccine 
should be considered. This could either take the form in using non-neutralising antibodies 
against Env, or for instance the bnAbs F105 and 447-52D used in this thesis for identifying 
misfolded Env trimers, to deplete poorly assembled trimers [385, 422]. Alternatively, bnAbs 
such as PG16, PGT145, CAP256 VRC26.08 and PGT151, which only recognise Env trimers 
in a native-like conformation, could be utilised to directly select for these well-folded Env 
trimers [371, 435]. However, the effect of harsh pH conditions affecting the Env structure in 
the latter approach should be considered. The use of suspension HEK293 or CHO cells might 
help to improve Env protein yields to make these selection methods viable alternatives. 
Furthermore, decreasing the addition of complex glycans by using GnTI negative cell lines 
could positively impact the formation of native-like Env trimers as well. Another interesting 
prospect is production of Env protein on potentially cheap and scalable plant platforms, which 
was recently used successfully in our group to produce soluble, trimeric Env in a transient 
expression system in N. benthamiana [358, 421, 471].  
For the development of the recombinant MVA vaccines, a selection method novel for the lab 
was used where the expression of the vaccinia virus (VACV) K1L gene, only present after 
successful recombination of the transfer construct into the MVA genome, is required for MVA 
to replicate in RK13 cells [316, 441]. After initial problems of generating MVA recombinants 
(data not shown), when the promoter for K1L was changed to the synthetic VACV promoter 
pSS, the generation of recombinant MVA vaccines was greatly improved and high titre stock 
can now be acquired within 6-8 weeks. This is aided as well by a novel way of isolating MVA 
DNA from infected cells developed during this project (not discussed, described in Appendix 
A) which resulted in better PCR success rates for the verification of correct integration of the 
transfer construct into the MVA genome. 
For the DNA and MVA HIV-1 vaccines made in this thesis, the Env had a truncated 
transmembrane domain (gp150), thereby anchoring it into the cell membrane and not 
secreting it into the media as with the protein vaccine. Therefore, cell based assays could be 
developed to characterise the conformation of Env and the presence of Env bnAb epitopes. 
Initially a live-cell staining assay imaged on a fluorescent microscope was performed. Because 
the live-cell staining was difficult to quantify, it acted as a qualitative measure of Env bnAb 
binding. This was subsequently solved by adapting the live-cell staining to a FACS assay 
based on a protocol from Samal et al. (2019), which allowed quantifying the presence of Env 
bnAb epitopes after expression of the Env from HIV-1 DNA and MVA vaccines [466]. Although 
expression of Env from DNA (live-cell staining and FACS) and MVA vaccines (live-cell 
staining) led to some misfolded Env trimers as observed by binding of the bnAbs F105 and 
447-52D, the epitope for the V3-glycan supersite was detected with bnAbs PGT128 and 
PGT135, the CD4-binding site with VRC01 and the V2-glycan with PG9. Most encouragingly, 
bnAbs PG16, PGT145 and CAP256 VRC26.08 showed binding as well, indicating that Env 
expressed from DNA and MVA HIV-1 vaccines can form native-like trimers. When this was 
quantified in the FACS assay for the HIV-1 DNA vaccine, about 20% of Env trimers were in 
this native-like conformation when compared to VRC01. This heterogeneous population of 
Env trimers, ranging all the way from completely misfolded to native-like conformation, is 
similar to what was observed for BG505 SOISP.664 when expressed via MVA or simian 
adenovirus [343]. 
The reason for expressing Env that will be embedded into the membrane from DNA and 
recombinant MVA vaccines was to investigate if these would be incorporated into Gag virus-
like particles (VLPs). Including Gag has the distinct possibility to improve an HIV-1 vaccine on 
two fronts. First of all, cell-mediated immune responses to HIV-1 Gag (CD4+ and CD8+ T-cell 
responses) have been implicated in viraemic control of HIV-1 infected individuals [226]. 
Secondly, incorporation of Env into Pr55gag VLPs has been shown in in vitro co-expression 
studies, and anchoring Env into the native environment of a lipid bilayer could potentially 
stabilise the trimeric conformation, and has been shown to improve immunogenic properties 
of Env [405-412, 442, 443, 445, 450, 472]. For this thesis, a HIV-1 mosaic Gag (GagM) 
sequence was selected for co-expression with Env. This GagM sequence, designed in silico 
to maximise potential T-cell epitopes for HIV-1 subtype C, improved immunogenicity in mice 
as a BCG, DNA and recombinant MVA vaccine [272, 413, 414]. VLP formation was confirmed 
by electron microscopy when GagM and Env were co-expressed from DNA and MVA vaccines. 
Subsequently, a two-step OptiPrep gradient centrifugation protocol was developed to isolate 
these VLPs to verify the inclusion of Env into the Gag VLPs. Since then, the VLP isolation 
protocol has been simplified, which has drastically reduced purification time and cost (data not 
included in thesis) [353]. 
Although inclusion of Env into these VLPs was observed, with native Env spike density on the 
HIV-1 virion being relatively low when compared to other viruses [464], it was speculated that 
this could very well be the same for these VLPs. A potential strategy to increase the Env 
spiked density is by generating chimaeric constructs between HIV-1 Env and the 
transmembrane (TM) and cytoplasmic tail (CT) of glycoproteins from different viruses. For this 
project the H5 haemagglutinin (HA) stalk from influenza A was chosen as it has previously 
been shown that substituting the TM and CT of HIV-1 gp41 with the corresponding elements 
of the HA stalk from influenza A improved the spike density [399]. A similar design was 
employed to generate gp140HA2tr, whereas for the second chimaera the whole of gp41 was 
replaced by the HA2 stalk, resulting in gp120HA2 (referred to as Env:HA2 chimaeras). 
Surprisingly, no improvement in spike density between Env and the Env:HA2 chimaeras was 
observed in vitro, either by western blotting of isolated VLPs or on the plasma membrane 
using the bnAb FACS assay. Possibly differences in Env and Env:HA2 chimaeras design are 
responsible for the discrepancy between these results and those reported by Wang et al., 
2007 (Table 4.8) [399]. Especially modifications included here for gp150 Env could have 
improved Env levels on the plasma membrane and subsequently incorporation into VLPs, to 
a degree not seen for gp160 in the study by Wang et al. 
More concerning, it was seen that trimer folding of the Env:HA2 chimaeras was impaired, 
especially upon expression of gp120HA2: here no native-like Env trimers were observed, with 
the highest percentage of misfolded trimers as assessed by binding of bnAbs F105 and 447-
52D in the FACS assay. Although expression of gp140HA2tr could result in the Env trimer 
assembling into a native-like conformation with binding of bnAbs PG16, PGT145 and CAP256 
VRC26.08 observed, in general superior presentation of bnAb epitopes by gp150-FL-IP (Env) 
was detected. Therefore, before considering using Env chimaeras as HIV-1 vaccines, the 
presence of bnAb epitopes and especially those recognising the native-like trimer should be 
assessed. 
As HIV-1 is particularly efficient in evading the immune system, an effective vaccine will almost 
certainly require the activation of both cellular and humoral immunity. Considering the different 
qualities of the vaccine platforms developed in this thesis (DNA: cellular immunity; MVA or 
other viral platforms: cellular+humoral immunity; and protein: humoral immunity), 
heterologous vaccine platform prime-boosting regimens could potentially broaden the immune 
response by activating both arms of the adaptive immune response and preventing potential 
development of vector-based immunity when multiple vaccines are required. This strategy 
turned out to be particularly effective here when two DNA Env priming vaccines were followed 
by two vaccine-matched MVA Env vaccines and subsequent boosting with two soluble Env 
vaccines in rabbits (DDMMPP), resulting in low serum neutralisation titres (1:74 and 1:104) 
towards autologous Tier 2 pseudo-virions in 2 out of 4 animals after the final protein vaccine. 
As mentioned earlier, presentation of Env its natural membrane bound state in particles has 
been shown to lead to increased immunogenicity [442, 443, 445, 450]. This was observed in 
these experiments as well, with the inclusion of Gag (Env+GagM) into DNA and MVA vaccines. 
In this group, not only did more animals develop Tier 2 neutralising antibodies (4 from 5), but 
titres were improved (ranging from 1:54 to 1:1294) and Tier 2 neutralisation in general started 
to develop after less vaccinations, where in three animals this was observed after the second 
MVA inoculation. This suggests that the right poxvirus-based HIV-1 vaccine regimen can 
induce Tier 2 neutralisation without the need of protein vaccines. It should however be 
emphasised that almost no Tier 2 cross-neutralisation titres were observed. 
When GagM in combination with the Env:HA2 chimaeric DNA and MVA vaccines were tested 
in rabbits using the DDMMPP regimen, an inferior immune response was observed, with 
gp120HA2 completely failing to induce autologous Tier 2 neutralisation responses. With the 
gp140HA2tr-FL-IP group such titres developed on a delayed time scale with lower median 
neutralisation titres compared to gp150-FL-IP. These results emphasise the importance for 
HIV-1 vaccines in presenting the Env antigen in a well folded conformation and at least 
partially as a native-like trimer [277, 388]. 
In this project a heterologous HIV-1 vaccine platform regimen (DDMMPP) has been developed 
that can induce high titre binding antibodies for Env and for the V1V2-loop of Env in rabbits. 
Encouragingly, when both CAP256 gp150-FL-IP and subtype C mosaic Gag are included in 
the DNA and MVA vaccines, this leads to strong autologous Tier 2 neutralisation responses 
in most animals. However, improving the immunogenicity of vaccine regimen should be 
considered in order to elicit stronger and more robust autologous Tier 2 responses and 
possibly Tier 2 cross-neutralisation. An obvious first target would be gp150-FL-IP, to further 
modify the Env sequence based on BG505 SOSIP.664, which is now in its tenth iteration, 
starting with the inclusion of the internal disulphide bond (SOS), which has been shown to 
improve Env sequences where flexible linkers have been used [371, 377, 379, 380, 382, 384, 
385, 473-475]. The bnAb FACS assay developed for this thesis can be used as a screening 
tool for assessing the effects that these modifications to membrane bound Env will have on 
the trimeric structure. This could benefit all three different vaccine platforms investigated here. 
Even though the HIV-1 DNA vaccine used here was reasonably effective in priming the 
subsequent HIV-1 MVA vaccines, there is the potential for a large gain in improving the 
immunogenicity of the DNA vaccine. Delivery by needleless devices such as supplied by 
PharmaJet have shown to improve the vaccine immune response of DNA vaccines to delivery 
by needle and/or electroporation [303-305]. Besides improving vaccine immunogenicity with 
needleless devices, other benefits for these systems in a clinical setting such as dose sparing, 
increased safety (no needle injuries), and preferred delivery method by vaccinators and 
caregivers, which could lead to increased vaccine uptake and compliance, should be taken 
into consideration as well [476, 477]. This approach could even be combined with adjuvanting 
the DNA with simple and inexpensive solutions such as formulation in lipids and polymers or 
addition of CpG oligodeoxynucleotides (CpG ODNs), with the latter aimed at TLR9 signalling 
and B-cell activation [286, 478]. 
Unfortunately, the rabbit model is limited to measuring vaccine induced antibody responses 
alone. With the inclusion of both Env and Gag into the DDMMPP vaccine regimen leading to 
the strongest immune responses in this thesis, it would be extremely interesting to interrogate 
the T-cell response that is induced. Even simple ELISpot assays to measure vaccine induced 
IFNγ, IL2 and IL4 towards Env and Gag would be insightful. With commercial T-cell assays 
mainly geared towards mice and non-human primates (macaques), lack of antibody pairs for 
rabbit cytokines and a general lack of knowledge about the rabbit immune system, it would be 
very informative to test the Env+GagM DDMMPP from this thesis in macaques to measure 







APPENDIX A. Routine molecular biology protocols 
1 DNA isolation and manipulation 
1.1 Small scale plasmid DNA isolation 
Grow bacterial (E. coli) culture in 3ml LB medium with appropriate antibiotics at 37 °C 
overnight (O/N) whilst shaking (250rpm). Transfer O/N culture to a 2 ml Eppendorf tube, and 
spin down cell culture at high speed for 30 seconds in table-top centrifuge and discard 
supernatant. Add 250μl of resuspension solution (P1 buffer) into each tube and resuspend 
cell pellet by pipetting up and down. Add 250μl of lysis solution (P2 buffer) and mix by gently 
inverting the tube 5-6 times. Add 350μl of neutralizing solution (P3 buffer) and mix by inverting 
the tubes several times. Centrifuge the tubes at >12000g for 10 min. Carefully transfer 750μl 
supernatant to a new labelled 1.5 ml Eppendorf tube with a 1 ml pipette. Add 525μl ice-cold 
isopropanol and cool on ice for 15 min. Spin down plasmid DNA precipitate at >12000g for 20 
min. Remove the supernatant, add 180μl 70% ethanol (ice cold), spin at >12000g for 1 minute. 
Discard supernatant and air dry (~5min) without over-drying. Resuspend the DNA pellet with 
50μl TE. 
1.2 Large scale plasmid DNA isolation 
Zyppy™ Plasmid Maxiprep Kit (Zymo Research, Irvine) was used for all large scale plasmid 
DNA isolations. Buffers P1-P3, wash buffers and Elution Buffer were supplied with this kit. 
Grow bacterial (E. coli) culture in 100ml LB medium with appropriate antibiotics at 37 °C O/N 
whilst shaking (250rpm). Transfer O/N culture to a 3x 35ml tubes, spin down cell culture at 
6000g for 15 minutes at 4°C and discard supernatant. Add 5ml P1 buffer into each tube and 
resuspend cell pellet by pipetting up and down. Add 5ml P2 buffer into each tube and mix by 
gently inverting the tube 5-6 times. Add 7ml chilled P3 buffer into each tube and mix by gently 
inverting the tube until the colour has changed to yellow. Place on ice for 5 minutes. Centrifuge 
the tubes at 6000g for 15 minutes at 4°C. Carefully transfer all supernatant to Zymo-Spin™ VI 
column and apply vacuum until all liquid has gone through. Add 11ml of Endo-Wash Buffer 
and apply vacuum until all liquid has gone through. Add 11ml of Zyppy™ Wash Buffer. and 
apply vacuum, keep vacuum for an additional 5 minutes after all liquid has gone through to 
dry the membrane. Place Zymo-Spin™ VI column into 50ml, add 3ml pre-warmed (50°C) 
Elution Buffer and incubate for 5 minutes at room temperature. Spin for 10 minutes at 3000g. 
Collect eluate and measure the concentration on a NanoDrop (Thermo Fisher Scientific, 
Waltham). Concentrate to 1µg/µl using the protocol described below. 
 
1.3 DNA precipitation 
Add 1/10 volume of 3M Sodium acetate (pH5.5 using glacial acetic acid) and 0.7 volume ice-
cold isopropanol to DNA. Leave on ice for 10 minutes. Spin at >12000g for 20 minutes. 
Remove the supernatant, add 180μl 70% ethanol (ice cold), spin at >12000g for 1 minute. 
Discard supernatant and air dry (~5min) without over-drying. Resuspend the DNA pellet with 
required volume of TE for 1µg/µl. 
1.4 Restriction enzyme digestion of plasmid DNA 
FastDigest restriction enzymes (Thermo Fisher Scientific, Waltham) were used for all DNA 
restrictions. Single digests were performed in 15µl reactions with 1µg of plasmid DNA, 1µl 
restriction enzyme and 1.5µl FastDigest buffer. Double digests were performed in 25µl 
reactions with 1µg of plasmid DNA, 1µl restriction enzyme each and 2.5µl FastDigest buffer. 
Digests were incubated at 37°C for 15 minutes and subsequently run on 0.8% agarose gel. 
1.5 DNA isolation from agarose gels 
All purifications were performed using Zymoclean Gel DNA Recovery kit (Zymo Research, 
Irvine). All buffers were supplied with the kit. Excise band from agarose gel on blue-light 
illuminator (BLooK LED transilluminator (GeneDireX, Zhunan Township)), place in 1.5ml 
Eppendorf tube and weigh. Three volumes of ADB buffer was added and the tube was 
incubated at 50°C to completely dissolve the agarose gel. The solution was transferred to 
Zymo-Spin™ Column in a Collection Tube and spun for 30 seconds at >12000g. Flow-through 
was discarded, 200µl wash buffer was added to the Zymo-Spin™ Column and spun for 30 
seconds 12000g. Wash was repeated and after discarding the flow-through, the Zymo-Spin™ 
Column was dried by spinning for 1 minute at 12000g. The Zymo-Spin™ Column was 
transferred to a new 1.5ml Eppendorf tube and 30µl of pre-warmed (50°C) elution buffer was 
added and incubated at room temperature for 1 minute. DNA was eluted by spinning for 30 
seconds at 12000g. 
1.6 DNA ligation 
All DNA ligations were performed in 20 µl reactions using 1µl T4 DNA ligase  (Thermo Fisher 
Scientific, Waltham), 2µl T4 DNA ligase buffer, 1µl plasmid backbone (agarose purified 
restriction digest of 1 µg DNA) and 3µl DNA insert (agarose purified restriction digest of 1 µg 
DNA). Ligations were incubated at room temperature for 1 hour before transformation into E. 
coli. Control ligations were as above but without DNA insert or without DNA insert and T4 DNA 
ligase. 
 
1.7 Transformation of plasmid DNA into E. coli 
E. cloni 10G Chemically competent cells (Lucigen, Middleton) were used to plasmid DNA 
transformation. In short, 15µl aliquots of competent cells were defrosted on ice, 1µl of ligation 
reaction 1ng of plasmid DNA was added and incubated on ice for 30 minutes. After a 30 
second heat shock (37°C) cells were placed on ice again for 2 minutes. 400µl recovering 
media (supplied with kit) at 37°C was added and the transformation was placed at 37 °C for 
one hour whilst shaking (250rpm). 140µl of the transformation was plated onto LB Agar plates 
with an antibody selection and plates were incubated O/N at 37 °C. 
2 rMVA isolation 
2.1 Isolation of rMVA for PCR 
Use buffer P1-3 from small scale plasmid DNA isolation. Add 250μl of resuspension solution 
(P1 buffer) to a well (6-, 12-, or 24-well plate) infected with rMVA, pipette up and down until all 
cells have detached and transfer to 1.5ml Eppendorf tube. Add 250μl of lysis solution (P2 
buffer) and mix vigorously by pipetting up and down. Add 350μl of neutralizing solution (P3 
buffer) and mix vigorously by pipetting up and down. Centrifuge the tubes at >12000g for 10 
min. Carefully transfer 700μl supernatant to a new labelled 1.5 ml Eppendorf tube with a 1 ml 
pipette. Add 490μl ice-cold isopropanol. Spin down rMVA/DNA precipitate at >12000g  for 20 
min. Remove the supernatant, add 180μl 70% ethanol (ice cold), quickly spin at max speed. 
Discard supernatant and air dry (~5min) without over-drying. Resuspend the rMVA/DNA pellet 
with 30μl ddH2O. 
2.2 Large scale production of rMVA 
When single foci picked from serial dilution plates were verified for correct integration and 
expression of Env, Env:HA2 chimaeras and/or GagM they were expanded in a T75 containing 
70-80% confluent RK13 cells. Infection was monitored by eGFP expression and after 3-4 days 
when nearly all cells had lifted, cells were lysed by repeated freeze-thaw cycles in the T75 
flask (3 in total) and viral titres were determined in BHK cells where GFP positive plaques 
were counted 48 hours after infection of a serial dilution range (in steps of 1 in 10) and 
calculated as plaque forming units (pfu)/ml. This titre was used to infect 4*107 RK13 cells with 
an MOI of 0.001 at 37°C/5%CO2 in a total volume of 10ml RK13 media to generate a seed 
stock. After 1 hour, infected cells were added to a full bottle of RK13 media (~550ml), this was 
poured into a Hyperflask and the flask was transferred to a tissue culture incubator 
(37°C/5%CO2). Infection was monitored by eGFP expression and after 5-6 days when nearly 
all cells had lifted, nearly most media (~50ml left) was poured off into 50ml tubes. Both tubes 
and the hyperflask were frozen (-80°C) and thawed (37°C). The remaining media from the 
Hyperflask was added to the 50ml tubes and freeze-thawing was repeated twice. After the 
final thaw, supernatant was cleared by low speed spin (5 minutes, 275g) and divided between 
16x 35ml tubes. The supernatant was underlayed with 2ml 36% sucrose (in H2O), spun for 1 
hour at ~26900g (4°C) with the centrifuge brake disengaged after which the supernatant was 
discarded. The pellets were reconstituted in a total volume of 5ml PBS, aliquoted and stored 
at -80°C. Furthermore, 10µl of concentrated rMVA was plated onto LB Agar plates without 
antibody selection, plates were incubated for 3 days at 37 °C to test for bacterial, fungal and 
yeast contamination. The titre of this seed stock was determined from a frozen aliquot as 
described above and used to generate high titre stocks (working stocks) for animal 
experiments. Working stocks were generated and titred in the same way as the seed stock 
described above with the following permutations: 1) three hyperflasks were seeded; 2) cell 
pellet after clearing was lysed in 10ml of 0.1mM Tris pH 9.0 per hyperflask and after another 
low speed clearing step, this lysate was added to the initial lysate; 3) pellets from the first 
sucrose cushion were resuspended in 20ml of PBS per hyperflask and run on a second 
sucrose cushion (2x 35ml tubes) and 4) these pellets were reconstituted in in a total volume 
of 10ml PBS+10% glycerol.  
3. PCR 
3.1 PCR protocol 
KAPA2G Robust HotStart ReadyMix PCR Kit (Kapa Biosystems, Cape Town) was used for 
rMVA PCR screening. All PCRs were run with the same protocol as described in the table 
below. Primers to screen for correct integration in rMVA constructs are described below in 3.2. 
Primers to sequence these PCR products are described in 3.3. 
    
3.2 PCR primers for rMVA screening 





PCR-grade water Up to 25μl
5X KAPA2G Robust HotStart 
ReadyMix2
12.5μl
10 μM Forward Primer 1.25μl
10 μM Reverse Primer 1.25μl
Template DNA4 1μl
Step Temperature Duration Cycles
Denaturation 95ºC 3 minutes 1
Denaturation 95ºC 15 seconds
Annealing 55ºC 15 seconds
Extension 72ºC 3 minutes
Extension 72ºC 3 minutes 1
40
name sequence size TM PCR product
eGFP rev AGATGAACTTCAGGGTCAGC 20 60
I8R f2 GAAAAGGAAGAGTAGGAAGAG 21 60
note
For pSSPEx final recombinant PCR
870bp
Binding site outside pSSPEx flank
Recombination into G1L flank. Size of this PCR product will also verify full-length integration 
of Env and Env:HA2 chimaeras 
 
PCR for gagM insertion site 
 
3.3 Sequencing primers for rMVA 
 
4 Protein characterization 
4.1 SDS-PAGE 
Mini-PROTEAN® Electrophoresis System (Bio-Rad, Hercules) was used with 8% resolving / 
4% stacking gels cast when required (Appendix C). Samples were boiled for 5 minutes at 95°C 
in 4x protein loading dye (Appendix C). Gels were run for ~1 hour at 200V using 1x SDS PAGE 
Running buffer (Appendix C). Color Prestained Protein Standard, Broad Range (NEB, 
Ipswich) was used for molecular weight determination. 
 
name sequence size TM PCR product
PEPV DR fwd GGGTGTAGCTAACAACCCTG 20 60
G1L r2 GGCCATGTGTAACACTAGAG 20 60
*PCR products for Env:HA2 chimaeras is ~200 base pair shorter




name sequence size TM note PCR product
A11_f GCAAATTTGAACGGGTCTCCC 18 58 Binding site outside recombination flank
A12_r  GCGATGGATGGTCAGATTGTC 21 64 Binding site outside recombination flank
2240bp
name sequence size TM locus Env or Env:HA2 construct
TPA F CTGTTGCGTGCTGCTG 16 52 TPA GP120HA2/GP140HA2tr/GP150
CGP120 F1 CACTCGCGAGGAAATC 16 52 GP120 GP120HA2/GP140HA2tr/GP150
CGP120 F2 TTATCGTCCACCTGAAC 17 50 GP120 GP120HA2/GP140HA2tr/GP150
CGP120 F3 TATCAACATGTGGCAGG 17 50 GP120 GP120HA2/GP140HA2tr/GP150
CGP41 F1 GCTGTCTGGCATCGTC 16 52 GP41 GP140HA2tr/GP150
CGP41 F2 GGCTGTGGTACATTAAG 17 50 GP41 GP140HA2tr/GP150
HA2 F1 GGTGACTAACAAGGTCA 17 50 HA2 GP120HA2
HA2 F2 TCTGTGGATGTGCAGC 16 50 HA2 GP120HA2/GP140HA2tr
CGP120 R1 CGTAAGACTTTGCATCG 17 50 GP120 GP120HA2/GP140HA2tr/GP150
name sequence size TM locus Note
Gagm F1 GGATAAGATCGAGGAAG 17 50 Gag mosaic Gag
Gagm R1 CCGCTGCATCATGATG 16 50 Gag mosaic Gag
name sequence size TM
A11_f GCAAATTTGAACGGGTCTCCC 18 58
A12_r  GCGATGGATGGTCAGATTGTC 21 64
G1L r2 GGCCATGTGTAACACTAGAG 20 60  Binding site in G1L, outside Env recombination flank
locus
 Binding site in A11R, outside GagM recombination flank
 Binding site in A12L, outside GagM recombination flank
4.2 BN-PAGE 
Precast NativePAGE™ Novex® 3-12% Bis-Tris Protein Gels (Thermo Fisher Scientific, 
Waltham) were run. Anode buffer: dilute 20X NativePAGE™ Running Buffer (Thermo Fisher 
Scientific, Waltham) 1 in 20. Cathode buffer: dilute 20X NativePAGE™ Running Buffer 
(Thermo Fisher Scientific, Waltham) 1 in 20 and 20X NativePAGE™ Cathode Additive 
(Thermo Fisher Scientific, Waltham) 1 in 200. Samples were prepared in 4x NativePAGE® 
Sample Buffer (Thermo Fisher Scientific, Waltham). Gels were run at 150V for ~2 hours. 
NativeMark™ Unstained Protein Standard (Thermo Fisher Scientific, Waltham) for native gel 
electrophoresis was used for estimating molecular weight. 
4.3 Coomassie staining 
After SDS-PAGE or BN-PAGE, gels were washed 3x in H2O. Gels were incubated with ~20ml 
Bio-Safe™ Coomassie Stain (Bio-Rad, Hercules) for 1 hour at room temperature whilst gently 
shaking. Gels were washed 3x in H2O again and scanned on an A4-scanner or imaged on a 
Molecular Imager® Gel Doc™ XR+ Imaging System (Bio-Rad, Hercules). 
4.4 Western blotting 
Trans-Blot® SD Semi-Dry Transfer Cell (Bio-Rad, Hercules) blotting system was used to 
transfer protein from SD-PAGE or BN-PAGE gels onto PVDF membranes (Bio-Rad, Hercules) 
sandwiched between Whatman filter papers (Bio-Rad, Hercules) soaked in 1x transfer buffer 
(Appendix C). Blotting was performed at 20V for 1 hour after which PVDF membranes were 
blocked in PBST + 2.5% BSA (block) at room temperature for 1 hour. Primary antibody 
incubation was performed in block for 2 hours or overnight, followed by 3x 5 minute washes 
with PBS. AP-linked secondary antibody in block was added for 1 hour at room temperature 
after which membranes were washed with PBST for 5 minutes (3x) and signal was detected 
with BCIP/NBT Phosphatase Substrate (KPL, Milford). 
4.5 Antibodies and dilutions for western blotting 
 
4.6 Protein DC assay 
Protein quantification was performed using the DC™ Protein Assay (Bio-Rad, Hercules). A 
BSA standard (Bio-Rad, Hercules) was used to make a dilution range (20, 16, 12, 8, 4, 2, 1 
Primary Antibody Supplier dilution
Goat anti-HIV-1 gp120 BioRad 5000-0557 1:1000
Goat anti-HIV-1 p24 (Gag) BioRad 4999-9007 1:1000
Detection Antibody (secondary)
mouse monoclonal anti-goat/sheep IgG–AP GT34 Sigma 1:10000
and 0 mg/ml) in PBS and added in triplicates on a NunC 96 well plate (Sigma, St Louis). Then, 
triplicate experimental samples were pipetted into separate wells. To each well, 25µl Solution 
A was added, followed by 200µl Solution B. After 15 minutes incubation at room temperature 
(whilst slightly shaking), the absorbance at 750nm was measured on a VersaMax ELISA 
Microplate Reader (Molecular Devices, Sunnyvale). Data was plotted in Microsoft Excel 
(Microsoft Corporation, Redmond) and a trendline was generated. Experimental protein 
concentrations were determined from the formula of this trendline. 
  
APPENDIX B. Routine tissue culture protocols 
1. Growth and medium of HEK293, HEK293T, RK13, BHK cells and HEK293 CAP256 
gp140-FL-IP stable cell line 
CHO-K1, HEK293, HEK293T, RK13 and BHK cells were grown in DMEM High Glucose + L-
Glutamine (Lonza, Basel) + 10% FCS + 1x Pen/Strep (both Thermo Fisher Scientific, 
Waltham). Media for CHO and HEK293 stable cell lines (expressing CAP256 gp140-FL-IP or 
CAP256 gp140-FL-IP-His) was similar with the addition of 6ml Geneticin (Thermo Fisher 
Scientific, Waltham). Serum-free medium: DMEM High Glucose + L-Glutamine + 1x 
Pen/Strep. 
All cells were grown in a humidified tissue culture incubator at 37°C/5% CO2. BHK, CHO-K1 
and CHO stable cell lines line were split 1 in 8 on Monday and Wednesday and 1 in 12 on 
Friday. For a T75 flask, media was removed, 2ml of Trypsin (Thermo Fisher Scientific, 
Waltham) was added for 2-5 minutes in the incubator, flasks were tapped to dislodge cells and 
10ml of media was added to inhibit the trypsin. Cells were pipetted up and down to break-up 
cell-clumps and the appropriate volume was transferred to a new flask. All other cells were 
split 1 in 4 on Monday and Wednesday and 1 in 8 on Friday.  
2. Transfection of cells 
Per well of a 24-well plate. Setup two 1.5ml Eppendorf tubes and add 25µl DMEM (room 
temperature). Add 1µg of DNA to one tube and 3µl branched PEI (Sigma, St Louis) or X-
TremeGENE (Roche, Basel) transfection reagent to the second tube. Mix briefly and transfer 
DMEM + transfection reagent to the tube containing DMEM + DNA. Mix by pipetting and 
incubate at room temperature for 30 minutes after which add to cells in drop-wise manner. 
Note: for downstream large scale soluble Env protein isolation, replace medium on cells before 
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Special conditions for rMVA recombination
APPENDIX C: Buffers, growth media and solutions 
Unless stated otherwise, chemicals were acquired from Sigma (St Louis) 
1. BUFFERS: 
10x PBS: 80 g NaCl + 2.0 g KCl + 14.4 g Na2HPO4-2H2O + 2.4 g KH2PO4 in 800ml ddH2O. 
Set to pH7.4 using HCl and make up to 1L. Or ordered as 10x PBS (Lonza, Basel). 1x PBS 
(Lonza, Basel or Thermo Fisher Scientific, Waltham). 
PBST: PBS [pH 7.4], 0.1 % Tween20 
2. SDS-PAGE 
8% resolving gel (for 2 gels): 5.3ml ddH2O, 2ml 40% acryl-bisacrylamide mix, 2.5ml 1.5M Tris 
pH8.8, 0.1ml 10% SDS, 0.1ml 10% APS, 6µl TEMED 
4% stacking gel (for 2 gels): 3.8ml ddH2O, 0.5ml 40% acryl-bisacrylamide mix, 0.63ml 1.5M 
Tris pH6.8, 50µl 10% SDS, 50µl 10% APS, 5µl TEMED 
10x SDS page Running buffer. Dissolve: 10g SDS, 30.3g Tris, 29g Glycine into 800ml ddH2O. 
Adjust volume to 1000ml. Store at room temperature (SDS will precipitate). 
4 × protein loading buffer: 4 ml 100% glycerol, 1.6 ml 1.5 M Tris/HCl [pH6.8], 0.8 SDS, 4 mg 
bromophenol blue, 0.5 ml β-mercaptoethanol, 3.9 ml H2O 
10x western blotting transfer buffer. Dissolve: 3.7g SDS, 58g Tris, 144.1g Glycine into 800ml 
ddH2O. Adjust volume to 1000ml. Store at 4°C. Add 20% methanol for 1x transfer buffer. 
3 GROWTH MEDIA: 
LB Broth: 10g/l Tryptone, 5g/l NaCl, 5g/l Yeast Extract 
LB Agar: 10g/l Tryptone, 5g/l NaCl, 5 g/l Yeast Extract, 15g/l Agar 
4. SOLUTIONS: 
Resuspension solution (P1 buffer): 50mM glucose, 10mM EDTA, 25mM Tris [pH 8.0], 
100μg/ml RNAse (Sigma, St Louis) 
Lysis solution (P2 buffer): 0.2 M NaOH, 1% SDS 
Neutralizing solution (P3 buffer): 3M KOAc [pH 5.5] (adjusted using glacial acetic acid) 
TE: 1mM EDTA, 10mM Tris-HCl, pH 8.0 
  
APPENDIX D: Live-cell staining for Env and Env:HA2 chimaeric DNA 
vaccines 
 
Table D.1 Abbreviations for Env and Env:HA2 chimaeric DNA vaccines 
Abbreviation Env insert 
DNAC5 CAP256 gp150-FL-IP 
DNAC2 CAP256 gp120HA2-FL 








Figure D.1. Live cell staining using bnAb 10E8 against the gp41 MPER domain in HeLa cells 
transfected with DNA vaccines.  
(A-C) HeLa cells transfected with DNA vaccines were visualised by their Env expression using a 
rabbit α-Env polyclonal antibody which was detected with α-rabbit IgG-FITC (RB; visualised in green). 
The bnAb 10E8 was detected with anti-human IgG-Cy3 (HMAb; visualised in red). Overlapping signal 
between the rabbit α-Env polyclonal and bnAb appears as yellow.  
Bar represents 20µm 
 
  
A) DNAC5 PGT128 
 
B) DNAC5 PGT135 
 
C) DNAC5 447-52D 
 
D) DNAC2 PGT128 
 
E) DNAC2 PGT135 
 
F) DNAC2 447-52D 
 
G) DNAC4 PGT128 
 
H) DNAC4 PGT135 
 
I) DNAC4 447-52D 
 
Figure D.2. Live cell staining using bnAbs against the Env V3-glycan supersite of vulnerability 
in HeLa cells transfected with DNA vaccines.  
(A-I) HeLa cells transfected with DNA vaccines were visualised by their Env expression using a rabbit 
α-Env polyclonal antibody which was detected with α-rabbit IgG-FITC (RB; visualised in green). The 
bnAbs PGT128, PGT135 and 447-52 were detected with α-human IgG-Cy3 (HMAb; visualised in 
red). Overlapping signal between the rabbit α-Env polyclonal and bnAbs appears as yellow. PGT128 
and PGT135 detect the Env V3-glycan supersite, whereas 447-52 binds the V3 loop of gp120 and 
not considered broadly neutralising.  
Bar represents 20µm. 
  
A) DNAC5 VRC01 
 
B) DNAC5 F105 
 
C) DNAC5 PG9 
 
D) DNAC2 VRC01 
 
E) DNAC2 F105 
 
F) DNAC2 PG9 
 
G) DNAC4 VRC01 
 
H) DNAC4 F105 
 
I) DNAC4 PG9 
 
Figure D.3. Live cell staining using bnAbs against the Env CD4 binding site or the non-trimer 
specific V2-glycan in HeLa cells transfected with DNA vaccines.  
(A-I) HeLa cells transfected with DNA vaccines were visualised by their Env expression using a rabbit 
α-Env polyclonal antibody which was detected with α-rabbit IgG-FITC (RB; visualised in green). The 
bnAbs VRC01, 447-52D and PG9 were detected with anti-human IgG-Cy3 (HMAb; visualised in red). 
Overlapping signal between the rabbit α-Env polyclonal and bnAbs appears as yellow. MAbs VRC01 
and F105 detect the Env CD4 binding site, whereas PG9 binds the V2-glycan. F105 is not considered 
broadly neutralising.  
Bar represents 20µm. 
 
  
A) DNAC5 PG16 
 
B) DNAC5 PGT145 
 
C) DNAC5 VRC26.08 
 
D) DNAC2 PG16 
 
E) DNAC2 PGT145 
 
F) DNAC2 VRC26.08 
 
G) DNAC4 PG16 
 
H) DNAC4 PGT145 
 
I) DNAC4 VRC26.08 
 
Figure D.4. Live cell staining using bnAbs against the Env trimer specific V2-glycan in HeLa 
cells transfected with DNA vaccines.  
(A-I) HeLa cells transfected with DNA vaccines were visualised by their Env expression using a rabbit 
α-Env polyclonal antibody which was detected with α-rabbit IgG-FITC (RB; visualised in green). The 
bnAbs PG16, PGT145 and CAP256 VRC26.08 (VRC26.08) were detected with anti-human IgG-Cy3 
(HMAb; visualised in red) and are considered to only detect native-like Env trimers. Overlapping 
signal between the rabbit α-Env polyclonal and bnAbs appears as yellow.  
Bar represents 20µm. 
 
  
APPENDIX E: Live-cell staining for Env and Env:HA2 chimaeric MVA 
vaccines 
 
Table E.1 Abbreviations for Env and Env:HA2 chimaeric DNA vaccines 
Abbreviation Env insert Mosaic Gag present 
MVAC5 CAP256 gp150-FL-IP x 
MVAGC5 CAP256 gp150-FL-IP Yes 
MVAGC2 CAP256 gp120HA2-FL Yes 










Figure E.1. Live cell staining using bnAb 10E8 against the 
gp41 MPER domain in HeLa cells infected with HIV-1 MVA 
vaccines.  
(A-D) HeLa cells infected with MVA vaccines were visualised by 
their eGFP expression (visualised in green) present in MVA. The 
bnAb 10E8 was detected with anti-human IgG-Cy3 (visualised in 
red).  
Bar represents 20µm. 
 
  
A) MVAGC5 PGT128 
 
B) MVAGC5 PGT135 
 
C) MVAGC5 447-52D 
 
D) MVAGC2 PGT128 
 
E) MVAGC2 PGT135 
 
F) MVAGC2 447-52D 
 
G) MVAGC4 PGT128 
 
H) MVAGC4 PGT135 
 
I) MVAGC4 447-52D 
 
J) MVAC5 PGT128 
 
K) MVAC5 PGT135 
 
L) MVAC5 447-52D 
 
Figure E.2. Live cell staining using bnAbs against the Env V3-glycan supersite of vulnerability 
in HeLa cells infected with HIV-1 MVA vaccines. 
(A-L) HeLa cells infected with MVA vaccines were visualised by their eGFP expression (in green) 
present in MVA. The bnAbs PGT128, PGT135 and 447-52 were detected with anti-human IgG-Cy3 
(in red). PGT128 and PGT135 detect the Env V3-glycan supersite, whereas 447-52 binds the V3 
loop of gp120 and is not considered broadly neutralising.  
Bar represents 20µm. 
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B) MVAGC5 F105 
 
C) MVAGC5 PG9 
 
D) MVAGC2 VRC01 
 
E) MVAGC2 F105 
 
F) MVAGC2 PG9 
 
G) MVAGC4 VRC01 
 
H) MVAGC4 F105 
 
I) MVAGC4 PG9 
 
J) MVAC5 VRC01 
 
K) MVAC5 F105 
 
L) MVAC5 PG9 
 
Figure E.3. Live cell staining using bnAbs against the Env CD4 binding site or the non-trimer 
specific V2-glycan in HeLa cells infected with HIV-1 MVA vaccines.  
(A-L) HeLa cells infected with MVA vaccines were visualised by their eGFP expression (in green) 
present in MVA. The bnAbs VRC01, F105 and PG9 were detected with anti-human IgG-Cy3 (in red). 
bnAbs VRC01 and F105 detect the Env CD4 binding site, whereas PG9 binds the V2-glycan. F105 
is not considered broadly neutralising.  
Bar represents 20µm. 
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C) MVAGC5 VRC26.08 
 
D) MVAGC2 PG16 
 
E) MVAGC2 PGT145 
 
F) MVAGC2 VRC26.08 
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H) MVAGC4 PGT145 
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J) MVAC5 PG16 
 
K) MVAC5 PGT145 
 
L) MVAC5 VRC26.08 
 
Figure E.4. Live cell staining using bnAbs against the Env trimer specific V2-glycan in HeLa 
cells infected with HIV-1 MVA vaccines.  
(A-L) HeLa cells infected with MVA vaccines were visualised by their eGFP expression (in green) 
present in MVA. The bnAbs PG16, PGT145 and CAP256 VRC26.08 (VRC26.08) were detected with 
anti-human IgG-Cy3 (visualised in red) and are considered to only detect native-like Env trimers.  
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